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Mutations in the endoglin gene lead to Haemorrhagic Telangiectasia Type 1 (HHT1), an 
inherited vascular disease, demonstrating the importance of endoglin in the vasculature. Haplo-
deficiency of endoglin also leads to reduced angiogenesis in mice in several pathologies, 
indicating a pro-angiogenic role for endoglin. However, the precise role of endoglin in 
development and maintenance of the vasculature is still unclear. The aim of this project 
therefore was to investigate the role of endoglin during vascular development and maintenance 
and whether its pro-angiogenic properties can be used to enhance cardiac recovery following 
myocardial infarction (MI).  
Using immunofluorescence staining of mouse cardiac tissue, I showed high endoglin 
expression in coronary veins endothelial cells (ECs), capillaries & endocardium and weak 
expression in coronary arteries ECs, valve mesenchyme & in epicardially derived cells 
(EPDCs) during development. I hypothesised that during cardiac development endoglin is 
essential for EC proliferation and migration, and plays a key role during EPDC proliferation, 
migration and differentiation. Induced knockdown of endoglin in murine epicardial cells using 
Wt1-Cre led to a reduced number of EPDCs in E15.5 hearts but did not lead to any detectable 
vascular defects in E17.5 hearts.  
In contrast, EC-specific endoglin knockdown in the first week of postnatal life (which is known 
to lead to retinal AVMs) was associated with the development of eccentric cardiomyopathy and 
cardiomyocytes (CM) hypertrophy, but no obvious coronary vasculature defects. Deletion of 
endoglin in venous ECs and capillaries in first week of postnatal life also led to development 
of AVMs in P11 retinas coupled with the development of cardiac hypertrophy. A similar 
eccentric cardiomyopathy phenotype with CM hypertrophy was observed after endoglin 
deletion in adult ECs (Eng-iKOEC). Microbeads were used to show increased vascular shunting 
in the systemic but not the pulmonary vasculature of Eng-iKOEC mice. Ultimately Eng-iKOEC 
mice developed high output heart failure due to reduced vascular resistance cause by systemic 
AVMs. This data confirms that endoglin is vital for maintaining the adult vasculature.  
Finally, I analysed the role of endoglin in a heterogeneous population of cardiac derived stem 
cells known as cardiosphere derived cells (CDCs). CDCs express endoglin which I showed is 
vital for their pro-angiogenic paracrine effect when delivered to the infarcted heart. 
Furthermore, endoglin not only promotes paracrine mediated proliferation of ECs in the infarct 
zone but also helps in maturation of the neo-vasculature by recruitment of smooth muscle cells.  
In conclusion, the results from this thesis show the critical importance of endoglin in the 
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1.1. Heart Development 
The heart is the first organ to form in a vertebrate embryo. It has a mesoderm origin and requires 
various progenitor cells during the course of development. The mouse and the avian heart have 
been intensively studied as models of cardiac development [reviewed in (1, 2)]. In mammals, 
heart development begins with the formation of a cardiac crescent at the midline of the embryo 
at embryonic day 7.5 (E7.5) in mice. At around E8.0, the crescent then transforms into the linear 
tube which consists of a myocardial layer and an inner endocardial layer, separated by cardiac 
jelly (3). This linear tube then undergoes the process of looping between E8.5 to E10.0 in mice 
to form a primitive heart structure (Figure 1). The tube is elongated by the addition of progenitor 
cells (second heart field cells) at the atrial and venous poles of the heart. By E9.5, various other 
structures start to appear, including sinus venosus (SV, draining systemic blood into the 
common atrial chamber), atrioventricular (AV) canal (initial connection between common atrial 
chamber and left ventricle) and bulboventricular canal (connection between the primitive 
ventricles). The outflow tract (OFT) also connects to the primitive right ventricle by E9.5. 
Subsequently, the atrial chambers expand on both sides of the atrial pole while ventricle 
development occurs in the looping region via the process of ballooning. During ballooning, the 
interventricular septum (IVS) starts to form between the ventricles. Around the same time, 
formation of the endocardial cardiac cushions occurs in the AV canal (develop into AV valves) 
and in the common OFT [develop into semilunar (SL) valves]. Endocardial cushion formation 
is followed by the septation of the OFT and valve formation. Finally, the heart is remodelled to 
form the four chambered heart (Figure 1.1) [reviewed in (1, 2)]. 
 
Figure 1.1: Schematic of mice heart development [adapted from (4)]: Heart development begins with a 
formation of a cardiac crescent around E7.5/ E8.0 in mouse (A). This then forms a linear tube like structure (B) 
which then undergoes the process of looping (C) and ballooning (D) to form a four-chamber heart (E). 
Abbreviations: OFT - Outflow tract; IFT - Inflow tract; EV - embryonic ventricle; a - atria; AVC - Atrioventricular 




1.2. Vasculogenesis and Angiogenesis during Development 
The circulatory system provides the required nutrients and gasses for the growing embryo. The 
formation of vessels occurs by three processes: first vasculogenesis followed by angiogenesis 
and finally arteriogenesis. By definition, vasculogenesis is “the de novo formation of blood 
vessels by the formation of primary endothelial plexus” (5). Angiogenesis is “the process of 
blood vessel formation from these pre-existing plexus and expansion of the vasculature” (5). 
Primitive arteries are then matured to cope with the circulatory system by the process of 
arteriogenesis [reviewed in (6-8)].  
Vasculogenesis begins in the embryonic mesoderm, extra-embryonic yolk sac, allantois and 
placenta (9), with the formation of blood island-like structures around E6.5 in the yolk sac just 
after the formation of the cardiac crescent (10). Hemangioblasts in the extra-embryonic yolk 
cells, give rise to these blood islands which later on fuse with each other to form the initial 
endothelial plexus (11). These blood islands consist of two types of precursor cells: angioblasts 
and haematopoietic cells. The angioblasts differentiate to form endothelial cells (ECs) which 
then form primitive tube-like structures in the embryo which then undergo network remodelling 
to form a secondary plexus (11, 12).  
The process of coronary vasculogenesis is controlled by many factors. An in vitro analysis 
showed that vascular endothelial growth factor (VEGF) and its receptors are vital for the 
process of vasculogenesis (13, 14). VEGF-A, a vascular permeability factor (15) is important 
for vasculogenesis. VEGF is expressed in the extra-embryonic visceral endoderm and in the 
extra-embryonic mesoderm. At E8.5, strong VEGF expression is noted in the endodermal cells 
in contrast to the lower expression in the mesodermal cells during intra-embryonic endothelial 
plexus formation. Deletion of even one of the VEGF alleles led to embryonic lethality by E11 
due to vasculogenesis defects (16, 17). The VEGF receptor 2 (also known as flk1) null mice 
resulted in absence of vasculogenesis causing complete embryonic lethality by E8.5 or E9.5 
(18). On the other hand, the VEGF receptor 1 (also known as flt1) null mice lack the proper 
organisation of the blood islands causing disruption in the localization of angioblasts and ECs 
(19). Remodelling and expansion of the vessels via angiogenesis can occur either by sprouting 
angiogenesis or by intussusceptive angiogenesis (IA) (Figure 1.2). In mice, angiogenesis begins 
around E9.5 and is responsible for the formation of majority of blood vessels in an embryo 




Figure 1.2: Process of Vasculogenesis and Angiogenesis [adapted from (20)]: Formation of blood vessels in 
embryos start by recruitment of angioblasts (A) to form initial endothelial plexus (B) by the process of 
vasculogenesis. These initial plexuses are then expanded and remodelled via angiogenesis process (C). Vessels 
expansion by angiogenesis can occur by two ways: (D) Sprouting angiogenesis or (E) intussusceptive 
angiogenesis. 
The mechanisms of angiogenesis have been reviewed extensively (6-8, 21, 22). Briefly, in 
sprouting angiogenesis (Figure 1.2D) new capillaries develop by the formation of endothelial 
sprouts from the pre-existing vessels. This process is initiated by degradation of the basement 
membrane of the nascent vessels and migration of ECs in response to the angiogenic stimuli 
(e.g. hypoxia or VEGF). The ECs align and form a stalk like structure. The tip of this stalk like 
structure contains specialised ECs, known as “tip cells”. These tip cells respond to the 
angiogenic stimulus and migrate towards it. This migration of the tip cell ECs is paired with 
proliferation of the stalk ECs which results in the formation of a vessel lumen. The vessel is 
then stabilised by deposition of vascular smooth muscle cells (vSMCs) and adventitial 
fibroblasts. Blood flow in these vessels begins soon after the formation of the lumen. While in 
case of IA (Figure 1.2E), the expansion of the vascular network occurs by division of the pre-
existing vessel by forming a tissue column in the middle [reviewed in (6, 7)]. In mouse, the 
process of coronary vasculogenesis is completed by mid-gestation while the process of 
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angiogenesis and arteriogenesis of the vessels continue until three weeks of postnatal life 
[reviewed in (23)]. 
Many signalling molecules have been shown to play an important role during the process of 
angiogenesis including VEGF (discussed above) and Notch signalling pathway. Notch 
signalling controls sprouting of the ECs. In vessels, Notch receptor 1 and 4 are expressed in the 
endothelium while Notch receptor 3 is expressed in vSMCs. Various ligands of Notch signalling 
have been also observed in vessels including Jagged1, Jagged2, Delta like ligand (Dll) 1, Dll3 
and Dll4 (24). Notch1 null mice die by E11 due to vessel degradation and abnormal vessel 
remodelling although the initial primary endothelial plexus was formed normally (25). 
Homozygous deletion of both Notch1 and Notch4 showed severe defects as compared to Notch1 
deletion alone including defects in the major vessels (25). Continuous Notch-4 signalling in 
ECs led to embryonic lethality by E10 due to impaired vessel formation (26). Dll4 has been 
shown to bind to both Notch 1 and 4 (expressed in ECs) and is critical for angiogenesis as 
deletion of a single allele of Dll4 resulted in embryonic lethality by E10.5 due vascular 
remodelling defects (27). The expression of Dll4 and Notch signalling has been shown to be 
controlled by VEGF (28) and blockage of VEGF has been shown to cause reduced levels of 
Dll4 in vessels and inhibited sprouting (29). Notch signalling has also been shown to act as a 
negative feedback of the VEGF signalling as activation of Notch signalling in ECs led to 
reduced VEGF receptor 2 (VEGFR2) (29).  
Once the vasculature is formed, it undergoes maturation. This step is critical for stabilisation of 
vessels and for proper functioning of the vessels. During this phase, vSMCs and fibroblasts are 
deposited over the endothelium. Improper or incomplete deposition of either of vSMCs or 
fibroblasts can lead to hyper-permeable vessels which can lead to the formation of oedema 
leading to developmental defects. Several factors are involved during the maturation of vessels 
as well. For instance, platelet derived growth factor (PDGF) is important for recruitment of 
vSMCs. Mice lacking PDGFB or PDGF receptor β (PDGFRβ) led to embryonic lethality due 
to reduced number of vSMCs causing hyper-permeable vessels and oedema (30). 
Another factor which plays a major role during vasculature development is hypoxia. Hypoxia-
inducible factor (HIF) is a transcription factor and consists of two subunits: HIF-1β and HIF-
1α. Under normal oxygen levels (normoxia), HIF-1α is degraded, while in hypoxic conditions 
HIF-1α is expressed during development or in ischemic conditions (31). Embryos lacking HIF-
1α die by mid-gestation, because of vasculature related abnormalities in yolk sac and in the 
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embryo (32), while overexpression of HIF-1α led to an increase in various factors including 
VEGF and PDGF causing significant increase in neovascularisation (31).  
1.2.1. Anatomy of Mature Coronary Circulation 
The fate of blood vessels is decided by the expression of ephrin family protein and their Eph 
receptors. Endothelium expression of ephrinB2 is seen in developing arteries while expression 
of its receptor EphB4 is restricted to endothelium of the developing veins (33). Lack of any of 
these two led to embryonic lethality by E10.5 due to vascular defects in both the yolk sac and 
embryo itself. It is also shown that Ephrin guides the arteriovenous anastomoses by inhibition 
of ECs simulation by VEGF and angiopoietin1 (33, 34). Arteries and veins also show 
differential expression of members of the Notch signalling family. For example, Notch3, Dll4 
and Gridlock expression is restricted to arteries. In addition, Neuropilin-1 expression is 
restricted to endothelium of the arteries while Neuropilin-2 expression is shown to be restricted 
to venous endothelium (35).  
The mature mammalian coronary circulation consists of two parts: an arterial system and a 
venous system (Figure 1.3). The major arteries and veins branch out to form various small 
vessels which then give rise to capillaries to supply blood to cardiomyocytes (36). 
 
Figure 1.3: Coronary circulation tree [Based on the data from (36, 37)] 
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1.2.1.1. Coronary Arteries 
Coronary arteries supply oxygenated blood to myocardium and are connected to the aorta via 
the coronary ostium (Figure 1.4). These arteries do not grow out of the aorta rather they grow 
into the aorta at their ostium (38). There is variability from person to person between the precise 
anatomy of coronary arteries and their connection to the aorta.  
 
Figure 1.4: Coronary arteries and their attachment at the aorta (ostium). 
There are two main coronary arteries (Figure 1.5): right coronary artery (RCA) and left 
coronary artery (LCA). The RCA during its course from the ostium to the crux (the point where 
the AV groove meets the interventricular groove) gives rise to multiple branches which further 
branch out to give oxygenated blood to the majority of the right side of the heart (Figure 1.5). 
Clinically, the RCA is divided into three parts: first segment, mid segment and distal segment 
(36). 
The LCA also known as the left main coronary artery travels laterally between the base of the 
pulmonary trunk and left atrium (Figure 1.5). The LCA and its branches [the Left Anterior 
Descending artery (LAD) and the Left Circumflex artery (LCx)] are responsible for majority 
of circulation of the left side of the heart (Figure 1.5). The LAD is responsible for supply blood 
to the left ventricular (LV) and IVS in human (36). In contrast, IVS is supplied by a separate 
septal coronary artery in mice originating from the right sinus of Valsalva or from the right 




Figure 1.5: Coronary arteries [taken from (40)] 
1.2.1.2. Coronary Veins 
The coronary veins drain the deoxygenated blood and metabolic waste from the heart into the 
right atria of the heart. The blood pressure in coronary veins is low compared to the coronary 
arteries. The coronary veins also contain valves to prevent the back flow of blood. Presence of 
these valves and lower blood pressure reduce the risk of stress related injuries in veins in 
comparison to arteries. These factors also make coronary veins less prone to atherosclerotic 
plaque (41, 42). 
The majority of the coronary veins drain the venous blood in the coronary sinus with some 
draining directly into the right atria (Figure 1.6). The coronary sinus then empties the blood into 




Figure 1.6: Coronary Veins [taken from (40)] 
1.3. Cells in Coronary Vessels Development 
The need of blood circulation within the myocardium is no different from other parts of the 
body; it is required to exchange gases and nutrients. At the beginning of heart development, at 
the primitive heart tube stage (E9.5 in mouse; Figure 1.1), there is no need for coronary vessels 
as nutrients and gases can be exchanged through simple diffusion. But as the thickness of the 
myocardium increases and the simple tubular structure turns into a complex organ, the need for 
a coronary circulation becomes critical as without the gases and nutrient exchange, the 
myocardial cells will die due to ischemia and necrosis. Development of the coronary 
vasculature in mouse begins with formation of vascular plexus around E11.5 (Figure 1.7) and 
continues through the process of angiogenesis until three weeks in post-natal life (43, 44). In 
an adult heart, nearly of all the cardiomyocytes are closely associated with coronary capillaries 
(45, 46). Coronary vessels are primarily composed of three types of cells: ECs, vSMCs and 





Figure 1.7: Development of Coronary Vasculature [adapted from (43)]. (A) During the process of coronary 
vessel development, endothelial cells (ECs) first start to migrate from sinus venosus on to the myocardium around 
E11.5. These ECs migrate into the myocardium from the sub-epicardial side. (B) ECs originating from the 
endocardium migrate inwards around E14.5. (C) After anastomosis of the coronaries with aorta, coronary vessels 
can be observed throughout the myocardium around E15.5. (D) These vessels then under maturation to form the 
coronary vessel network observed in the adult hearts Abbreviations: la – Left Atria; sv – Sinus venosus; ra – Right 
Atria; lv – Let Ventricle; rv – Right Ventricle; ot – Outflow tract; avc – Atrioventricular canal; rca – Right 
Coronary Artery; lca – Left coronary artery; cv – coronary vein; and cap – Capillaries. 
1.3.1. Role of Epicardium in Coronary Vessel Development 
The epicardium is the outer layer of the heart, covering the myocardium (Figure 1.8); it consists 
of connective tissue and epithelial cells. The epicardium is derived from an extra-cardiac cell 




Figure 1.8: Layers of the Heart [based on data from (47)]. The trabecular layer of the heart consists of two 
layers: myocardium and endocardium. The myocardium is covered by next layer called as the epicardium. The 
myocardium and epicardium are separated by a sub-epicardial space filled with extracellular matrix. The 
epicardium is covered by another layer called as the pericardium. 
The proepicardium cells that originate from the splanchnic mesoderm near the inflow region of 
the heart forms the epicardium that covers the heart chambers (Red, Figure 1.9) while 
proepicardial cells generated from the splanchnic mesoderm near the outflow pole form 
epicardium over the OFT (Green, Figure 1.9) (50).  
 
Figure 1.9: Heart with epicardium from two different sources (Red and Green) [Adapted from (47)]. 
Abbreviations: RA – Right Atria; RV – Right Ventricle; LA – Left Atria; LV – Left Ventricle; AVC – 
Atrioventricular Canal; OFT – Outflow Tract. 
The process of epicardium formation has been extensively reviewed (23, 47-50). Briefly, 
formation of the epicardium begins around during the process of looping of the heart with the 
migration of the proepicardial progenitor cells on the surface of the heart. In mice, migration of 
these progenitor cells occurs via formation of protrusions at the posterior surface of the 
pericardial cavity which cross the coelom to reach the surface of the heart at E9.5 (51, 52). The 
septum transversum releases free-floating aggregates of epicardial cells that float across and 
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attach onto the myocardium and subsequently spread out to form the complete epicardium (53). 
The AV and the interventricular grooves are the initial regions to be covered by this single layer 
of epicardial cells in mice. The ventricles are covered next, followed by the atria and then the 
OFT. The whole heart in mice is covered by epicardium by E10.5 (53). OFT epicardial cells 
generally do not undergo EMT while the epicardial cells over the heart chamber do undergo 
EMT to form mesenchymal like cells known as epicardially derived cells (EPDCs) (50).  
1.3.1.1. Epicardial EMT & Importance in Coronary Vessel Development 
The epicardium and the myocardium are not in direct contact but are separated by the sub-
epicardial space filled with extracellular matrix (ECM) produced by the epicardium and 
myocardium by E12.5 in mice (Figure 1.8) (46). This sub-epicardial space is rapidly filled by 
EPDCs formed by epicardial to mesenchymal transition (EMT) of epicardium cells. The EPDCs 
first fill the sub-epicardial space then start to invade the myocardium around E12.0 (54). This 
process of myocardial invasion of EPDCs occurs in parallel to myocardial wall thickening and 
is important for myocardium layer compaction and maturation (49).  
Not all of the epicardial cells undergo EMT, according to Pérez-Pomares and de la Pompa (55); 
epicardial cells which can undergo EMT are either genetically predisposed or exposed to local 
signals. Several signalling pathways are involved in the activation of epicardial cell EMT. 
These signals work in a coordinated manner to down-regulate epithelial cell markers, promote 
mesenchyme marker expression, reorganise the cytoskeleton and the ECM. The Wilms’ tumor 
1 (Wt1) gene plays a major role in the EMT of epicardial cells; it is expressed in the early 
proepicardium, in the epicardium and in EPDCs (56, 57). During the process of epicardial EMT, 
TGFβ (Transforming Growth Factor Beta) signalling  also plays an important role by activating 
ALK5 receptor [activin receptor-like kinase, TGFβ type 1 receptor (58-60)] and promotes 
expression of genes such as Pai-1 and Snai1 (Figure 1.10A). These genes in turn supresses 
epicardial markers such as β-catenin & VCAM-1 (vascular cell adhesion protein-1) and 
promotes the expression of mesenchymal markers such as phalloidin & αSMA (Figure 1.10B) 




Figure 1.10: During Epicardial EMT, TGFβ signalling occurs via ALK5 Mediated Type 1 Receptor 
[adapted from (20, 64)]. (A) Activated TGFβ ligand activate TGFβR2 which in turn phosphorylates ALK5 type 
1 receptor. This pathway then leads to expression of Pai-1 and Snai1 which in turns promotes the epicardial cell 
EMT. (B) Snai1 triggers the expression of mesenchymal marker such as phalloidin and αSMA in EPDCs and 
inhibit the expression epicardial markers such as β-cateinin and VCAM-1. 
1.3.1.2. EPDCs in Coronary Vessel Development 
Lineage tracing experiments using both avian and mammalian models showed that EPDCs 
differentiate majorly into vSMCs of coronary vessels and fibroblast cells (Figure 1.11) (54, 70-
75). In avian models, a significant percentage of ECs also arise from differentiated EPDCs (76, 
77) while in mammals, only a minimal percentage of EPDCs differentiate into ECs (43, 44, 73, 
78, 79). Furthermore, some studies have shown that EPDCs also differentiate into 
cardiomyocytes (78, 80, 81) however this contribution is still debatable (82, 83).  
 
Figure 1.11: Fate of epicardial cells: Epicardial cells undergo EMT under the influence of signalling proteins to 
form EPDCs. These EPDCs then differentiate into vSMCs, fibroblasts, ECs (minor contribution in mammals) and 
may be cardiomyocytes depending upon the interaction with various signalling factors.  
The differentiation of EPDCs begins as soon as they come in contact with the factors in the 
subepicardial space provided by the epicardium, EPDCs themselves, and the adjacent 
myocardium [reviewed in (23, 55, 84-86)]. Table 1.1 lists a few of the differentiating factors 
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and their expression pattern in developing heart. These factors are essential during the EPDCs 
differentiation and can cause to mild to severe phenotypic effects in their absence (Table 1.1). 
Table 1.1: Molecules Involved in EPDCs differentiation during coronary vasculature development. 
Name Expression Phenotype in the coronary vascular system 
α4 integrin PEO & epicardium (87) 
Mutant embryos lacked epicardium & suffer pericardium 
haemorrhage (88, 89) 
Bves 
PEO, migrating epicardium, 
EPDCs & vSMCs (90) 
Treatment with anti-Bves antibodies inhibit epicardial 
migration of vasculogenic cells from the proepicardium in 
vitro. In vivo, lack of Bves leads to abnormal epithelial 
cell integrity (91, 92). 
Connexin43 PEO, epicardium & vSMCs (93) 
Increased migration & proliferation rate of pro-epicardial 
cells. Abnormal migration of fibroblast & vSMCs, 
resulted in multiple coronary artery patterning defects (93) 
EPO & 
EPOR 
EPOR expressed in epicardium 
& pericardium (94) 
Detached epicardium, abnormal vascular network & 
reduced number of cardiomyocytes (94) 
Ets-1/Ets-2 
EPDCs & cushion mesenchyme 
(95) 
Thinner epicardium, reduced number of EPDCs, lack of 
vSMCs in the peripheral coronary arteries, disorganised 
coronary arteries & capillaries (95) 
FGF 
Several FGF ligands & receptors 
are expressed in pro-epicardium 
(96) 
Neutralizing antibodies to basic FGF inhibit capillary 
formation & arteriolar growth [reviewed in (97)]. 
FOG-2 
At E8.5, in ventral tube & 
septum transversum. Later on, in 
atria, ventricles & pericardium 
(98) 
FOG-2 knockdown mutants displayed intact epicardium 
however coronary vasculature was absent due to lack of 
sub-epicardial mesenchyme & endothelium (98). 
GATA-4 
Epicardium, endocardium & 
myocardium of developing heart 
(99) 
Incorrect cardiac looping, lack of epicardium due 
improper pro-epicardium migration, thin myocardium & 
lack of endocardial cushions (99). 
MRTF A & 
B 
Epicardium, EPDCs & 
endocardium (100) 
Detached & disorganised epicardium, reduced EPDCs 
migration, incomplete coronary vessels penetration over 
ventricles & reduced number of pericytes (100). 
NPHS1 
Epicardium & coronary vessels 
during embryonic development 
(101) 
Nephrin knockout embryos showed abnormal epicardial 
cell morphology & reduced number of coronary vessels 
(101) 
rhoA-RhoK 
Myocardium (atria & ventricles), 
trabeculae, endocardial cushions 
& OFT (102) 
Treatment with inhibitor Y27632, hindered cardiac 
looping process, prevented expression of coronary vSMCs 
makers on migrating EPDCs & trabeculae formation (102, 
103). 
SRF 
Epicardium, EPDCs & vSMCs 
(100) 
Prevent vSMCs marker expression in vitro & in vivo. In 
vivo time course study revealed failed EPDCs migration 
(100, 103, 104). 
VCAM-1 Cardiomyocytes (105) 
Lack epicardium, thinner myocardium & suffer from 
pericardium haemorrhage (106). 
VEGF -A 
ECs of highly vascular regions of 
the developing heart (16, 107) 
Neutralizing antibodies to VEGF inhibit capillary 
formation and arteriolar growth. Regulated endogenous 
VEGF is vital for vascular patterning and lumen size 
regulation. Changes in the expression pattern led to severe 
cardiac abnormalities including absence of coronary 
plexus & was fatal by E12.5 to E14.5 (108-111). 
VEGF-B 
Developing myocardium, OFT, 
dorsal aorta & pericardium (112) 
Healthy and fertile, however reduced heart size & 
impaired coronary growth post MI (113). 
VEGF-C Epicardium (44) 
Absence inhibited coronary growth in dorsal & lateral side 





ECs (16, 19, 114) 
Essential during the organization of embryonic 
vasculature, however is not important for ECs 
differentiation. The absence of VEGFR1 induces an 




ECs & endocardium (16, 115) 
Endocardium specific knockdown led to lack of coronary 
plexus, defective coronary arterial network & pericardium 
haemorrhage (111) 
Wt1 
PEO, epicardium & EPDCs (56, 
116, 117) 
Epicardial cells fail to undergo EMT (116, 118) 
Abbreviations: Bves – Blood vessel epicardial substance; EPO – Erythropoietin; EPOR - EPO Receptor; FGF 
– Fibroblasts Growth Factor; FOG-2 – Friend of GATA, MRTF – Myocardin related transcription factor; 
NPHS1 – Nephrin; RhoK – Rho-associated protein kinase; SRF – Serum Response Factor; VCAM – Vascular 
Cell Adhesion Molecule; VEGF – Vascular Endothelial Growth Factor; VEGFR – VEGF Receptor; Wt1 – 
Wilms tumor 1 
 
1.3.2. Origin of the Endothelial Component of Coronary Vessels 
The development of coronary vessels starts around E11.5 in mice (43, 44). As the cardiac 
development progresses, the coronary arterial network is formed in the myocardium while 
coronary veins are formed in the sub-epicardial space (43, 119). The origin of coronary ECs is 
controversial. However, results from the past two decades showed that coronary ECs potentially 
arise from three different sources (Figure 1.14): (i) SV [sinus venosus, (41, 42, 67)]; (ii) 
endocardium (67, 99, 108) and (iii) epicardium (41, 42, 61, 66, 67). 
Red-Horse et al. (43) performed immuno-histochemical and clonal analysis to determine the 
origin of the ECs of the coronary vessels. Using the apelin-nlacZ knock-in mouse to specifically 
mark coronary ECs in mouse embryo hearts, followed by Xgal wholemount analysis at various 
time points (E11.5 to E15.5) they showed that coronary vasculature formation begins near the 
SV. Red-Horse et al. (43) also showed that the interaction between the SV and the ventricular 
epicardium is important for ECs sprouting from the SV via their functional culture assay on 
E10.5 apelin-nlacZ mice hearts (43). Furthermore, this SV origin of the coronary vasculature 
was confirmed by repeating the experiment using VE-cadherin-creER; brainbow transgenic 
mice that marked the VE-cadherin+ ECs clones with different multicolour markers. The marker 
analysis showed that VE-cadherin+ cells originate in the SV and migrate into the myocardium 
between E12.5 to E14.5 (43).  
These VE-cadherin+ cells expressed venous markers (like EphB4) when they sprout from the 
SV but as these ECs migrate towards the myocardium and differentiate to form coronary arteries 
ECs, venous marker expression was reduced and expression of arterial marker like ephrinB, 
Dll4 and Notch4 increased. The ECs that remain in the sub-epicardial region form mature 
coronary veins (43). During the histological analysis of apelin-nlacZ mice, Red-horse and 
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colleagues (43) also found isolated clusters of ECs in the interventricular groove at E15.5. These 
clusters have been termed as blood islands in the past and have an unknown origin. In this study, 
it is speculated that these clusters may have an endocardial origin (43). 
Chen et al. (44) and Tian et al. (79) supported this SV and endocardial contribution to coronary 
ECs using immuno-histochemical and clonal analysis of AplnCreERT2; embryo hearts at various 
stages of development (E11.5 to E15.5) using different reporters (Rosa26LacZ, Rosa26RFP and 
Rosa26mTmG). They showed that the majority of coronary vessel ECs (both arteries and veins) 
are formed by the sub-epicardial ECs of the nascent coronary plexus. The sub-epicardial vessels 
migrate into the myocardium to form coronary arteries and the vessels that remained in the sub-
epicardial space contributes to the formation of coronary veins (79). During these clonal 
analysis studies, they found that the ECs in the IVS do not form from the sub-epicardial ECs. 
They speculated that these ECs or blood islands in the IVS may have an endocardial origin(79).   
In a contrasting study, Wu et al. (111) used various in-vivo and in-vitro analyses to show that 
ECs of coronary arteries primarily arise from the endocardium of the heart. They showed that 
the endocardium of the heart is not terminally differentiated but retains angiogenic potential. 
Immuno-histochemical and clonal analysis of endocardial cells and their descendants using a 
Nfatc1-cre mouse line (Nfatc1 is an endocardial specific marker in the heart) from E11.5 to 
E16.5 revealed that approximately 80% of coronary artery ECs have an endocardial origin while 
only a third of coronary vein ECs were derived from endocardium (111). However this 
conclusion was challenged by a recent publication showing nascent expression of Nfatc1-Cre 
in SV (120).  
Using a more endocardial specific promoter (Npr3) to drive Cre expression, Zhang et al. (120) 
showed GFP (Cre-reporter) expression only in the ventricular endocardium until E10.5 (120). 
As the development of coronary vessels development begins, GFP expression was observed in 
these vessels at E14.5 and E15.5. However, in contrast to earlier studies significantly reduced 
number of coronary vessels ECs were observed to arise via the endocardial route (120). A 
majority of these endocardially originating coronary vessel ECs were observed in the IVS with 





Figure 1.12: Potential origin of coronary endothelial cells through three different progenitor cells [adapted 
from (121)]. Cartoon showing embryonic heart structure at (A) E9.5 and (B) E13.5. (C) Epicardial Origin: At 
E9.5, progenitor cells migrate towards developing heart to form epicardium. The epicardial cells then undergo 
EMT to form EPDCs around E11.5. These EPDCs then invade the myocardium and differentiate primarily into 
SMCs and fibroblasts with a minor contribution towards ECs. (D) Sinus Venosus Origin: SV is potentially the 
major source of coronary ECs. At E10.5, ECs migrate from SV endothelium towards atria (black arrow) and 
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ventricular (black arrowhead) myocardium contribute towards most of the coronary ECs in the free ventricular 
walls. These migrating ECs initially observed to express venous ECs markers. However, as ECs to migrate deeper 
into the myocardium, venous markers are replaced with atrial markers. Thus, indicating origin of coronary atrial 
ECs via coronary vein ECs. (E) Endocardial Origin: There is controversial evidence regarding the percentage of 
ECs originating via endocardium. It is speculated that endocardium either undergo budding, sprouting or EndMT 
to form coronary ECs. It is also suggested that the endocardium contributes towards coronary ECs primarily in the 
IVS during development and in trabeculae compaction during postnatal heart development.  Abbreviations: A –
Atria; AVC – AtrioVentricular Canal; CA – Coronary Arteries; CV – Coronary Veins; EPDCs – EPicardially 
Derived Cells; Epi – Epicardium; LP – Liver Permodia; LV – Left Ventricle; OFT – OutFlow Tract; PEO – 
ProEpicardial Organ; RV – Right Ventricle; SMCs – Smooth Muscle Cells; SV – Sinus Venosus. 
In a study by Tian et al. (122), it is postulated that formation of the coronary vessels occurs in 
three waves (Figure 1.13). They showed that, the first wave for coronary development starts 
around E10.5, second wave starts around E13.5 in parallel to myocardium thickening and the 
final wave starts in early post-natal life in parallel to trabeculae compaction (122). They also 
proposed that coronary vessels formed in the outer part of free ventricular wall are formed 
during the first wave, vessels in the IVS are formed during the second wave while the vessels 
in the trabeculated myocardium are formed during the third wave in post-natal life (122). 
 
Figure 1.13: Different waves of Coronary Vessels formation during mouse heart development and in post-
natal life [adapted from (122)]. During coronary vessels development, vessels in the outer ventricle wall are 
formed during the first wave; during second wave, in the IVS and in the third wave in the inner ventricle wall.  
1.4. TGFβ and Endoglin in Coronary Vasculature Development 
1.4.1. TGFβ Ligands and its Receptors  
TGFβ signalling is known to be involved in regulation of many cellular functions including 
proliferation, differentiation, migration and survival of many cell types. In mammals, TGFβ 
superfamily consist of various ligands including TGFβs, bone morphogenetic proteins (BMPs) 
and growth & differentiation factors (GDFs). These ligands are formed in latent form and are 
activated prior to signalling by cleavage of the latent unit with the help of proteases such as 
proprotein convertases [reviewed in (123-125)]. During the signalling cascade, activated ligand 
binds to a high affinity TGFβ type 2 receptor which then recruits and phosphorylates a specific 
TGFβ type 1 receptor. Canonical signalling involves phosphorylation of SMADs by the type 1 
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receptor while non-canonical signalling occurs by phosphorylation of ERK, PI3K/AKT, JNK 
or p38 MAP kinases [reviewed in (123, 125, 126)].  
In mammals, there are seven kinds of type 1 receptors (ALK 1, 2, 3, 4, 5, 6 and 7) and five 
kinds of type 2 receptors (TGFΒR2, BMPR2, ACVR2A, ACVR2B and AMHR2) [reviewed in 
(123-125)]. The molecular structure of both TGFβ type 1 and type 2 receptors are quite similar 
(Figure 1.14A). The extra-cellular domain of both receptors consists of a small cysteine rich 
region followed by a single trans-membrane sequence. The intracellular domain of both the 
receptors consists of serine/threonine kinases. In case of type 1 receptor, a GS domain is also 
present (site for phosphorylation by type 2 receptor). The two type 1 and 2 receptors exist as 
homodimers (monomers linked by disulphide bonds) on the cell surface. During signalling, 
these homodimers combine to form a heterodimer complex [reviewed in (123, 125)].  
 
Figure 1.14: Structure of TGFβ receptor [adapted from (123)]. (A) Cartoon of TGFβ type 1 and 2 receptor 
showing extracellular and intracellular domain of the receptors. (B) Cartoon of TGFβ type 3/ co-receptor: Endoglin 
and β-glycan. 
During the TGFβ signalling process, type 3 co-receptors (β-glycan and endoglin) are also 
involved. The interaction of type 1 and type 2 TGFβ receptors is influenced by type 3 co-
receptors. The two co-receptors, β-glycan and endoglin are trans-membrane receptors with 
similar molecular structure. In both co-receptors, a large extracellular domain is present 
followed by a hydrophobic transmembrane domain and a short intracellular domain (Figure 
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1.14B). In case of endoglin, monomer units are linked via disulphide bonds while β-glycan 
monomer units are connected by non-covalent interactions [reviewed in (123, 125)].  
1.4.2. Endoglin: TGFβ type 3 co-receptor 
Endoglin also known as CD105 is critical for proper angiogenesis. Knockout of endoglin leads 
to complete mortality around E10.5 due to angiogenic defects (problems with SMCs 
recruitment) in both the embryo (heart & body) and the yolk sacs (127-129). 
Human endoglin is an 180KDa homodimeric disulphide linked trans-membrane glycoprotein 
(130). The 14 exon endoglin gene in humans is located on chromosome 9q34 and encodes a 
protein of 658 amino acids (131) and belongs to the ZP (zona pellucida) family of proteins. The 
structure of human endoglin has recently studied in a great detail by Saito et al. (130). 
Structurally, human endoglin is composed of a large extracellular domain, followed by a single 
transmembrane domain and a small intracellular domain (Figure 1.15). The extracellular N-
terminal consists of an orphan region (OR1 & OR2 with 18% identical sequence and 102 
overlapping residues) while the C-terminal consist of ZP domain [~260 amino residues, (130) 
and reviewed in (126, 131-133)]. Endoglin has shown to have higher affinity towards BMP9/ 
BMP10 (130, 134). During the signalling pathway the highly conserved Q270 and I271 residues 
of OR1 domain of endoglin had shown to be essential for binding with conserved regions of 
BMP9/10 (130). Once BMP9/10 binds to the OR1, the ZP domain next aids in dimerization of 
the complex (130). In humans, the extracellular domain also contains an Arg-Gly-Asp (RGD) 
tripeptide and glycosylation sites (four N-linked and one O-linked) and is a cell-recognition site 
for various cell adhesion proteins present in the ECM (126, 130-133). This RGD peptide is 
absent in murine, porcine, rat and canine endoglin. In ECs, the two monomer units of the 
homodimeric endoglin protein are arranged in an anti-parallel fashion to form a dome like 
structure with a cavity at one end [reviewed in (126, 131-133)].   
The intracellular domain of endoglin contains a PDZ domain-binding motif (Ser-Ser-Met-Ala) 
which regulates EC migration by interacting with the scaffolding protein synectin [GAIP (Gα-
interacting protein) – interacting protein C-terminus, GIPC]. The intracellular domain of 
endoglin does not have any enzymatic motifs but contains many serine/threonine residues. The 
phosphorylation of these residues by TGFβ receptors occurs at specific sites. In ECs, TGFBR2 
phosphorylates endoglin at Ser634 and Ser635 followed by phosphorylation on Thr640, Thr647 and 
Thr654 by ALK1. On the other hand, ALK5 phosphorylates endoglin at Ser646 and Ser649. The 
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reason for the phosphorylation of these endoglin residues is still unclear but is said to be crucial 
for TGFβ mediated signalling in ECs [reviewed in (126, 133)]. 
 
Figure 1.15: Structure of Endoglin [adapted from (126, 130)]. The extracellular (EC) region of the endoglin 
protein composed of orphan regions (OR1 and OR2) at the N-terminal end followed by a zona pellucida region 
(ZP-N and ZP-C) at the C-terminal end. The endoglin protein also consist of a trans-membrane region followed 
by small intra-cellular (IC) domain comprises of PDZ motifs. 
There are two isoforms of endoglin observed in humans, L-endoglin (long-endoglin) and S-
endoglin (short-endoglin) with differences in the length of their intracellular domain, 
distribution in tissues and degree of phosphorylation (Figure 1.16). L-endoglin has an 
intracellular domain of 47 residues is present dominantly in the ECs and promotes angiogenesis 
(Figure 1.16A). While S-endoglin on the other hand contains only 14 residues (Figure 1.16C), 
is expressed significantly in lungs and liver and has been shown to have an anti-apoptotic effect.  
S-endoglin is formed by alternate splicing mechanism regulated by ASF (alternate splicing 
factor) and SF-2 (splicing factor-2) in quiescent ECs. The L and S isoform of endoglin only 
have 7 amino acid residues in common [reviewed in (126, 131, 132)].  
The extracellular domain of endoglin, known as sol-endoglin (soluble-endoglin, Figure 1.16B) 
can also be found in the circulation. Sol-endoglin is shed from the cells and has been shown to 
have an anti-angiogenic effect [reviewed in (126, 132)]. The mechanism of formation of sol-
endoglin is not clear but it is proposed that exposure of TNFα (Tumour Necrosis Factor-α, an 
inflammatory cytokine) can lead to shedding of endoglin from ECs via MMP14 (matrix 




Figure 1.16: Molecular structure of different endoglin isoforms [adapted from (131)]. (A) Structure of pro-
angiogenic, long endoglin isoform. (B) Shedding of L-endoglin from ECs leads to formation anti-angiogenic, 
soluble endoglin isoform. (C) Anti-angiogenic, short endoglin structure is similar to L-endoglin with a smaller 
intracellular domain.   
1.4.2.1. Cellular Expression of Endoglin  
Previous studies have shown the expression of endoglin in the ECs of various specific vessels 
of developing mouse embryo e.g. dorsal aorta, branchial arches, inter-somatic vessels, cardinal 
vein, optic vessels and yolk sac (127, 129, 137). During development, endoglin is also  highly 
expressed in ECs of the endocardium and in the cardiac cushions (138). Endoglin expression is 
also observed in the syncytiotrophoblasts of the placenta and in case of pre-eclampsia the level 
of Sol-endoglin is highly elevated (139). In the haematopoietic system, endoglin is involved in 
efficient myelopoiesis and erythropoiesis. Endoglin is also shown to be expressed in adult bone 
marrow haematopoietic stem cells and termed as a functional marker of long-term repopulating 
haematopoietic stem cells (140). In postnatal and adult life, the expression of endoglin is more 
restricted. Pulmonary blood vessels express high levels of endoglin (141) while the expression 
of endoglin in some quiescent ECs is very low. This expression of endoglin in adult ECs 
increases during active phases of angiogenesis like wound healing, heart repair and tumour 
angiogenesis. (131). Other cell types like activated monocytes express endoglin and the level 
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of endoglin increases during monocyte to macrophage transition. Endoglin is also said to play 
an important role during monocyte mediated vascular repair (131).  
1.5. TGFβ and Endoglin in Coronary Vessel Development 
The development of the coronary vessels is a complex process and involves not only different 
cell populations (discussed above in section 1.2) but also different signalling pathways that 
regulate the complex series of events required to form the mature coronary vasculature.  
1.5.1. TGFβ and Endoglin in Endothelial Cells 
The TGFβ signalling pathway plays an important role in coronary vessel development. In ECs, 
canonical TGFβ signalling via SMADs phosphorylation plays a dual role (Figure 1.17). There 
are three different types of SMADs: (i) receptor regulated (R-SMADs 1, 2, 3, 5, & 8) which 
interacts with and are phosphorylated by TGFβ type 1 receptors; (ii) common mediator (Co-
SMAD 4), which interacts with phosphorylated R-SMADs to facilitate transport to the nucleus 
and (iii) inhibitory SMADs (I-SMADs 6 & 7), competitively inhibit interaction between R-
SMADs and Co-SMAD [reviewed in (123-126)]. 
During the activation phase of angiogenesis, EC proliferation and migration is promoted by 
TGFβ signalling via phosphorylation of SMAD1/5/8 via an ALK1 BMPR2 complex (Figure 
1.17). The phosphorylated SMAD1/5/8 then combines with SMAD4 and translocates to the 
nucleus to initiate transcription of pro-angiogenic genes such as inhibitor of DNA binding 1 
(Id-1) [reviewed in (123-126, 142)]. Id-1 promotes EC proliferation and migration via 




Figure 1.17: Dual role of canonical TGFβ/ BMP signalling in endothelial cells [adapted form (20)]. TGFβ 
signalling initiates by auto-phosphorylation of type 2 serine/threonine kinase under the influence of active 
TGFβ/BMP ligands. This interaction of TGFβ ligand and type 2 receptor is mediated by TGFβ type 3 receptors. 
This ligand and type 2 receptor complex then phosphorylate type 1 receptor to form heterodimer complex. This 
heterodimer complex then phosphorylates receptor SMADs (1/5/8 or 2/3) which then combines with common-
mediator SMAD4. This phosphorylated SMADs complex then translocates into the nucleus and trigger 
transcription of effector genes. In ECs, TGFβ signalling plays a dual role. In proliferative phase of ECs, active 
BMP ligands combine with BMPR2 and ALK1 receptor to phosphorylate SMAD1/5/8 which leads to transcription 
of pro-angiogenic genes such as Id1 (142). This pro-angiogenic effect of TGFβ/BMP ligands is promoted by 
endoglin. Endoglin promotes the binding of active ligands to type 2 receptor and ALK1 while suppressing ALK5 
mediated pathway at SMADs level. In contrast, during resolution phase EC or in quiescent ECs, active TGFβ 
ligands signals via SMAD2/3 by interacting with TGFβR2 and ALK5 heterodimer complex to transcribe effector 
genes such as PAI-1 (142).  
In the resolution phase of angiogenesis, EC proliferation and migration is inhibited and 
basement membrane is reformed. The vessels are then stabilised by mesenchymal cell 
recruitment and their differentiation into vSMCs and fibroblasts. This maturation of vessels is 
promoted by TGFβ signalling via ALK5 type 1 receptor (Figure 1.17). During the signalling 
process, TGFβR2 auto-phosphorylates under the influence of activated TGFβ ligand. This 
phosphorylated receptor then recruits the ALK5 type 1 receptor and phosphorylates it at the GS 
motif. This heterodimer complex then phosphorylates SMAD2/3 which then forms a complex 
with SMAD4 and translocates into the nucleus to initiate transcription of effector genes such as 
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plasminogen activator inhibitor type 1 (PAI-1) [reviewed in (123-126, 142, 144)]. In vitro 
studies showed that PAI-1 inhibits ECs proliferation and migration by interrupting FGF-2 (145) 
and/ or VEGFR2 (146) mediated angiogenesis.  
A balance between the two TGFβ mediated pathways is vital for proper vascular development 
and for maintenance during adulthood. The balance between these pathways is maintained by 
endoglin (144, 147). In vitro analysis showed that endoglin is highly expressed in actively 
proliferating ECs (144). Endoglin was also shown to be an essential component for efficient 
ALK1 mediated signalling and ECs without endoglin failed to proliferate. Endoglin stimulates 
TGFβ/ALK1 mediated SMAD1/5 phosphorylation, indirectly inhibiting the TGFβ/ALK5 
pathway (Figure 1.18). Lebrin et al. (144) also saw that reduction in endoglin levels led to 
reduced ALK5 levels suggesting a regulatory adaptation response by the ECs.  
 
Figure 1.18: Endoglin in TGFβ mediated angiogenesis [adapted from (144)]. (A) Endoglin promotes ECs 
proliferation via ALK1 type 1 receptor and inhibiting ALK5 mediated pathway at SMAD levels. (B) While in 
quiescent ECs, ALK5 mediated pathway is active. 
Hypoxia is amongst the major stimuli which promote endoglin expression in ECs. Various other 
factors have been observed to initiate the expression of endoglin and these include TGFβ, 
BMP9 and activated ALK1 [reviewed in (123)]. During TGFβ mediated signalling in ECs, 
endoglin indirectly helps in the binding of the TGFβ ligands to specific TGFβ receptors. In the 
presence of TGFβR2, endoglin is known to bind to TGFβ1 and TGFβ3 (142, 148, 149).  
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Recently, it has become clear that endoglin binds BMP9 and BMP10 ligands at much higher 
affinity compared to TGFβ ligands (130, 134). In vitro analysis in my host laboratory showed 
that loss of endoglin in mesenchymal cells led to reduced levels of phosphorylated SMAD1/5/8 
and this loss was partially rescued by treatment with active BMP9 ligands (150). In contrast, 
sol-endoglin has been observed to reduce TGFβ ligand availability by binding to the ligand 
[reviewed in (123, 126, 128).  
1.5.2. TGFβ Ligands and Receptors in Vasculature Development  
TGFβ signalling pathway plays an essential role during angiogenesis (20, 123, 125, 126, 148). 
For instance, TGFβ/ALK5 signalling has been shown to be important for the normal attachment 
of epicardium over the myocardium (60). Knockout of Alk5 in epicardial cells using Gata5-Cre 
led to formation of thinner myocardial growth with reduced proliferation rate due to improper 
attachment of epicardium (60). The Alk5-KO embryos at E18 showed ventral body 
gastroschisis and an increased number of capillaries in the myocardium. The coronary vessels 
had a defective vSMC layer due to improper vSMC differentiation. The cell adhesion molecule 
N-cadherin was also down-regulated in the mutant embryos along with reduced ZO1 junction 
protein signalling suggesting that ALK5 mediated TGFβ signalling is important for epicardium 
attachment (60). 
Smooth muscle cell specific knockout of Tgfβr2 led to coronary vessel defects and embryo 
lethality prior to birth (151-153). Immuno-histochemical analysis of mutant embryos at various 
time points (E11.5 to E18.5) after partial knockout of Tgfβr2 using SM22α-Cre showed various 
defects related to cardiac and vascular development. Severe myocardial hypoplasia was seen 
due to impairment of EPDC differentiation into vSMCs leading to lack of coronary vasculature 
formation (153).  
Global knockouts of TGFβ and its receptors cause embryonic lethality at mid-gestation due to 
major angiogenesis defects. For instance, homozygous knockout of Tgfβr2 in mice resulted in 
embryonic lethality by E10.5 mainly due to haematopoiesis and vasculogenic defects in the 
yolk sac (154). In contrast, genetic depletion of individual ligands has more minor defects, 
likely due to some compensatory or overlapping functions in angiogenesis (Table 1.2). In the 
case of mice that are null for the Tgfβ1 ligands, the phenotype is dependent on genetic modifiers. 
Knockout of Tgfβ1 in mice of a mixed genetic background led to death of 50% embryos in utero 
due to angiogenic defects and the rest survived to approximately 3 weeks postnatally and died 
from auto-immune defects (155-157). Tgfβ2 null mice show perinatal mortality due to various 
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heart defects including incomplete ventricular septation, double-outlet right ventricle (DORV), 
interrupted aortic arch (IAA) (158, 159). While in Tgfβ3 null mice, hypoplasia of ventricular 
wall was observed along with some minor defects including position of aortic arch but no major 
heart defects are reported (160). 
Global knockout of endoglin is embryonic lethal at E10.5 due to defects in yolk sac vasculature 
and developing hearts. The embryos displayed fragile vessels due to lack of SMC recruitment 
(127, 128, 161). A similar phenotype was observed after global deletion of Alk1 (147) with 
embryonic lethality at E10.5. These embryos also failed to recruit vSMCs leading to formation 
of fragile and dilated vessels. Furthermore, Alk1 knockout embryos displayed significantly 
fewer capillaries compared to controls (147). The summary of various defects in mouse and 
humans caused due to systemic and cell specific knockdown of TGFβ ligands or its receptors 
is shown below in Table 1.2.   
Table 1.2: Defects in mice and humans due to knockout or depletion of TGFβ ligands and/or its receptors 




and Cre line 




1. Modifier dependent phenotype; 
2. Embryonic lethal at E10.5 – angiogenic defects; 
3. Postnatal lethal – major autoimmune response 
 
Tgfβ2 Systemic 




Tgfβ3 Systemic Perinatal lethality – thin ventricular walls & cleft palate 
Ventricular 
Hypoplasia 













1. Embryonic lethal at E13.0 – reduced AV cardiac 
cushion, thin & poorly trabeculated myocardium; 














Perinatal lethal – OFT defects & aortic elastin defects. 











1. Embryonic lethal at E10.0 to E12.0 – angiogenic & 
inferior AV cushion defects; 
2. Embryonic lethal at E15.5 when Cre activated at E11.5, 






1. Embryonic lethal at ~ E17.0 – VSD, aortic dilatation & 
coronary vessel defects; 
2. Embryonic lethal at ~ E12.0 – underdeveloped heart & 
angiogenic defects 





1. Embryonic lethal at ~ E11.0 – reduced cardiac cushion 
cellularity & angiogenic defects; 





1. Embryonic lethal at E14.5 – reduced number of 
coronary vessels, DORV, VSD & thin myocardium; 
2. Embryonic lethal between E16.0 & birth – poorly 




Abbreviations: AV – AtrioVentricular; AVMs – ArterioVenous Malformations; CHD – Congenital Heart 
Disease; DORV – Double Outlet Right Ventricle; E – Embryonic Day; HHT – Hereditary Haemorrhagic 
Telangiectasia; IAA – Interrupted Aortic Arch; NCC – Neural Crest Cells; OFT – OutFlow Tract; PTA – 
Persistent Truncus Arteriosus; VSD – Ventricular Septal Defect; vSMCs – Vascular Smooth Muscle Cells. 
 
1.5.3. TGFβ Signalling during EMT 
The process of EMT of endocardial and epicardial cells is important for development of the 
valves and coronary vasculature (section 1.3.1.1). The expression of TGFβ2 ligand is shown in 
the myocardium around the endocardial cushions and in the migrating mesenchymal cells while 
TGFβ3 expression is only observed in the mesenchymal cells in later stages (162). This 
expression in TGFβ2 in mesenchymal cells continue during the whole process of AV valve 
formation (162). Mouse models with global knockdown of Tgfβ2 led to perinatal mortality due 
to defects in EMT dependent organs such as heart, lungs and limbs (163). In vitro studies by 
Sanford et al. (162), showed that blocking Tgfβ2 but not Tgfβ3 inhibited EMT (162). However, 
they suggested that the later expression of Tgfβ3 is also vital for correct AV valve remodelling 
(162).  
During the process of EMT, Tgfβr2 is also expressed in AV cushion mesenchymal cells and is 
necessary for migration & activation of EMT by Tgfβ ligands (58, 59). In vitro studies using 
collagen gel assay on AV explants from E9.25 embryos from Tgfβr2fl/fl; Tie2-Cre mouse line 
showed that in the absence of Tgfβr2, endocardial cells failed to undergo EMT (59). However, 
depletion of Tgfβr2 in vivo using Tie2-Cre mouse line did not affect the EMT process in AV 
cushions but did lead to reduced proliferation of mesenchymal cells in AV cushions (59).  Jiao 
et al. (59) also showed that Tgfβ is essential for remodelling of AV canal & cardiac looping in 
vivo and in its absence, E12.5 embryos displayed double-inlet left ventricle (DILV). 
The TGFβ co-receptor β-glycan is necessary during the process of EMT. Immunohistochemical 
analysis on chick hearts showed expression of β-glycan in the endocardial cell adjacent to AV 
cushions and in the migrating mesenchymal cells (164). In vitro analysis on AV cushion 
explants from stage 14-18 chick embryos showed that blocking of β-glycan using antisera 
reduced numbers of mesenchymal cells due to inhibition of endocardial EMT (164). Global 
knockdown of β-glycan led to poorly developed IVS, thin non-compacted myocardium in E14.5 
to E18.0 embryos (165, 166). Furthermore, Compton et al. (166) showed that knockdown of β-
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glycan led to reduced number of coronary vessels in E14.5 embryos along with various heart 
defects including DORV and detached epicardium. 
In vitro analysis by Bax et al. (64) has shown that adult EPDCs after EMT attain a spindle like 
structure (similar to SMCs) and start to express endoglin while expression of VCAM1 is 
inhibited via an ALK5 mediated pathway (64). Inhibition or knockdown of endoglin did not 
prevent TGFβ mediated EMT in vitro, and the authors concluded that endoglin is probably not 
involved during the beginning of epicardial EMT but is potentially important during 
mesenchymal cells differentiation following EMT (64). This hypothesis was tested in the 
current study during coronary vasculature development in vivo.  
1.6. Hereditary Haemorrhagic Telangiectasia (HHT)  
Hereditary haemorrhagic telangiectasia (HHT) also known as Osler-Weber-Rendu disease is an 
autosomal dominant vasculature related disorder and affects 1 in 5000 individuals (167). 
Genetically, in over 80% cases HHT is caused due to haplo-deficiency of either endoglin or 
ALK1 gene. This results in two main variants of HHT: (i) HHT1, caused due to mutations in 
endoglin gene (168); and (ii) HHT2, caused due to mutations in ALK1 gene (also known as 
ACVRL1) (169).  
The HHT patients clinically presents with epitaxies (nosebleeds), telangiectasias and 
arteriovenous malformations (AVMs). In normal individuals, the arteries and veins are not 
directly linked but are separated via a mesh of capillary bed which helps gas and nutrient 
exchange with the tissues (Figure 1.19A). However, in HHT patients, there are localised AVMs 
where arteries and veins are directly connected bypassing the capillary bed (Figure 1.19B). 
These AVMs range from small to large size and are found primarily in brain, lungs & liver. The 
location and size of these AVMs determine disease severity. For instance, larger AVMs in liver 
are reported to lead to high output heart failure (HOHF) (170-172). The smaller AVMs also 
called telangiectases are formed due to dilation of post-capillary venules which eventually 
connect with arterioles and present as red spots on skin or mucosal surface (173). The vessels 
within a telangiectasis are quite fragile and are prone to rupture or haemorrhage. As a 




Figure 1.19: Arteriovenous Malformation in HHT [adapted from (20)]. (A) The normal capillary network 
present in most vascular beds and interconnects an arteriole and a venule. (B) Formation of an arteriovenous 
malformation in hereditary haemorrhagic telangiectasia (HHT). 
HHT1 and HHT2 patients exhibit similar symptoms (e.g. AVMs and telangiectases). However, 
the occurrence of symptoms within HHT1 or HHT2 patients differ from individual to individual 
potentially due to environmental factors and genetic modifiers [reviewed in (175)]. 
Furthermore, HHT1 patients are prone to pulmonary and cerebral AVMs while in HHT2 
patients gastrointestinal (GI) tract and liver AVMs are more common (176-179). 
Clinically, a patient is diagnosed with HHT if at least three out of four Curacao criteria are met 
(174). These criteria are: (i) spontaneous recurrent epitaxies especially at night time; (ii) 
presence of telangiectases on lips, mouth, nose or inner mucosal lining; (iii) AVMs in visceral 
organs such as brain, lungs &/or liver; and (iv) family history. Further confirmation of HHT is 
made via genetic testing of the suspected or clinically diagnosed patients and family members 
(167, 174). AVMs are high risk symptom of HHT and depending on its location & size it can 
be fatal. For instance, pulmonary AVMs are asymptomatic until cyanosis, stroke (caused due 
to entrance of small clots from pulmonary circulation to systemic circulation via AV shunts 
instead of filtering though the capillary network) or brain abscess or AVMs in liver can lead to 
HOHF [reviewed in (178, 180-182)]. However, the mechanism behind AVMs formation is still 
elusive and there are many unanswered questions regarding their origin and tissue-specific 
locations. 
Since the identification of the genes involved with HHT a lot of research has focused on 
understanding the mechanism behind the clinical phenotypes observed in HHT patients. As 
discussed in section 1.5.1, all the genes identified in HHT play a critical role during the 
angiogenesis process and are predominantly expressed in ECs [reviewed in (123-126, 175)]. 
This indicates that HHT is caused primarily due to defects in TGFβ signalling in ECs [reviewed 
in (20, 123, 126, 131, 175, 181-183)].  
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 Role of TGFβ Signalling in HHT 
TGFβ signalling plays a dual role in ECs (section 1.5.1). The TGFβ/ALK1 mediated signalling 
is vital for ECs proliferation and migration, while TGFβ/ALK5 signalling is crucial for 
recruitment of SMCs or pericytes to stabilise the vessels. An imbalance in this pathway in 
endothelial cells can potentially explain some of the vascular defects in HHT.  
As over 80% of HHT patients suffer from haplo-deficiency of endoglin or ALK1, these two are 
considered as the most potent therapeutic targets. Many studies using genetic in vivo and in 
vitro models focusing of these two genes have shed some light regarding potential origin of 
AVMs [reviewed in (20, 126, 175, 181-183)]. It has been suggested that AVMs occur due to 
loss of arterial and venous identity of the vessels (184, 185). Urness et al. (185) observed that 
global knockdown of Alk1 lead to formation of shunts between dorsal aorta & cardinal vein 
around E8.5 and which enlarged by E9.0. By E9.5, multiple AV shunts were observed, vSMC 
recruitment was impaired and led to embryonic lethality by E10.5 (185). Further immuno-
histochemical analysis on E8.5 and E9.5 embryo sections also showed downregulation of 
arterial marker Efnb2 in the affected vessels. They concluded that Alk1 is necessary to establish 
arterial and venous identity of the vessels. Any disruption in vessel identity lead to formation 
of AV shunts (185).   
In a study by Sorensen et al. (184), they analysed the effect of global endoglin loss on vessel 
identity. In comparison to Alk1 null embryos, AV shunts were only observed between dorsal 
aorta & cardinal vein in global endoglin knockout embryos. These shunts were far less dilated 
and occurred slightly later (at E9.0). Furthermore, no loss of arterial identity was observed in 
the AV shunts after endoglin knockdown. However, haematopoietic clusters (functional marker 
of arterialisation) were observed budding from the walls of the cardinal vein of E10 endoglin 
null embryos as well as higher expression of the arterial marker CD34 (184).  
As majority of the vasculature appears normal in HHT1 and HHT2 patients, it supports the idea 
that haplo-deficiency of the affected genes alone does not cause AVMs. A trigger such as injury 
(186), inflammation, angiogenic stimuli (187-190) possibly combined with a further somatic 
mutation (190) is required which leads to formation of AVMs [reviewed in (175, 191)]. 
Mahmoud et al. (188) using wholemount immuno-histochemical studies showed formation of 
AVMs in P7 neonatal retinas after using conditional deletion of endoglin in EC at P2 and P4 
using Cdh5(PAC)CreERT2 mice. They showed that the AVMs originated due to increased ECs 
proliferation in the absence of endoglin however no change in the phosphorylation of 
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Smad1/2/3/5/8 was observed. These AVMs expressed venous marker EphB4 but arterial vessel 
identity remained unchanged. However, veins were observed to be significantly dilated and the 
retina vasculature progression was significantly delayed (188).  
In another study, AVMs were reported in P6 retinas by wholemount immuno-histochemical 
analysis after Alk1 knockdown at P4 in ECs using Cdh5(PAC)CreERT2 mice (187). Dilated veins 
were observed as well as loss of the arterial identity of the vessels with no difference in the 
venous marker EphB4. They also observed a reduction in the phosphorylation of Smad1/5/8 
(187). However, the retina vasculature progression was unaffected, but an increased number of 
branch points were observed in the Alk1 null retinas. Tual-Chalot et al. (187) speculated that 
the increased number of branch points coupled with reduced phosphorylation of Smad1/5/8 was 
potentially due to lack of BMP9 & BMP10 mediated signalling. A similar increase in the 
number of branch points were observed in BMP10 depleted BMP9 knockout P6 retinas (192). 
 Treatment for HHT 
HHT patients in most cases, initially present with nosebleeds caused by telangiectasias while 
the formation of AVMs in GI tract, brain, lungs or liver occur much later in life (193). These 
AVMs can be detected via CT scan or Doppler ultrasound and in certain cases, can be treated 
by embolization performed under general anaesthesia (194, 195).  
Recently, VEGF neutralising antibody, bevacizumab has been shown to be quite effective in 
epitaxies treatment in HHT patients (196, 197). However, the mechanism behind this 
improvement is unclear.  Han et al. (198), used an HHT2 mouse model to understand the 
mechanism behind VEGF neutralising antibodies. They showed using intravital hyperspectral 
imaging system with dorsal window chamber that in the absence of Alk1 in ECs, AVMs are 
formed in presence of an angiogenic stimuli (wound) and these AVMs were formed by 
development of new connections between vessels rather than by regression of pre-existing 
capillary network (198). They next showed the VEGF can trigger AVM formation in 
subcutaneously injected PLGA implant (containing VEGF or lipopolysaccharides) in Alk1-iKO 
mice. While in the presence of VEGF neutralising antibody (G6.31), the formation of AVMs 
in LPS implants was inhibited (198).  
Han et al. (198) also showed that treatment with VEGF neutralising antibody (G6.31) not only  
inhibited VEGF induced AVM formation but also the ones initiated due to a wound or in Alk1 
knockdown in mice. In this study AVMs formation was classified into three phases: (i) initiation 
(2-4 days after wounding); (ii) maturation (4-6 days after wounding) and (iii) maintenance (7-
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9 days after wounding). They showed that, treatment with G6.31 antibody during the initiation 
phase only led to formation of a few small AV shunts; treatment during maturation phase 
decreased total number of AV shunts as well as regressing those that were still developing. 
While treatment during maturation phase did not affect the large AVMs, however small and 
intermediate regressed slightly.  
Ola et al. (199) showed the effect of Vegfr2 knockdown was analysed  in Alk1-iKO mice. 
During this study, they showed AVMs near the centre of P5 retinas in Alk1-iKO pups as well 
as BMP9/10 antibody treated pups. Retinas in both groups also showed increased vessel area 
and branch points near the angiogenic front (199). In addition to retinas, AV shunts were also 
observed in the GI tract of these mice. Quantification of AVMs (in both retinas and GI tract) 
showed a higher probability of AV shunts in Alk1-iKO mice compared to BMP9/10 antibody 
treated group (199). The qPCR analysis on isolated and primary cultured lung ECs from Alk1-
iKO mice showed a downregulation of Alk1, Eng and Vegfr1 but no change in Vegfr2 was 
observed. Furthermore, downregulation of arterial markers such as Notch1 & Jag1 and an 
upregulation in venous marker EphB4 was also observed in these cells (199). This reduction in 
Vegfr1 as well as Jagged1 potentially led to enhanced VEGF signalling leading to formation of 
AVMs. 
To test this hypothesis, Ola et al. (199) first showed an increased phosphorylation of VEGFR2 
and downstream genes pERK and pAKT in siRNA mediated Alk1 depleted HUVECs (199). 
Next, they tested the effect of Vegfr2 depletion (using Vegr2fl/fl) in vivo in Alk1-iKO mice. A 
varying phenotype was observed in these mice depending on the level of Vegfr2 deletion. A 
mild loss of Vegfr2 led to almost normal retina vasculature was observed in P5 retinas. 
However, further depletion of Vegr2 significantly reduced angiogenesis in P5 retinas and in 
case of complete loss, no retina vasculature was observed (199). In vitro analysis showed BMP9 
regulates activity of PI3K/AKT pathway. Next, in vivo inhibition of PI3K using an inhibitor 
(Wortmannin or Pictilisib) efficiently normalised the vasculature of P5 retinas of both Alk1-
iKO and BMP9/10 antibody treated mice. Inhibition of PI3K also prevented AV shunt 
formation in GI tracts (199) and was able to promote regression of established retinal AVMs. 
These potentially make PI3K a novel target for treatment of AV shunts in HHT2 patients.  
These studies have focused on rescue of the Alk1 (HHT2) mutant phenotype with very little 
work on endoglin (HHT1). During the current study, I analysed the effect of BMP9 treatment 
to try and rescue AVM formation in P7 retinas in an established HHT1 mouse model (188). I 
also studied the effect of venous ECs endoglin knockdown on AVMs formation.   
 
56 
1.7. Myocardial Infarction 
Cardiovascular disease (CVD) is the biggest cause of death worldwide. Presently, ~7 million 
people are living with CVD in the UK alone and one third of this population is suffering from 
coronary artery or ischemic heart disease (200). A heart attack is the most common cause of 
death in these patients (200). A healthy adult heart has high energy demand. To fulfil this 
demand, each cardiomyocyte (CM) is in the vicinity of a coronary capillary (45, 46). Blockage 
of any coronary artery supplying these capillaries leads to myocardial hypoxia or myocardial 
infarction (MI), also known as a ‘heart attack’ (201). The severity of MI differs depending on 
the location of the coronary artery involved, and whether occlusion is proximal or distal to the 
aortic ostia. Acute MI most frequently occurs due to the formation of a thrombus following 
local rupture of an atherosclerotic plaque in a coronary artery causing an arterial blockage. If 
left untreated, completely occluded vessels can be fatal (202). Clinically, MI is divided into 6 
types as shown in Table 1.3 (201). 
Table 1.3: Clinical classification of Myocardial Infarction [taken from (201)]. 
MI Classification Symptoms 
Type 1 
Spontaneous MI related to ischemia due to a primary coronary event such as 
plaque erosion and/or rupture, fissuring, or dissection.  
Type 2 
MI secondary to ischemia due to either increased oxygen demand or decreased 
supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, 
hypertension, or hypotension. 
Type 3 
Sudden unexpected cardiac death, including cardiac arrest, often with symptoms 
suggestive of MI, accompanied by presumably new ST elevation, or new LBBB, or 
evidence of fresh thrombus in a coronary artery by angiography and/or at autopsy, 
but death occurring before blood samples could be obtained, or at a time before the 
appearance of cardiac biomarkers in the blood. 
Type 4a MI associated with PCI. 
Type 4b MI associated with stent thrombosis as documented by angiography or at autopsy.  
Type 5 Myocardial infarction associated with CABG. 
Abbreviations: CABG – Coronary Artery Bypass Grafting; LBBB – Left Bundle Branch Block; MI – 
Myocardial Infarction; PCI – Percutaneous Coronary Intervention. 
 
The death of cardiomyocytes (CM) post-MI is inevitable but for a better prognosis it is essential 
that CM loss is minimal. To reduce CM loss, acute MI patients are subjected to primary 
percutaneous coronary intervention (PPCI) to restore the blood supply to the affected region 
(203). Occurrence of MI results in a cascade of cellular responses to initiate heart repair. This 
process of heart repair is divided into three phases: the inflammatory phase; the proliferative 
phase and the maturation phase (Figure 1.20) (204-208). Briefly, in the inflammatory phase is 
an influx of innate immune cells attracted by the release of alarmins by necrotic CM (157). This 
phase lasts for 3 to 4 days in mice (207). The dead CM are then removed by phagocytes which 
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in turn suppresses the inflammatory response and promote cardiac healing by initiating the 
proliferative phase (204).  
 
Figure 1.20: Phases of Cardiac Healing [Reviewed in (204)]. 
During the proliferative phase, ECM is secreted by myofibroblasts and new blood vessels are 
formed through the process of angiogenesis in the infarcted region (204). During cardiac 
remodelling, MI induced hypoxia in the heart leads to secretion of VEGF and activation of 
angiogenesis. The final phase of cardiac healing is the maturation phase. During this phase, a 
mature scar, rich in collagen, is formed and neo-vessels are stabilised through the process of 
arteriogenesis (204, 205).  
1.7.1. Importance of TGFβ during Heart Repair 
The importance of TGFβ signalling in myocardial injury, repair and vascular remodelling has 
been extensively reviewed (204, 206, 207, 209-212). After MI, the expression of TGFβ is 
upregulated in hearts where it drives various functions in different cell types during the cardiac 
healing phase (Figure 1.21). For example, TGFβ is involved in promoting deposition of fibrous 
tissue in the infarcted area during the maturation phase of cardiac healing (204, 205, 211). TGFβ 
also plays an essential role during angiogenesis. In ECs TGFβ stimulates or inhibits 
angiogenesis depending upon whether it signals via TGFβ/Alk1 or TGFβ/Alk5 pathway, 




Figure 1.21: Role of TGFβ during Cardiac Healing [adapted from (204)]. 
The importance of TGFβ in heart repair has been shown by Frantz et al. (210) by blocking 
TGFβ ligand with an antibody before and after MI leading to high mortality. The left ventricle 
of these mice also showed higher dilation and lower contractibility. Thereby concluding that, 
auto and paracrine signalling by TGFβ plays a vital role in heart repair (210).  
Endoglin plays an important role during TGFβ mediated angiogenesis (section 1.5.1). 
Expression of endoglin has also been observed to be elevated in injury state [reviewed in (131, 
213, 214)]. In solid tumours, endoglin is also used as a biomarker for tumour angiogenesis with 
elevated levels correlated with increased metastasis [reviewed in (131, 213, 214)]. In clinical 
trials, anti-endoglin antibody (TRC105) has been used to reduce angiogenesis in tumour size 
[reviewed in (214)]. Currently, TRC105 is being used to treat hepatocellular carcinoma. In 
studies involving MI models, expression of endoglin was reported to be elevated in the ECs of 
infarcted region as well other types including myo-fibroblasts and SMCs (215-217). Mice 
heterozygous for endoglin showed reduced angiogenesis in the peri-infarct region (216) 
consistent with a role for endoglin in promoting angiogenesis in the infarct border zone. 
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The need for angiogenesis in post-MI cardiac healing is no different from any other wound 
healing process. Restoration of the blood flow is vital to exchange of nutrients and to promote 
survival of the nearby cells. During cardiac remodelling, MI induced hypoxia in the heart leads 
to secretion of VEGF. This leads to activation of the developmental like processes to promote 
angiogenesis (section 1.2). Angiogenesis and arteriogenesis are critical processes for healing 
but are generally insufficient at the endogenous level to preserve the CM which results in the 
necrosis of the heart muscle tissue and this may ultimately lead to heart failure (218). Ongoing 
research to promote angiogenesis in hearts and mechanisms to stabilise neovessels is therefore 
critically important (218). 
1.7.2. Cell Mediated Therapy in Post-MI 
To improve the outcomes post-MI, transplantation of stem cell or stem cell like cells has proved 
to be beneficial in augmenting heart repair. These cells have been shown to act via two main 
routes (Figure 1.22): (i) direct repair via cellular contribution or (ii) indirect contribution via 
secretion of paracrine factors (219).  
 
Figure 1.22: Direct and indirect mechanism of cell-mediated heart repair [adapted from (219)]. Stem cells 
transplantation after MI could mediate cardiac healing in two ways: (A) Direct effect during which transplanted 
cell differentiate directly into cardiac cells. (B) Stem cells could also improve cardiac healing via paracrine 
mechanism. These could be reduction in cell apoptosis or secrete various cell signalling factors which could lead 
to activation of resident stem cell. These cells can then either differentiation into cardiac cell types or increase 
angiogenesis to promote cardiac healing. Stem cells could remodel matrix which could help to stabilise the scar.   
Many cell types have been tested to exploit their cardiac regenerative potential [reviewed in 
(220)]. These cells include bone marrow mesenchymal stem cells (BM-MSCs), embryonic stem 
cells (ES cells) and cardiosphere derived cells (CDCs) (219). Amongst these cells, BM-MSCs 
and CDCs have been tested in clinical studies. Many clinical trials involving BM-MSCs showed 
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no global functional difference between control and treated group (221-224). However, in pre-
clinical studies, CDCs showed promising results predominantly via paracrine mechanism 
resulting in reduced CM apoptosis, increased CM proliferation and angiogenesis, modulation 
of inflammatory phase and promotion of host healing process including pro-angiogenic factors 
[reviewed in (220)].  
Injection of CDCs in post-MI hearts showed beneficial effects including improved heart 
function and reduction in scar size 3 weeks after MI in mice (225). CDCs are also observed to 
provide more paracrine contribution than direct cellular contribution in CDC mediated heart 
repair as few CDCs differentiated into CM or any other cardiac cell type (225). Furthermore, 
these paracrine benefits of CDCs have been studied using CDC-conditioned media (CDC-CM) 
in vitro, which showed an anti-apoptotic effect on neonatal rat ventricular myocytes by release 
of pro-angiogenic factors like VEGF and HGF (human growth factor). Similar beneficial effects 
of CDC-CM were seen in vivo upon immediate injection of CDC-CM in post-MI mice hearts 
(225).  
Due to these beneficial effects of CDCs on cardiac function and angiogenesis, these cells are 
currently being investigated in multiple clinical trials (226-229), with a primary goal to reverse 
ventricular dysfunction after MI. CDCs are delivered to the heart by intracoronary injection and 
led to reduction in scar mass and increased viable myocardium mass. But unlike animal models, 
no significant change in the LV function was observed 6 and 12 months after the injection 
(226). This clearly shows the need to study these cells in more detail and to further characterise 




1.8. Aims  
1. To investigate the role of Endoglin and TGFβR2 in the epicardium and EPDCs during 
mouse heart development. 
2. To investigate the role of Endoglin in coronary vessel endothelial cells during mice heart 
development. 
3. To investigate the effect of Venous Endoglin knockdown on AVMs formation. 
4. To study the occurrence AVMs/ shunts or dilated vessels in the lungs and liver in Eng-
iKO adult mice. 
5. To determine the role of Endoglin in CDC-mediated angiogenesis in the adult mouse 
heart after a myocardial injury. 
 
1.9. Hypotheses 
1. Endoglin iKO (induced knockout) or TGFβR2 iKO in epicardial cells and EPDCs 
during mice heart development will affect coronary vessel formation.   
2. Endoglin iKO in coronary vessel ECs during mice heart development will affect 
coronary vessel formation. 
3. Endoglin iKO in venous ECs leads to AVMs formation in neonatal retinas.  
4. Systemic Eng-iKO using VE-CadCre-ERT2 mouse line leads to HOHF in adult mice due 
to formation of AVMs or vasodilation in the peripheral vasculature. 
5. Endoglin iKO in the CDCs will impede the process of angiogenesis during cell-
mediated heart repair in an adult mouse heart post-myocardial injury by altering the 




















2.1. Mouse Strains and Genotyping      
All animal procedures were performed with local ethical approval and under UK Home Office 
licence and national guidelines for the care and use of laboratory animals were adhered to. Mice 
were housed in a ventilated, germ free facility in a 12-hour light-dark cycle and fed with 
standard diet and water.  
2.1.1. Mouse Strains 
C57Bl/6 Mouse Line: C57Bl/6 mice were provided by either in-house breeding or bought from 
Charles River Laboratories, UK. Mice from this line were used to study expression of endoglin 
in the developing & adult heart (chapter 3) and the role of endoglin in CDC promoted 
angiogenesis in the adult heart post-MI (chapter 6). 
Wt1Cre-ERT2/+; Rosa26eYFP/eYFP Mouse Line:  Wt1Cre-ERT2/+ mice (78) were provided by Dr Helen 
Phillips (Newcastle University, UK) and were crossed with in-house available C57Bl/6 
background Rosa26eYFP/eYFP reporter mice (230). Wt1Cre-ERT2 mice express tamoxifen inducible 
Cre recombinase (Cre-ERT2) enzyme under regulation of wilm’s tumor 1 protein (78). 
Rosa26eYFP reporter mice express enhanced yellow fluorescence protein (eYFP) with a 
transcriptional stop sequence flanked by loxP sites (230). In the presence of an active Cre 
recombinase, the stop sequence is removed, which leads to expression of enhanced yellow 
fluorescent protein (eYFP) (Figure 2.1). Mice from this line were used to optimise the activation 
of Wt1Cre-ERT2 and to study the expression of endoglin in EPDCs during heart development 
(chapter 4).  
 
Figure 2.1: Transgenic Rosa26 locus with floxed stop eYFP gene. In the presence of active Cre recombinase, 
the stop sequence is removed which leads to expression of eYFP protein.  
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Engfl/fl; Wt1Cre-ERT2/+; Rosa26eYFP/eYFP Mouse Line: Endoglin floxed mouse was generated in 
my host laboratory by inserting loxP sites flanking exon 5 and 6 (231). In the presence of active 
recombinase Cre enzyme, exon 5 and 6 are removed leading to the production of truncated non-
functional endoglin protein (Figure 2.2). Engfl/fl mice were crossed with Wt1Cre-ERT2/+; 
Rosa26YFP/YFP mice to generate an Engfl/fl; Wt1Cre-ERT2; Rosa26eYFP/eYFP mouse line and were 
maintained in C57Bl/6 genetic background.  Mice from this line were used to study the role of 
endoglin in EPDCs during heart development (chapter 4). 
 
Figure 2.2: Floxed Endoglin gene showing the LoxP sites flanking exon 5 and 6. In the presence of Cre 
recombinase exon 5 and 6 are removed to form a truncated non-functional endoglin protein. 
Tgfbr2fl/fl; Wt1Cre-ERT2/+; Rosa26eYFP/eYFP Mouse Line: Tgfbr2 floxed mice were available in-
house, and were originally created by flanking exon 4 with loxP sites (232).  In the presence of 
an active Cre recombinase exon 4 is removed, which leads to a frameshift mutation and 
formation of a non-functional transcript (Figure 2.3). These mice were crossed with Wt1Cre-
ERT2/+; Rosa26YFP/YFP mice to generate a Tgfbr2fl/fl; Wt1Cre-ERT2; Rosa26eYFP/eYFP mouse line and 
were back crossed 5 generations with C57Bl/6 mice. Mice from this line were used to study the 
role of Tgfbr2 in EPDCs during heart development (chapter 4). 
 
Figure 2.3: Floxed Tgfbr2 gene showing the LoxP sites flanking exon 4. In the presence of Cre recombinase 
exon 4 is removed leading production of a non-functional Tgfbr2 protein. 
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Dll4in3Cre-ERT2/+; Rosa26eYFP/eYFP Mouse Line: Dll4in3Cre-ERT2 is an arterial endothelial cell 
specific Cre mouse line, provided by collaborator Dr Sarah de Val (Oxford University, UK). In 
this mouse line, a transcriptional enhancer in the highly conserved third intron of Dll4 (233) is 
cloned upstream of Cre recombinase. Multiple copies of this sequence (Dll4in3-Cre) were then 
randomly inserted into a mouse genome to produce a transgenic mouse. Mice from this line 
were crossed with Rosa26eYFP reporter mice to generate a Dll4in3Cre-ERT2/+; Rosa26eYFP/eYFP 
mouse line. Activation of Dll4in3Cre-ERT2 after tamoxifen injection leads to expression of eYFP 
protein in all Dll4in3 positive cells and daughter cells (Figure 2.1). Mice from this line were 
used to optimise activation of Dll4in3-Cre (chapter 5).   
VE-CadCre-ERT2/+; Rosa26eYFP/eYFP Mouse Line: VE-CadCre-ERT2 (also known as Cdh5 (PAC) 
Cre-ERT2) mice were obtained from Dr Ralf Adams (CRUK, UK). This line expresses inducible 
Cre recombinase under the control of the vascular endothelial cadherin (VE-Cadherin or Cdh5) 
promoter (234). These mice were crossed with Rosa26eYFP reporter mice to enable the labelling 
of all the VE-Cad expressing cells following tamoxifen treatment (Figure 2.1). Mice from this 
line were maintained in C57Bl/6 genetic background and were used to map the expression 
pattern of VE-CadCre-ERT2 (chapter 5). 
Engfl/fl; VE-CadCre-ERT2 Mouse Line: VE-CadCre-ERT2 mice were crossed with Engfl/fl mouse 
model to generate an Engfl/fl; VE-CadCre-ERT2 mouse line. In the presence of tamoxifen Cre-
ERT2 is activated leading to knockdown of endoglin from all VE-Cad-Cre positive cells (Figure 
2.2). This mouse line was used to study the role of endoglin in ECs (chapter 5). 
ApjCre-ERT2/+; Rosa26mTmG/+ Mouse Line: ApjCre-ERT2 is an inducible Cre recombinase under the 
control of the Apj promoter. Apj is predominantly expressed in the venous ECs (43). ApjCre-ERT2 
mice were crossed with a dual reporter Rosa26mTmG mice (235) to generate a ApjCre-ERT2/+; 
Rosa26mTmG/+ mouse line. ApjCre-ERT2; Rosa26mTmG mice (43) were provided by Dr. Kristy Red-
Horse (Stanford University, US). Cells expressing Rosa26mTmG reporter express red florescence 
in the absence of an active Cre recombinase, while in the presence of an active Cre recombinase, 
green fluorescence is emitted (Figure 2.4). Mice from this line were backcrossed for 5 
generations with C57Bl/6 mice to generate a syngeneic line and were used to optimise the 




Figure 2.4: Transgenic Rosa26 locus with mTmG reporter sequence. Cells expressing mTmG reporter prior 
have red fluorescence due to expression of membrane-targeted tandem dimer Tomato (mT). In the presence of an 
active Cre recombinase the mT sequence is removed resulting in the expression of green fluorescence due to 
expression of membrane-targeted enhanced green fluorescent protein (mG).  
 
Engfl/fl; ApjCre-ERT2/+; Rosa26mTmG/+ Mouse Line: To study the role of endoglin in ApjCre-ERT2 
positive endothelial cells (chapter 5), ApjCre-ERT2/+; Rosa26mTmG/+ mice are crossed with Engfl/fl 
mice to generate Engfl/fl; ApjCreERT2/+; Rosa26mTmG/+ mouse line. In the presence of tamoxifen, 
Apj-Cre is activated which leads to knockdown of endoglin in Apj-Cre positive cells (Figure 
2.2).  
Engfl/fl; RosaCre-ERT2/Cre-ERT2; CAGGFP/GFP Mouse Line: CAG-farnesyl-eGFP mice were 
obtained from Prof Alexander Medvinski (Edinburgh University, UK). In these mice the 
expression enhanced green fluorescent protein (eGFP) is under control of the CAG promoter (a 
combination of the chicken beta actin promoter and the CMV promoter). The farnesyl group 
restricts location of the eGFP to the cell membrane (150). These mice were crossed with 
ubiquitously expressed RosaCre-ERT2 mice line (obtained by from Di Li, Connecticut, USA) and 
in-house available Engfl/fl mice to obtain Engfl/fl; RosaCre-ERT2/Cre-ERT2; CAGGFP/GFP in C57Bl/6 
genetic background. Mice from the resulting line were used to culture CDCs and study the 
importance of endoglin in these cells (Chapter 6). 
2.1.2. Tamoxifen 
To activate inducible Cre recombinase (Cre-ERT2), tamoxifen was injected. Tamoxifen was 
prepared in two stages during this study. First, 10 or 15mg of tamoxifen was dissolved in 100µl 
of absolute ethanol followed by the addition of 900µl of peanut oil to give a final concentration 
of 10 or 15mg/ml, respectively. Dose of tamoxifen and mode of injection depended upon the 
age of the mice.  
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1. Pregnant females – 100µl tamoxifen is given from a 10mg/ml stock solution for 2 or 3 
days (depending on experiment requirement), via subcutaneous or 
intraperitoneal (IP) route. Total dose: 2 to 3mg. 
2. Pups – 33 or 40µl tamoxifen is given from a 15mg/ml stock solution for 1 or 2 days 
(depending on experiment requirement) via subcutaneous route. Total dose: 0.5 to 
1.2mg. 
3. Adult Mouse – 200µl tamoxifen is given from a 10mg/ml stock solution via IP route for 
5 consecutive days. Total dose: 10mg. 
2.1.3. Dissection of Embryos, Pups and Adult Hearts 
Embryo Dissection: The day of vaginal plug was considered as E0.5. The Cre-ERT2 was then 
activated on specific days by injecting tamoxifen via subcutaneous or IP route. The pregnant 
females were euthanized either via cervical dislocation or exposure to CO2. The embryos were 
then harvested from the peritoneal cavity of the mice following a standard dissection protocol. 
Briefly, lower abdominal skin and muscle was lifted using forceps and an incision was made to 
expose the embryos. Embryos were carefully transferred to a petri dish containing 1xPBS for 
imaging (Section 2.10.1) and then transfer to 0.2% or 4% PFA for fixation at 4°C O/N on an 
orbital shaker. In case of E15.5 and E17.5 embryos, embryonic hearts were harvested post 
fixation and then embedded either in paraffin or OCT (Section 2.2). Prior to fixing, forelimbs 
of the embryos were also harvested imaged and stored at -20°C for genotyping (Section 2.3.1). 
Pups Dissection: The day pups were born was considered as P0. To activate Cre-ERT2 
tamoxifen was injected via a subcutaneous route on specific days (for specific details of days 
and dose, refer to chapter 5). Pups were sacrificed by cervical dislocation. Pups’ hearts were 
harvested by making an incision just below the diaphragm, followed by upward cut from within 
the thoracic cavity. The heart was carefully removed and put in a petri dish containing 0.1M 
potassium chloride to stop the heart in diastole. Blood was removed from the heart by gently 
squeezing the heart using wide forceps. Hearts were imaged (Section 2.10.1) and fixed either 
using 0.2% or 1% PFA at 4°C O/N on an orbital shaker followed by embedding in OCT over 
dry ice (Section 2.2.2). 
Retinal Dissection: To harvest pups eyes the protocol described by Tual-Chalot et al. (236) 
was followed. Briefly, skin covering the eyes was removed using scissors. Eyes were then 
enucleated using forceps & scissors and placed in 24 well plate containing 4% PFA (in 2xPBS) 
at RT for 10mins. After 10mins, eyes were transferred to a 24 well plate containing cold 2x 
PBS. To dissect retinas from the eyes they were transferred to a petri dish using a wide bore 
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pipette. With the help of forceps and scissors, excess fat and the optic nerve was removed. 
Forceps were then carefully inserted between the retina and sclera. Sclera layer was carefully 
removed with minimal or no damage to the retina. If possible, the choroid layer was also 
removed at this stage. Next, the lens and hyaloids vessels were removed using forceps followed 
by 4 to 5 radial incisions to create a ‘petal’ shape (Figure 2.5). Excess PBS and remaining tissue 
debris were removed using a Pasteur pipette and cold 100% methanol (-20°C) was slowly added 
to fix and permeabilise the retinas. Retinas were then transferred to a 2ml tube and stored at -
20°C in 100% methanol until further use. To genotype pups, tail tips or ears were harvested and 
stored at -20°C. 
 
Figure 2.5: ‘Petal’ shape appearance of freshly dissected neonate retina (image courtesy of Kathleen R. 
Allinson). 
Adult Mice Dissection: Adult mice with or without tamoxifen treatment were scarified 
following one of the three protocols according the experiment specification.  
1. Cervical dislocation; 
2. CO2 chamber followed by cervical dislocation to confirm death; or  
3. Intracardiac injection of euthatal. 
Organs including brain, heart, lungs, liver, kidneys, aorta, mesenteric artery and gut were then 
harvested in 1xPBS at specific time points according to experimental requirements. Once 
harvested, heart and lungs were flushed with 1xPBS to remove blood. Images of freshly 
dissected hearts were taken (Section 1.1.2.10.1) and all the tissues were fixed in PFA (Section 
1.1.2.2.2) prior to embedding. 
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2.2. Processing, Fixing and Embedding of Tissue 
2.2.1. Paraffin Embedding 
The method used to embed embryos and embryonic hearts in paraffin is summarised in Table 
2.1. Once embedded, paraffin blocks were stored at room temperature until required. 








4% PFA (At 4°C) 2 nights 3 nights 1 nights 
Rinse in 1x PBS to remove PFA 
Transfer to 50% EtOH in dH2O (shaker) 3 hours 3 hours 30 mins 
Transfer to 70% EtOH in dH2O (shaker) 3 hours 3 hours 30 mins 
Replace 70% EtOH in dH2O 
(Can store like this at RT) 
3 hours 3 hours 30 mins 
Transfer to 95% EtOH in dH2O (shaker) 3 hours 3 hours 30 mins 
Transfer to 100% EtOH (shaker)  3 hours 3 hours 30 mins 
Replace 100% EtOH (shaker) Over night Over night 1 hour 
Transfer to Histoclear (shaker) 15 minutes 15 minutes 10 mins 
Replace Histoclear (shaker) 15 minutes 15 minutes 10 mins 
Histoclear/wax (65°C oven) 1 hour 1 hour 20 mins 
Paraffin Wax (65°C oven) 1 hour 1 hour 30 mins 
Paraffin Wax (65°C oven) 1 hour 1 hour 30 mins 
Paraffin Wax (65°C oven) 1 hour 1 hour 30 mins 
Paraffin Wax (65°C oven) 1 hour 1 hour - 
 
For solution details, refer to Appendix 3 
2.2.2. Embedding for Cryo Sectioning 
This method was used to embed embryos, embryonic hearts and adult tissue in OCT for cryo-
sectioning are summarised in Table 2.2. E15.5 and E17.5 embryonic hearts were dissected out 
of chest cavity prior to embedding. 





(Chest cavity only) 




Fix – 0.2% or 1% PFA 
(4°C with gentle rocking) 
1 night 1 night 1 nights 1 night 
Wash in 1x PBS to remove PFA 
15% Sucrose in 1xPBS at 4°C 2 to 3 hours (until sunk) n/a 
30% Sucrose in 1xPBS at 4°C n/a n/a n/a 1 night 
Embedded in OCT over dry ice for coronal or transverse sectioning and stored at -80°C. 
 




2.3.1. Genotyping using Mouse Tissue 
To genotype mice or embryos, DNA was extracted from small tissue samples using alkaline 
lysis method. First, tissue samples were collected (ear clip for adult mouse, tail tip or ear clip 
for pups and limb for embryos) and submerged in 50 to 300µl of alkaline DNA extraction lysis 
buffer 1 (refer to Appendix 1). The samples were then incubated in a thermo-mixer at 95ºC, 
350 revolutions for 60mins to lyse the cells, vortexed for 15secs and neutralised by the addition 
of DNA extraction solution 2 (refer to Appendix 1) at a 1:1 ratio with lysis buffer 1. The samples 
were vortexed and centrifuged at 13,000g for 5mins. The supernatant was transferred to a fresh 
Eppendorf tube and stored at -20oC until use.  
Genotyping was performed on this extracted DNA by PCR, using primers and PCR reaction 
conditions described in Table 2.3 and Table 2.4 using Bio Rad Tetrad Thermal Cycler. A 
minimum of 150 ng/µl of DNA was used as a template. The PCR products were separated on a 
2% agarose gel containing 0.01% of ethidium bromide in 1x TAE buffer at 140 volts for 
45mins. The DNA bands were observed in a UVP benchtop UV trans-illuminator.  
For DNA extraction lysis buffer and solution details, refer to Appendix 1.  
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Table 2.3: PCR Reaction 
Step Reaction 1 Reaction 2 Reaction 3 
1 Initialisation 5mins at 95°C 5mins at 95°C 2mins at 95°C 
2 Denaturation 30secs at 95°C 30secs at 95°C 30secs at 95°C 
3 Annealing 30secs at 62°C 30secs at 58°C 30secs at 60.0°C 
4 Elongation 90secs at 72°C 90secs at 72°C 90secs at 72°C 
5 Final Extension 5mins 72°C 5mins 72°C 5mins 72°C 
6 Storage 15°C forever 15°C forever 15°C forever 
7 No. of Cycles (2 to 4) x35 x35 x35 
 
Table 2.4: PCR Conditions and Primer sequences (for PCR reaction temperature, refer to table 2.4) 














Cre Forward GAACCTGATGGACATGTTCAGG 0.10µl 
3.60µl 5.00µl 1µl 
Reaction 
1 
Cre = 320bp 
Cre Reverse AGTGCGTTCGAACGCTAGAGCCTGT 0.10µl 
Myo Forward TTACGTCCATCGTGGACAGC 0.10µl 
Myo = 250bp 
Myo Reverse TGGGCTGGGTGTTAGCCTTA 0.10 µl 
Eng PCR 
Forward F6 GACGCCATTCTCATCCTGC 0.10µl 
3.80µl 5.00µl 1µl 
Reaction 
2 
Engfl = 500bp 
Reverse R7 CCACGCCTTTGTCCTTGC 0.10µl Eng+ (WT) = 420bp 
Eng iKO 
PCR 
Forward F4 GGTCAGCCAGTCTAGCCAAG 0.10µl 
3.60µl 5.00µl 1µl 
Reaction 
2 
Eng- (iKO) = 602bp 
Reverse R7 CCACGCCTTTGTCCTTGC 0.10µl 
Myo Forward TTACGTCCATCGTGGACAGC 0.10µl 
Myo = 250bp 
Myo Reverse TGGGCTGGGTGTTAGCCTTA 0.10µl 
RFP PCR 
RFP Forward CCCATGGTCTTCTTCTGCAT 0.10µl 
3.80µl 5.00µl 1µl 
Reaction 
2 
RFP = 220bp 
RFP Reverse AAGGTGTACGTGAAGCACCC 0.10µl 
Rosa PCR 
(multiplex) 
R26 - WT GCGAAGAGTTTGTCCTCAACC 0.20µl 
3.10µl 5.00µl 1µl 
Reaction 
2 
R26eYFP = 310bp 
R26 - Trans GGAGCGGGAGAAATGGATATG 0.50µl 
R26+ (WT) = 600bp 






R26 - WT GCGAAGAGTTTGTCCTCAACC 0.10µl 
3.60µl 5.00µl 1µl 
Reaction 
2 
R26+ (WT) = 600bp 
R26 - Gtrgeo AAAGTCGCTCTGAGTTGTTAT 0.10µl 
Myo Forward TTACGTCCATCGTGGACAGC 0.10µl 
Myo = 250bp 
Myo Reverse TGGGCTGGGTGTTAGCCTTA 0.10µl 
SRY PCR 
SRY Forward GACTAGACATGTCTTAACATCTGTCC 0.10µl 
3.60µl 5.00µl 1µl 
Reaction 
1 
SRY = 183bp 
SRY Reverse CCTATTGCATGGACAGCAGCTTATG 0.10µl 
Myo Forward TTACGTCCATCGTGGACAGC 0.10µl 
Myo = 250bp 






3.80µl 5.00µl 1µl 
Reaction 
2 
Tgfbr2fl (Trans) = 
360bp 
















Tbr2 iKO = 450bp 
P5b – Reverse AATGGAAGGGGAGTGAGGAC 0.20µl 
Myo Forward TTACGTCCATCGTGGACAGC 0.20µl 
Myo = 250bp 




2.3.2. Genotyping using Mouse Tissue Section 
To extract DNA from OCT embedded tissue sections to confirm the knock down of Tgfbr2 
expression (chapter 4), slides were removed from -80°C storage, left at room temperature for 
60mins to dry followed by two 10min washes in sterile 1xPBS (pH 7.4) at RT to remove any 
traces of OCT. Slides were then dried and 50µl of DNA extraction lysis buffer 1 was added to 
the slides and the sections were scraped from the slides using a sterile scalpel. DNA extraction 
lysis buffer 1 containing tissue scrapes was collected in a 1.5ml Eppendorf tube. A minimum 
of two slides with around 10 to 12 sections each slide was used per sample. Once the samples 
were collected, tubes were placed in a thermo-mixer at 95°C, 350 revolutions for 30mins. 
Samples were then vortexed and briefly centrifuged at 13,000g to avoid cross-contamination. 
DNA extraction solution 2 was added to neutralise the solution (1:1 ratio to solution 1). Samples 
were vortexed then centrifuged at 13,000g for 5mins at RT. Approximately 3 quarters of the 
supernatant was transferred to a labelled fresh tube. Nucleic acid concentration was checked 
using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific) to confirm successful DNA 
extraction. Around 150 to 200 ng/µl of DNA was used to perform Tgfbr2iKO and Cre PCR 
using conditions described in Table 2.3 and Table 2.4  
For DNA extraction lysis buffer and solution details, refer to Appendix 1. 
2.4. Sectioning 
2.4.1. Paraffin Wax Sectioning 
Embryos were sectioned in transverse/ coronal orientation into sister/ serial sections according 
to the need of the experiment. One day prior to sectioning, paraffin blocks containing embryos 
were cooled overnight at 4°C and kept on ice until use. 8µm thick sectioned were cut at 5° angle 
on a Leica RM2235 rotary microtome. The sections were hydrated on Histobond Twinfrosted 
adhesion slides using Millipore filtered H2O on a 37°C hot plate. Once hydrated, excess water 
was removed and slides were baked overnight in an oven at 37°C. All slides were stored in slide 
boxes at room temperature until further use. 
2.4.2. OCT Cryo-Sectioning 
Cutting blade and tissue samples were cooled in a cryostat for 30mins prior to sectioning. 10µm 
thick sections were cut at 10° angle on Microm HM 560 CryoStart (Thermo Scientific) and at 
5° angle on Leica CM1860 cryostat. Serial or sister sections in transverse or coronal orientation 
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were cut according to the experimental requirement. All the slides were left for at least 30mins 
at room temperature before storage at -80˚C. 
2.5. Staining 
2.5.1. Haematoxylin and Eosin (H&E) Staining 
To study the histology of embryonic hearts slides were stained with haematoxylin and eosin. 
Paraffin embedded tissue sections were first incubated in a 60ºC oven for 1hr for dewaxing and 
increased fixing of tissue slides. The slides were then washed in histoclear twice at RT for 
10mins each to remove wax followed by washing in 100% ethanol to remove histoclear (twice 
- 5mins each). Slides were next re-hydrated through a descending ethanol series (90%, 70% and 
50% - 5mins each) and equilibrated in autoclaved Millipore filtered H2O. Once hydrated, slides 
were stained with haematoxylin (nuclear stain) for 2 to 10mins followed by a brief wash in 
acid-alcohol (appendix 1) solution (2 to 5dips). Slides were then washed under running tap 
water for 2 to 5mins (until sections turned dark blue). Next, sections were stained with 1% eosin 
to stain cytoplasm and blood cells for 2 to 5mins followed by washing in tap water by dipping 
(2 to 5 dips times three). Once stained, the slides were dehydrated using ascending ethanol 
series (50%, 70%, 95% and 100% - 5mins each) followed by histoclear for 10 minutes. These 
slides were then mounted with histomount and then kept in a fume hood overnight to set. 
OCT embedded tissue sections were taken out of -80°C freezer and left in the slide mailer at 
RT for 30mins to avoid condensation. Next, slides were air dried for 30mins at RT to make sure 
the tissue was affixed on to slides. Sections were then fixed with 4% PFA for 10mins at RT 
followed by three washes in 1xPBS (5mins each). Slides were then stained with haematoxylin 
and eosin using the protocol described above.  
For solution and reagent details, refer to Appendix 1. 
2.5.2. Immunohistochemistry (IHC) using DAB 
Selected paraffin embedded tissue section slides were dewaxed and hydrated as described in 
section 2.5.1. Once hydrated, sections were equilibrated in 1x PBS and then subjected to antigen 
retrieval using 0.1M citrate buffer (pH 6) in the microwave set at high power for 15mins. The 
slides were first cooled at bench for 15mins, followed by 15mins under running tap water and 
then incubation with cold 3% hydrogen peroxide solution (appendix 1) for 10mins to inhibit 
endogenous peroxidase activity. Next, slides were rinsed in 18.2mq filtered H2O and were 
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washed in TBS-Tx (3 times – 7mins each). Slides were then subjected to antigen blocking buffer 
(10% FCS in TBS-Tx) for 2hrs at RT. Primary antibody (Table 2.5) appropriately diluted in 
blocking solution was added to sections; and blocking solution was added to negative control 
sections. The slides were next incubated in a levelled humidified chamber at 4˚C overnight. 
Table 2.5: Primary Antibody Details for IHC-DAB Staining 












A5228 1 in 100 
 
Next day, primary antibody was carefully drained, and the slides were washed three times in 
TBS-Tx for 7mins at RT (1st wash of negative controls were performed separately to avoid 
exposure to antibody). Once washes were complete, biotinylated secondary antibody (Table 
2.6) was diluted in blocking solution and added to slides. Slides were then incubated in a 
levelled humidified chamber at RT for 2hrs.  
Table 2.6: Secondary Antibody Details for IHC-DAB Staining 
Antibody Raised In Company Cat. No. Dilution 
Biotinylated Anti-Rabbit IgG Antibody Goat Vector Lab BA-1000 1 in 300 
Biotinylated Anti-Mouse IgG Antibody Goat Vector Lab BA-9200 1 in 300 
 
AB Complex (standard) was made 30mins prior to use according to manufacturer’s instructions 
(appendix 3). Secondary antibody was carefully drained off the slides and the slides were again 
washed 3 times in TBS-Tx as above. The slides were then incubated with AB Complex in a 
levelled humidified chamber for 30mins at RT. AB complex was carefully drained off the slides 
and the slides were again washed 3 times in TBS-Tx as above. Liquid DAB was prepared 
(Appendix 1) and added over the sections. The sections were incubated with DAB for up to 
20mins or until brown staining was observed. The DAB reaction was stopped by placing slides 
in 1x PBS. Slides were then counterstained in Mayer’s Haematoxylin for 2mins and washed 
under running tap water for 5mins. Slides were dehydrated through an ascending ethanol series 
(50%, 70%, and 95% for 5mins each) and washed in 100% ethanol (twice for 5mins each). The 
slides were then washed in histoclear (twice for 10mins each), mounted using histomount and 
glass cover slides and left in fume cabinet overnight to set. 
For solution and reagent details – refer to Appendix 3. 
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2.5.3. Immunofluorescence on paraffin embedded sections 
Slides were dewaxed and hydrated using the protocol described in section 2.5.1. Hydrated 
sections were subjected to antigen retrieval using 0.1M citrate buffer (pH 6.3-4) in a pressure 
cooker. Approximately, 600ml of citrate buffer was warmed in a pressure cooker and a metal 
rack containing slides were completely submerged in the buffer with a set valve pressure of 
80kPa. Samples were allowed to steam for 5mins prior to cooling under cold running tap water. 
Slides were left to cool for a further 20mins at RT. Next, slides were rinsed in sterile 18.2mq 
filtered H2O followed by three washes in 1xPBS (5mins each). Slides were then incubated in a 
blocking solution containing 10% FCS in TBS-Tx for 1hr at RT. Primary antibody, rabbit anti-
Sm22α (Abcam, cat. No. ab14106) was diluted (1µg/100µl) in blocking solution and then added 
to sections. Blocking solution was added to negative controls. The slides were then incubated 
in a humidified chamber at 4˚C overnight on a level bench. 
Next day, primary antibody was removed by rinsing the slides briefly in 1xPBS followed by 3 
washes in 1xPBS (5mins each). Slides were next incubated with secondary antibody and 
Isolectin GS-IB4 appropriately diluted in blocking solution (Table 2.7) in a light protected 
humidified chamber for 3hrs at RT. Sections were then rinsed and washed as described above 
followed by mounting using Prolong Gold antifade reagent with DAPI and overnight incubation 
at 4°C to allow to set . 
For solution and reagent details – refer to Appendix 3. 
Table 2.7: Secondary Antibody and Isolectin Details 
Antibody Raised in Company Cat. No. Dilution 
Anti-Rabbit Alexa Fluor 488 Conjugated 
(H+L) Cross-Adsorbed 
Goat Life Technology A-11008 1 in 200 
Isolectin GS-IB4 from Griffonia 
simplicifolia, Alexa Fluor™ 594 Conjugate  
n/a Life Technology I-21413 1 in 50 
 
2.5.4. Immunofluorescence on OCT embedded sections 
Slides were removed from -80°C freezer, kept at RT for 30mins within slide mailers to reduce 
condensation, and then air dried on a slide rack for a further 30 mins. Whilst drying, sections 
were traced around with a hydrophobic barrier pen. Depending upon the type of antibody used, 
sections were subjected to post-fixing using 4% PFA on slide (as summarised in (Table 2.8), 
followed by washing in 1xPBS 3 times (5mins each) at RT (only 1 wash required if tissue not 
post-fixed). The slides were then incubated with blocking solution containing 5% secondary 
antibody specific serum (donkey or goat serum), 1% BSA and 0.5% Tween 20 in 1xPBS for 
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2hrs in a humidified chamber at RT. Excess blocking solution was removed by gentle tapping 
and primary antibody appropriately diluted (Table 2.8) in blocking solution was added to slides 
and incubated on a level bench, overnight at 4°C. 
Next day the primary antibody was carefully removed, and slides were rinsed briefly in 1xPBS 
followed by three washes in 1xPBS (5mins each). For some antibodies (please refer to Table 
2.8), slides were washes in PBST (1xPBS + 0.25% Triton-X 100) solution for 5mins at RT to 
reduce non-specific staining. Slides were next incubated in a light protected humidified 
chamber with an appropriately diluted secondary antibody (Table 2.9) for 2hrs at RT or 
overnight at 4˚C. The slides were then washed as mentioned above with minimal light exposure 
and mounted using Prolong Gold antifade reagent with DAPI. 
For solution details – Appendix 3. 
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Table 2.8: Primary Antibody Details for Immunofluorescence 
Cell Type Antibody 
Raised 
In 
Type Company Cat. No. Post-Fix on Slides Dilution Washes 
Cardiomyocytes 




4% PFA - 5mins at 
RT 




DSHB MF 20 
4% PFA - 5mins at 
RT 










With and without 4% 
PFA for 5mins at RT 
1 in 100 
With or without PBS 
and PBST washes 
Anti-Podocalyxin 
(0.2 mg/ml) 










With and without 4% 
PFA for 5mins at RT 
1 in 100 
With or without PBS 
and PBST washes 
Anti-Endoglin 
(0.2 mg/mL) 
Goat Polyclonal R & D AF1320 
With and without 4% 
PFA for 5mins at RT 
1 in 25 
With or without PBS 
and PBST washes 
Fibroblasts Anti-Vimentin Chicken Polyclonal Abcam ab24525 
4% PFA - 5mins at 
RT 
1 in 300 PBS and PBST washes 
GFP 
Anti-GFP Chicken Polyclonal Abcam ab13970 
4% PFA - 5mins at 
RT 
1 in 400 
(embryo) 
PBS and PBST washes 
4% PFA - 5mins at 
RT 
1 in 100 
(adult) 







4% PFA - 5mins at 
RT 
1 in 100 PBS and PBST washes 
Smooth Muscle 
Cells 
Alpha SMA Cy3 Mouse Clone 1A4 Sigma Aldrich C6198 No post-fix 1 in 100 PBS and PBST washes 
Anti-Sm22a Rabbit Polyclonal Abcam ab14106 
4% PFA - 5mins at 
RT 
1ug PBS and PBST washes 








With and without 4% 
PFA for 5mins at RT 
1 in 100 
With or without PBS 





Table 2.9: Secondary Antibodies Details for Immunofluorescence 
Cell Type Antibody Raised In Company Cat. No. Dilution 
Anti-
Chicken 





A-11039 1 in 200 





A-11041 1 in 200 





A-21449 1 in 200 
Anti-Goat 





A-21447 1 in 200 
Anti-Mouse 
Alexa Fluor 488 Conjugated 




A-11029 1 in 200 
Anti-Rabbit 





A-11008 1 in 200 





A-11011 1 in 200 
Alexa Fluor 568 Conjugated 




A-10042 1 in 200 
Anti-Rat 
 





A-11006 1 in 200 
Alexa Fluor 488 Conjugated 




A-21208 1 in 200 





A-11077 1 in 200 





A-21247 1 in 200 
 
2.5.5. Immunofluorescence on Whole-mount Retinas 
Retinas were carefully transferred from the 2ml tube into a 24-well plate containing 2xPBS and 
washed for 10mins at RT with gentle agitation. Once washed, PBS was replaced with blocking 
solution containing 0.3% Triton X-100, 0.5% Tween-20, 1% BSA and 5% normal goat serum. 
Retinas are blocked in the blocking solution for 4hrs at RT with gentle agitation. Next, primary 
antibody appropriately diluted (Table 2.10) in blocking solution was added and retinas were 
left overnight in a cold-room at 4°C with gentle agitation. 
Next day, retinas were washed 5 times in a PBSTTx solution at RT with gentle agitation 
(10mins each). Retinas were next incubated over-night with appropriately diluted secondary 
antibody and Isolectin (Table 2.10) in cold-room at 4̊C with gentle agitation. Third day, retinas 
were washed again with 5 changes of PBSTTx as above. Once washed, retinas were transferred 
on to a slide with the help of a wide Pasteur pipette, excess wash solution was carefully drained, 
and retinas were mounted using 30 to 50µl of Prolong gold antifade reagent per retina. 





Table 2.10: Antibodies details for Whole-mount Immunofluorescence 
Cell Type Antibody 
Raised 
In 











1 in 100 
GFP Anti-GFP Chicken Polyclonal Abcam ab13970 1 in 300 
Smooth 
Muscle Cells 







1 in 100 










I21411 1 in 50 
Anti-Rat 






A-11077 1 in 200 
Anti-Chicken 





A-11039 1 in 200 
 
2.6. Intra-Ocular BMP9 Injection  
BMP9 was injected into the left eye of the pups via intraocular (IO) route while PBS was 
injected into the right eye. IO injections were performed by Dr Rachael Redgrave on neonatal 
mice (day P4 or P5). During the procedure, mice were deeply anaesthetised with 4% isoflurane 
and were injected with 0.3µl of 1.5mg/ml BMP9 using a Hamilton syringe (27G needle). Once 
recovered from the anaesthesia, pups were returned to their mothers. Only the pups with 
successful injections were kept and others were euthanized by cervical dislocation. 
2.7. Injection of Microbeads 
Microbeads were injected into the circulation and to allow mapping of the vasculature as well 
as to identify the presence of any vascular abnormalities. 
2.7.1. 15µm3 Red Fluorescence Microbeads Perfusion 
15µm3 diameter red fluorescence microbeads (ThermoFisher, F21013) are normally trapped in 
the capillaries and were used to identify the presence of abnormal vessels. Microbeads were 
injected into the tail vein by Dr. Simon Tual-Chalot. To inject the beads into the tail vein 
injection, mice were terminally anesthetised using isoflurane and a catheter was placed in the 
tail vein using a 30G ½” needle. To confirm the catheter was correctly placed, saline was 
injected, and a small amount of blood was drawn. Once confirmed, 200µl of microbeads were 
slowly injected using a 1ml syringe with 30G ½” needle. Mice were scarified 1-minute post 
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injection by intra-cardiac injection of euthatal. Organs including brain, lungs, liver and kidneys 
were harvested in 1xPBS.  
2.7.2. 45µm3 Green Fluorescence Microbeads Perfusion 
To detect the presence of any abnormal vessels in brain, liver and kidneys, 45µm3 diameter 
green fluorescence microbeads (Polysciences, Inc., 18242-2) were injected into the LV of the 
mice by Dr. Simon Tual-Chalot. Mice were weighed then anesthetised using isoflurane. The 
heart was surgically exposed and 50 to 400µl of green microbeads were injected into the LV 
using a 1ml syringe with a 25G 5/8” needle. During the procedure, heart rate was monitored, 
and mice were sacrificed 1-minute post injection by intra-cardiac injection of euthatal and 
organs were harvested in 1xPBS for imaging. 
2.7.3. 15µm3 and 45µm3 beads perfused Organs: Tissue Mounting 
During this experiment, to avoid any accidently beads in-take after organ harvest, each organ 
was stored in separate vial in 1xPBS and prepared in separate petri-dishes for imaging. To 
capture the images the whole of organs, each organ was placed flat between two slides and 
secured between two slides using masking tape (Figure 2.6A). To image lung slices, the left 
lung lobe was frozen at -20°C for 45-60mins then sliced using mouse heart tissue slicer (Zivic 
Instruments, cat. no. HSMS005-1) into 1mm thick sections. The sliced lung tissue was next 
placed on slides in a chronological order, secured with coverslip and imaged (Figure 2.6B).  
 
Figure 2.6: Cartoon of a sample preparation for imaging whole organs and lung slices using M2 axio-imager 
microscope. (A) To image whole organs (big red circles), organ was placed in the middle of a slide and a second 
slide was used to secured it in place with the help of some masking tape (orange). To be certain, the organ does 
not get crushed between slides, second slide was raised slightly using rolled up masking tape (green). (B) Sliced 
lungs were placed flat in a chronological order on a slide and secured in place with coverslip using masking tape. 
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2.8. CDC Culture 
Heart Dissection: 3 to 6-weeks old Engfl/fl; RosaCreERT2/CreERt2; CAGGFP/GFP mice were culled 
via cervical dislocation and their hearts dissected using sterile instruments. Tissue was stored 
in ice cold culture media prior to processing in a tissue culture hood.  
Explant culture: Dissected hearts were washed in sterile PBS (pH 7.2) 3 times to remove any 
traces of blood/ connective tissue/ media. The tissue was then minced into small 1-2mm3 
fragments in the presence of 1ml of pre-warmed (37°C) 0.05% Trypsin/EDTA for 5mins. 
Trypsinisation was stopped by adding 4ml of pre-warmed (37°C) culture media containing 20% 
foetal bovine serum (complete explant media, CEM). Tissue fragments were placed on 
fibronectin coated 60mm petri-dishes and cultured as explants in 2ml CEM in an incubator at 
37˚C with 5% CO2. Every 3 to 4 days, 1ml of fresh CEM was added to the culture dishes. 
Explant culture was carried for approximately 2 weeks and within this time a confluent layer 
of mesenchymal-like cells grew. 
Cardiosphere Culture: These explant derived cells (EDCs) were harvested as follows; CEM 
was removed and dishes were rinsed with sterile PBS, this was followed by incubation with 
1ml of versene for 3mins to enhance trypsin activity at 37˚C. Next, dishes were incubated with 
1.5ml of 0.05% Trypsin/EDTA for 5mins at 37˚C and cells were removed by repeated 
trituration using 1ml pipette. To deactivate trypsin, 1ml of serum containing CEM was added 
to the plates and trituration was continued if needed. EDCs in suspension were transferred to 
falcon tube and centrifuged for 8mins at 800g. The supernatant was carefully discarded, and 
the cell/ explant pellet was re-suspended in 5ml of CEM and passed through a 70μM filter to 
remove explants/ debris. A 20µl sample of cell suspension was used to count the cells using a 
haemocytometer, while the filtered cell suspension was centrifuged again at 800g for 8mins. 
The supernatant was discarded, and cells were re-suspended in a specific, growth-factor 
enriched cardiosphere growth media (CGM) at a cell density of 5-7.5x105 cells per ml. 400μl 
of cell suspension was seeded per well of a of a poly-D-lysine coated 24 well plate and 
incubated at 37˚C incubator with 5% CO2. Following 4 days of culture an additional 200μl 
CGM was added to each well and on day 6-8, cardiospheres were harvested.  
Cardiosphere Harvesting: To remove cardiospheres, 0.5-1ml of PBS was added per well 
followed by gentle trituration to remove loosely adherent cardiospheres, which were transferred 
to a 50ml falcon tube. Cardiospheres were then allowed to settle at the bottom of the tube, the 
supernatant was carefully discarded. Cardiospheres were re-suspended in CEM prior to being 
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plated onto fibronectin coated tissue culture flasks and incubated in 5% CO2 incubator at 37˚C 
with growth media changes every 2 to 3 days. 
CDCs Passaging: Old growth media was discarded, and flasks rinsed briefly with pre-warmed 
sterile PBS. The flask was then incubated with accutase (10ml per T75 flask) for 5 to 10mins 
at RT. Cells detachment was visually checked under inverted microscope. The subsequent cell 
suspension was transferred to a 50ml falcon tube and centrifuged at 800g for 8mins. The 
supernatant was carefully discarded, and the cell pellet was re-suspended in 1ml CEM using a 
P200 pipette to break up any cell clumps. A 20μl sample from this solution was used to calculate 
cell density using a haemocytometer. Approximately 5x105 cells per 15ml of CEM were seeded 
per T75 flask and kept in 37oC/ 5% CO2 incubator. Media was changed every 3 to 4 days and 
cells were passaged at 80-90% confluency. 
Endoglin knockdown: To knockdown endoglin in CDCs, cells were incubated with culture 
media containing 3μM 4-hydroxy tamoxifen (4-OH) for 96hrs. An additional 4 days of standard 
culture was additionally required to allow for turn-over of existing endoglin protein. 
CDC Injections for Post-MI injections: Media was removed from the control and Eng-iKO 
T75 flasks (passage 2) and the flasks were briefly washed with 10ml PBS to remove any media 
traces. Flasks were then incubated with accutase (10ml per T75 flask) for 5 to 10mins at RT to 
detach cells. Flasks were gently knocked and triturated to encourage cell detachment (checked 
under microscope to confirm). The cell suspension was then collected in a 50ml falcon tube and 
flasks were rinsed with 10ml of CEM (also collected). The cell-suspension was then centrifuged 
for 10mins at 800g (repeated if necessary). Supernatant was carefully removed, and cell pellet 
was then re-suspended in 50 to 100µl of PBS (depending upon the pellet size). A 10µl sample 
was diluted in PBS and used for cell counting using the haemocytometer. The cell suspension 
was then re-suspended in more PBS to attain a cell concentration of 5x105 cells per 10μL. This 
cell suspension was then transferred to a screw cap vial and to deliver to FGU surgery suite on 
ice for intra-myocardial injections (5μL injections at two sites). 
For media details – refer to Appendix 4. 
2.9. MI Surgery and Intra-Myocardial Injection 
Myocardial surgeries were performed by Dr. Rachael Redgrave. Briefly, approximately 12-14 
weeks old C57Bl/6 male mice were pre-medicated with analgesic (fentanyl/fluanisone, 
0.4ml/kg) and anesthetized using isoflurane. Mice then underwent left-side thoracotomy and an 
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acute MI was achieved by permanent ligation of the LAD (left anterior descending) coronary 
artery using 7-0 prolene suture. Once confirmation of the MI was established by visible 
blanching of the myocardium  (Figure 2.7); two intra-myocardial injection of PBS, control CDC 
or Eng-iKO CDCs (5x105cells/10µl) at the infarct border (237). Following injection, the mouse 
chest was closed, and animals were allowed to recover in a warm oxygenated recovery chamber. 
Sham mice underwent the same thoracotomy but there was no ligation of the coronary vessel. 
At 4 weeks post-surgery, mice were euthanized by cervical dislocation, hearts were harvested, 
and atria were removed prior to embedding.  
 
Figure 2.7: Image of an adult mouse heart after a MI surgery (image courtesy Dr. Rachael Redgrave). MI 
was induced by ligating the LAD and confirmation of MI was established blanching of the myocardium (under the 
white dotted line). Yellow arrows show the site of intra-myocardial injections.  
2.10. Microscopy  
2.10.1. Organs/ Embryo Imaging 
To image whole embryos/ organs a stereo dissecting microscope (Stemi SV 6 (Carl Zeiss) or 
MZ6 (Leica) was used. Once dissected, embryos/ organs were placed in a petri-dish containing 
1xPBS and oriented to the desired position using forceps. For adult and neonatal heart imaging, 
an external measurement scale was used to determine heart size. To image fluorescent beads 
injected whole organs, tiled images were taken using Axioimager M2 (Carl Zeiss) microscope. 
2.10.2. Imaging Retinas 
To image whole mTmG retinas a Stemi SV 11 Apo stereo (Carl Zeiss) or Axioimager M2 (Carl 
Zeiss) microscope was used. Dissected retinas (section 2.1.3) were kept in 2xPBS and were not 
exposed to methanol to avoid interference with the fluorescent protein signal. During imaging, 
most of the PBS was removed to flatten the retina inside the well (12-well plate for SV 11 Apo 
stemi microscope) or on a slide (for Axioimager M2). To image retinas on SV 11 Apo stemi 
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microscope, flattened retinas were first focused using white light and were then exposed to UV 
light with red fluorescent protein (RFP) and GFP filter sets and visualised using Axioimager 
software. Individual channel images were taken at selected exposure times and these images 
were then overlaid using Adobe Photoshop software. To image retinas using Axioimager M2, 
a tiled imaged (9 to 12 tiles) was taken using Carl Zeiss filter set 10 and filter set 31 (Table 
2.11) at x5 magnification. Once imaged, retinas were stored in 100% methanol (see section 
2.1.3). 
2.10.3. Bright-field and Fluorescence Microscopy 
To image stained slides (bright-field and fluorescence), Carl Zeiss Axioimager M2 microscope 
equipped with low and high-power objectives (x5, x10, x20, x40 and x63) was used. 
Florescence imaging was doing using the filter sets mentioned in Table 2.11. During 
fluorescence imaging apotome was used along with focus off-set strategy for individual 
channels. To capture digital images, microscope was connected to image processor computer 
installed with Zen Pro software. To take bright-field images, 1.4megapixel AxioCam ICc1 R4 
colour camera was used and for fluorescence images 1.4megapixel AxioCam MRm Rev.3 
monochrome camera was used.  
Table 2.11: Carl Zeiss Axioimager M2 Filter Set Details. 













300 to 380 420 to 470 DAPI 359 461 
Filter Set 
10 
450 to 495 510 to 560 
FITC 495 519 
Alexa 488 495 519 
Filter Set 
31 
550 to 585 595 to 650 
Cy3 548 561 
Alexa 568 578 603 
Alexa 594 590 617 
Filter Set 
50 
620 to 660 665 to 720 Alexa 647 650 665 
 
To confirm there was no bleed through between different filter sets (Table 2.11), OCT 
embedded sections were stained with rat anti-CD105 primary antibody. To visualise, goat anti-
rat secondary antibody conjugated with either Alexa 488, Alexa 568 or Alexa 647 fluorophore 
(Figure 2.8) was used. Once stained, exposure for each filter set was set using a positive section 
(Figure 2.8 A, E and I) and then each section was imaged using all four filter sets mention in 
the Table 2.11. 
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2.10.4. Imaging and Analysis 
To analyse the whole section or whole organ, tiled image was created using Carl Zeiss 
Axioimager M2 microscope and Zen Pro software. Z-stack imaging allows analysis of 
expression of markers across all three axes (X-Y, X-Z and Y-Z) of a section. To take Z-stacks, 
Carl Zeiss Axioimager M2 microscope with Zen Pro/ Zen 2012 software was used.  Z-stack 
imaging is used to confirm the expression of endoglin in EPDCs (Chapter 4) and confirm the 
presence of AVMs P11 retinas (Chapter 5).  
During this project, data was generated by manual counting, intensity analysis; area and length 
measurements. To perform manual counting, ‘Event’ function of Zen Pro software was used. 
To perform line and area intensity analysis using Zen Pro software ‘Draw Spline Contour’ 
function was used. To measure length and area Zen Pro function, ‘Line’ and ‘Draw Rectangle’ 
was used. To perform intensity analysis using ImageJ software ‘Limit to Threshold’ function.  
To measure area using ImageJ software ‘Perimeter’ function was used. Prior to analysing any 
fluorescently stained images, same white and balance was set for all images.  
2.11. Statistical Analysis 
Unless otherwise stated all the experiments used at least three biological replicates. To perform 
statistical analyses GraphPad Prism software was used. To compare two independent groups, 
unpaired students t-test was used. In case where a single parameter was compared between 
multiple groups, one-way ANOVA with a Bonferroni post hoc test was performed to check for 
significance. To compare two parameters within a group, two-way ANOVA was performed 







Figure 2.8: Bleed through check for Carl Zeiss M2 Axioimgaer Filter Sets. E17.5 OCT embedded heart 
sections stained with rat anti-CD105 primary antibody. To detect the primary antibody, heart sections were stained 
with goat anti-rat secondary antibody conjugated with Alexa 488 (A,D&G) Alexa 568 (B,E&H) or Alexa 647 
(C,F&I) and counter-stained with DAPI (blue) to mark nuclei. Exposure times for each filter set was set using the 
sections shown in A, E and I. (B&C) Showing no bleed through from Alexa 568 and Alexa 647 conjugated 
secondary antibody stained sections in filter set 10. (D&F) Similarly, no bleed through was observed from Alexa 
488 and Alexa 647 conjugated secondary antibody stained sections in filter set 31. (G&H) Showing no bleed 
through from Alexa 488 and Alexa 568 conjugated secondary antibody stained sections in filter set 50. (J to L) 
Merged channel images showing no bleed through of fluorophores between the three filter sets. (M,O&Q) No 










Chapter 3. Endoglin Expression in the 





Endoglin is a TGFβ co-receptor that plays a vital role during angiogenesis (section 1.4.2 1.5.1). 
It is highly expressed in proliferating endothelial cells (ECs) (144, 238) while low levels of 
endoglin occur in quiescent ECs (141). In the heart, various studies have shown endoglin 
expression during development of cardiac valves, AV canal and endocardium or in pathological 
conditions. In vivo studies have showed expression of endoglin in the valvular mesenchymal 
cells during embryonic development (128, 138, 239, 240). In humans, endoglin is expressed in 
these cardiac valve mesenchymal cells, although this endoglin expression is downregulated 
during the latter phases of valve development (240). Using immunohistochemical and western 
blotting analysis, Qu et al. (240) showed the endoglin expression only in the primitive heart 
tube, ECs of coronary vessels and endocardium in 4 to 13-weeks old human embryos. They 
also showed endoglin expression in the mesenchymal cells of endocardial cushions [AV and 
semilunar (SL) valves] of 4 to 7-week old human embryos (240). St-Jacques et al. (138) used 
in situ hybridisation and immuno-histochemical analysis to show expression of endoglin in the 
mesenchymal cells of heart valves and in ECs of coronary arteries (138). Bourdeau et al. (161), 
also showed the presence of these endoglin expressing mesenchymal cells in the AV cushions 
of mice around E10.5 and were likely formed by endothelial to mesenchymal transition 
(EndMT) of adjacent endocardium. They also showed the expression of endoglin in the 
endocardium from E9.5 onwards (161).  
A similar pattern of endoglin expression was observed by Jonker and Arthur (137) with strong 
expression of endoglin in E9.5 endocardium and in heart valves at E12.5 & E13.5. Furthermore, 
endoglin expression was observed in the vascular endothelium of E12.5 and 13.5 embryos and 
observed strongest endoglin expression in capillaries, intermediate levels in arteries and 
weakest in veins (137). In a recent study, endoglin is also used as an early cardiac vascular 
marker at E8.5 and by E10.5 was observed in the endocardium & coronary vessel endothelium 
(241).  
Expression of endoglin has also been reported in chicks (242). At stage 15 in chicks, endoglin 
expression was shown in the endothelium of AV canal. At stage 17, expression of endoglin was 
also observed in the OFT endothelium, proepicardium and in the ECs of posterior cardinal veins 
(242); and by stage 18  endoglin was also detected  in the mesenchymal cells located in the 
OFT and AV canal (242). 
In adult porcine hearts, low level endoglin expression was observed in ECs, adventitial 
fibroblasts, and a minority of medial SMCs of normal hearts (215). However, 3, 7, and 14 days 
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after an arterial injury (balloon-injured) endoglin expression was significantly increased in ECs, 
myo-fibroblasts and medial SMCs. This expression of endoglin was significantly declined 28-
days post injury. This showed that endoglin is necessary during the active angiogenic phase 
(215). They also showed similar endoglin expression pattern in normal and atherosclerotic 
human coronary arteries (215). Furthermore, they observed 95% of cultured human SMCs 
express endoglin on their cell surface (215).  
Using situ hybridisation and immuno-histochemical analysis, Laake et al. (216) showed 
expression of endoglin primarily in the atria with low levels in ventricles of normal adult mice 
hearts (216). Endoglin expression was significantly increased in 1-week post-MI hearts in the 
infarcted region (216). Chen et al. (243), showed low level expression of endoglin mRNA and 
protein in cultured cardiac fibroblasts from adult male rats. 
Apart from early to mid-development and in few injury model studies using adult hearts, the 
expression of endoglin has not been reported during the course of coronary vasculature 
development in mice. Therefore, the aim of this chapter was to determine the normal pattern, 
timing and relative intensity of endoglin expression in the heart and coronary vessels from early 
development to maturity. As coronary vessel development begins around E11.5 (43, 44), 
expression of endoglin was studied at different stages from E11.5 to adult in wildtype C57Bl/6 
mice. 
3.2. Results 
3.2.1. Staining Optimisation 
Freshly dissected hearts were fixed in 0.2% PFA overnight and embedded in OCT (section 
2.2.2). Tissue was sectioned, and immuno-fluorescent staining was performed (as described in 
section 2.5.4) to evaluate endoglin expression in the heart with particular focus on the coronary 




Table 3.1: Antibodies used to characterise expression of endoglin in developing, postnatal and adult mouse 




Raised In Specificity within Heart Age Range 




Venous ECs & Endocardial 
(245) 




vSMCs (246-248) & 
Mesenchymal Cells (249) 
Coronary arteries specific 





Rat or Goat 




During the current study, two different anti-CD105 antibodies were used: rat anti-CD105 
antibody (monoclonal antibody MJ7/18) and goat anti-CD105 antibody (polyclonal). To verify 
at the outset that both anti-CD105 antibodies identify the same cell types, double 
immunofluorescence staining was performed on E15.5 and E17.5 embryo sections (Figure 3.1), 
confirming that both goat and rat anti-CD105 antibodies show excellent co-localisation and can 























































































































































































































































































































































To analyse the pattern of endoglin staining in heart in this chapter, images were taken from the 
mid plane of heart showing all four cardiac chambers (Figure 3.2A). Next, for intensity analysis 
images were taken from six regions of heart (boxed areas, Figure 3.2B) at x40 magnification to 
analyse endoglin staining intensity. These images were taken from three heart sections at least 
30 to 70µm apart to avoid duplicate imaging of same cell. Furthermore, at each age three 
separate hearts were analysed. To calculate mean fluorescent endoglin intensity, a line was 
drawn along the cytoplasmic region of an endoglin expressing cell using the spline contour 
function of Zen Pro software (Figure 3.2C).  
Endoglin expression was observed in both endothelial (CD31+ve) and some non-endothelial 
(CD31-ve) cells. To compare endoglin intensity between these two cell types, mean fluorescent 
endoglin intensity was measured from up to five CD31-ve; CD105+ve cells and 5 CD31+ve; 
CD105+ve per FOV (18 FOV per heart).  
3.2.2. Expression of Endoglin in Coronary Vessels during Embryogenesis  
I first analysed the expression of endoglin in transverse sections of E11.5 (n=3) embryos using 
goat anti-CD105 and anti-PECAM1 antibodies. Tiled image of E11.5 embryos showed partial 
septation of the ventricle chambers (asterisk, Figure 3.3A) consistent with this stage of heart 
development (2, 250). Analysis of x40 immunofluorescence images of RV and LV free walls 
showed that expression of endoglin was restricted to endocardium (Figure 3.3) and ECs of 




                       
                                  















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































At E13.5, development of aortic arch and septation of the OFT into aorta & pulmonary trunk is 
complete (2, 250, 251). The septation of primitive ventricle into right & left ventricles are 
underway (2, 250). Coronary vessel development also continues over the dorsal and ventral 
surface of the heart (44).  
Transverse sections of E13.5 hearts (n=3) were stained with goat anti-CD105 and anti-
PECAM1 (CD31) antibodies. Tiled immunofluorescence images showed almost complete IVS 
consistent with this stage of development and the presence of the coronary vessels in the 
ventricles & IVS (Figure 3.4A). High-power images of free ventricle walls showed strong 
endoglin expression in the endocardium (white arrows, Figure 3.4) and ECs (yellow arrows, 
Figure 3.4).  
However, cells with lower levels of endoglin expression that were also CD31 negative, were 
found in the IVS, sub-epicardial and mid-myocardial regions of the heart (red arrows, Figure 
3.4). These cells could be mesenchymal cells as endoglin is a known mesenchymal marker 
(252) with potential origin from the epicardium (also known as epicardially derived cells, 
EPDCs). At this stage of development, EPDCs are expected to be migrating into the 
myocardium to support the developing coronary vasculature (section 1.3.1.1). Bax et al. (64) 
reported that EPDCs cultured in vitro in their mesenchymal state express endoglin, in agreement 
with the idea that these low endoglin expressing cells observed in vivo (Figure 3.7) may be 
EPDCs. In this chapter, these cells are referred to as “presumed EPDCs” from here on. Mean 
endoglin intensity was calculated using spline contour function of Zen Pro software as 
described in Figure 3.2. Endoglin fluorescent intensity analysis of the sub-epicardial ECs was 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Next, the expression of endoglin was studied in E15.5 hearts. By this stage, the basic structure 
of the heart is almost complete. The right and left coronary arteries are connected at the base of 
the aorta thereby inducing blood flow in the nascent coronary plexus (38). This anastomosis of 
aorta and coronary vessels along with the hypoxia stimuli induced by myocardium thickening 
significantly promotes the growth of the coronary vasculature (43).   
Coronal sections of E15.5 hearts (n=3) were stained with goat anti-CD105 and anti-CD31 
antibodies. Tiled images show a four-chambered heart structure with thicker myocardium 
compared to E13.5 myocardium and presence of coronary vessels throughout the myocardium. 
High-power image analysis showed a similar pattern of endoglin expression to that previously 
seen in E13.5 embryonic mice hearts, with strong endoglin expression in endothelial (yellow 
arrows,) and endocardial cells (white arrows, Figure 3.5), but a three-fold lower endoglin 
expression in presumed EPDCs (red arrows, Figure 3.5 and Figure 3.5J). These presumed 
EPDCs were evenly dispersed throughout the myocardium, with some in clusters of 4 or more 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Next, expression of endoglin was studied at final stages of embryonic development at E17.5. 
At this stage, myocardium continues to thicken, valve mature (251) and is accompanied by 
differentiation of nascent vessels into coronary arteries and veins (43).  
Coronal sections of E17.5 hearts (n=3) were stained with goat anti-CD105 and anti-CD31 
antibodies. Analysis of high-power images now showed varying endoglin intensity in ECs. The 
endocardial cells (white arrows, Figure 3.6) and the ECs of sub-epicardial & sub-endocardial 
blood vessels (yellow arrows, Figure 3.6) continued to show strong endoglin expression, but 
vascular ECs in the mid-myocardium expressed lower levels of endoglin, although not as low 
as in presumed EPDCs (purple arrows, Figure 3.6). As the mid-myocardial vessels are arterial 
this difference in endoglin expression is further investigated in Section 3.2.4.  
A significant reduction in the density of presumed EPDCs (red arrows, Figure 3.6) was 
observed throughout the myocardium at E17.5 in comparison to E13.5 and E15.5 hearts (Figure 
3.11). Next, the expression of endoglin in presumed EPDCs and valve mesenchyme is studied 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.3. Endoglin in Mesenchymal Cells of Embryonic Mice Heart 
Mesenchymal cells are vital for normal heart development (discussed in section 1.1). 
Epicardium provides mesenchymal cells (EPDCs) that differentiate into vSMCs required for 
coronary vessel maturation and cardiac fibroblasts (discussed in section 1.3.1.1 and 1.3.2). 
These EPDCs start to migrate into the myocardium around E13.5 (78, 253). 
The endocardium is also known to provide mesenchymal cells required during AV & SL valve 
development (described in section 1.1.1) (254). Furthermore, mesenchymal cells are also 
known to express endoglin, (252). In this study, I analysed the intensity of endoglin expression 
in AV valve mesenchymal cells compared with presumed EPDCs and adjacent endocardium or 
vascular endothelium.  
Development of AV valves begins around E11.5 with the formation of endocardial cushions 
populated by mesenchymal cells provided by the adjacent endocardium around E12.5 (2, 250). 
Valvular mesenchymal cells from E13.5 (n=3), E15.5 (n=3) and E17.5 (n=3) heart sections 
were next analysed to determine the relative endoglin expression. Analysis of 
immunofluorescence images showed expression of endoglin in CD31-ve valvular mesenchymal 
cells at all three stages of development (red arrows, Figure 3.7) consistent with the results 
observed by Qu et al. (240), Arthur et al. (128) and Nomura-Kitabayashi et al. (239). The mean 
endoglin fluorescent analysis also showed significantly reduced levels of endoglin expression 
in valvular mesenchymal cells compared to adjacent endocardial cells at E13.5, E15.5 and 













Figure 3.7: Valvular mesenchymal cells express low levels of endoglin compared to adjacent endocardial 
cells. E13.5, E15.5 and E17.5 embryonic heart sections stained with anti-CD31 (endocardium and endothelium, 
red) and anti-CD105 (endoglin, green) antibodies. Nuclei stained with DAPI (blue). Split channel images of (A-
C) E13.5 (n=3), (D-F) E15.5 (n=3) and (G-I) E17.5 (n=3), heart valves (AV valves) showed lower levels of 
endoglin in mesenchymal cells (red arrows) compared to adjacent endocardium (yellow arrows). Quantification 
of fluorescent intensity reveals significantly reduced levels of endoglin expression in mesenchymal cells compared 
to adjacent endocardial cells at (J) E13.5 (0.414±0.015, n=3, p = < 0.0001), (K) E15.5 (0.454±0.012, n=3, p = < 
0.0001) and (L) E17.5: 0.474±0.021, n=3, p = < 0.0001). Data shown as mean±SEM and analysed using two 
tailed unpaired t-test (*** p < 0.0001). Scale Bars: A to I – 50µm. Abbreviations: AV – Arteriovenous; InL – 
Inferior Leaflet; MV – Mitral Valve; Spl – Superior Leaftlet and TV – Tricuspid Valve. 
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Next, endoglin expression in presumed EPDCs relative to adjacent ECs was compared with 
endoglin expression in valvular mesenchymal cells relative to the adjacent endocardium. The 
ratio of endoglin expression in both sets of mesenchymal cells compared to endothelial or 
endocardial cells was observed to be similar at approximately 0.4 (Figure 3.8).  
 
Figure 3.8: Similar Level of Endoglin Expression Observed in Valvular Mesenchymal Cells and Presumed 
EPDCs. The endoglin expression in valvular mesenchymal cells (relative to adjacent endocardium) at E13.5 
(0.415±0.009; n=3; p = 0.1540), E15.5 (0.453±0.008; n=3; p = 0.0620) and E17.5 (0.478±0.031; n=3; p = 
0.1070) was similar to expression of endoglin in presumed EPDCs (relative to adjacent ECs) observed at respective 
ages (E13.5: 0.480±0.036, n=3; E15.5: 0.372±0.031, n=3 and E17.5: 0.364±0.046, n=3). Data shown as 
mean±SEM and analysed using two tailed unpaired t-test. Abbreviations: ECs – Endothelial Cells and EPDCs – 
Epicardially Derived Cells. 
To further confirm that these presumed EPDCs are mesenchymal cells, heart sections from 
E11.5, E13.5, E15.5 and E17.5 were also stained with anti-SM22α and rat anti-CD105 
antibodies. The SM22α antibody is used to detect TAGLN gene and is also used as an early 
marker for mesenchymal cells and vSMCs in various studies (104, 249, 255). At E11.5, SM22α 
expression was only seen in the dorsal aorta of a developing heart (red arrow, Figure 3.9). From 
E13.5 onwards, strong SM22α expression was seen not only in the major vessels (aorta and 
pulmonary trunk) but also in newly muscularised vessels in the myocardium (yellow arrows,). 
Lower levels of SM22α expression were also observed in all low endoglin expressing presumed 
EPDCs observed at E13.5, E15.5 and E17.5 (red arrow, Figure 3.10), consistent with their 














Figure 3.9: At E11.5, SM22α expression was observed in the major arteries of the embryos. E11.5 transverse 
heart sections were stained with anti-CD105 (green), anti-SM22α [vSMCs (bright red) and mesenchymal cells 
(weak red)] antibodies and counterstained with DAPI to mark nuclei (blue). (A) Representative tiled image of a 
transverse section of an E11.5 embryo showed partially formed IVS (asterisk) and strong expression of SM22α in 
the dorsal aorta. (C-E) Split and merged channel images of free RV wall (white box A) showed expression of 
endoglin only in the endocardium (white arrows) and no SM22α expression in the myocardium (n=3). (B) No 
primary staining control. Scale Bars: A – 200µm; B-E – 20µm. Abbreviations: DAo – Dorsal Aorta; endo – 
Endocardium; epi – Epicardium; IVS – Interventricular Septum; LA – Left Atria; LV – Left Ventricle; Myo –































































































































































































































































































































































































































































































































































































































































































Quantification of numbers of the “presumed EPDCs” at different ages (n=3, per group) was 
performed by counting the total number of presumed EPDCs (CD105+ve and CD31-ve) 
divided by total number of nucleated cells per FOV (6 FOV per section and 3 sections per 
heart). A dynamic change in the number of these CD105+ve presumed EPDCs was observed 
from E13.5 to E17.5 (Figure 3.11, C). The CD105+ve presumed EPDCs were first observed at 
E13.5 at a density of 1.1% myocardial cells and significantly increased in E15.5 hearts to 1.4% 
(p = 0.0012) before dropping to 0.5% at E17.5 (p = <0.0001). The analysis of E11.5 to E17.5 
embryonic hearts showed that during development endoglin is expressed strongly by CD31+ve 
ECs and weakly in mesenchymal cells.  
 
Figure 3.11: The number of presumed EPDCs expressing low levels of endoglin peaks at E15.5 during mouse 
heart development. E13.5 (n=3), E15.5 (n=3) and E17.5 (n=3) heart sections were stained with anti-CD105 
(green) and anti-CD31 (red) antibodies. Nuclei stained with DAPI (blue). Digital zoomed split channel images of, 
(A-C) presumed EPDCs (CD31-ve cell with low levels of endoglin expression, red arrows) and (D-F) sub-
epicardial ECs (CD31+ve cell expressing strong levels of endoglin, yellow arrows). (G) Quantification showing 
significantly increased and maximal density of presumed EPDCs at E15.5 (0.012±0.001, n=3) compared to E13.5 
(0.015±0.001, n=3, p = 0.0012) and with lowest density at E17.5 (0.005±0.001, n=3, p <0.0001). The density of 
presumed EPDCs was observed to significantly reduced at E17.5 compared to E13.5 (p <0.0001). Data shown as 
mean±SEM and analysed using one-way ANOVA (** p < 0.01 and **** p < 0.0001). Abbreviations: ECs – 
Endothelial Cells and EPDCs – Epicardially Derived Cells.  
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3.2.4. Endoglin Expression in Coronary Arteries, Veins and Capillaries  
ECs of the coronary vessels in the sub-epicardium and sub-endocardium region of the heart at 
E17.5 expressed strong levels of endoglin while mid-myocardial coronary vessels express 
lower level of endoglin. As coronary arteries develop in the mid-myocardium region of the 
heart while coronary veins develop in the sub-epicardial and sub-endocardial region of the heart 
(43) this differential expression of endoglin could correspond to arterial and venous identity. 
Therefore, sister sections of the E17.5 hearts were stained to analyse whether this was the case. 
Furthermore, muscularisation of the arteries precedes the veins possibly due to increased 
pressure in arteries due to blood flow (256-258). Hence, SM22α provides a useful marker to 
identify arteries (246-248). 
The intra-myocardial vessels at E17.5 showed strong SM22α staining (purple arrows, Figure 
3.12, C,J,Q) whilst most of the sub-epicardial vessels were non-muscularised or have a very 
thin layer of vSMCs (yellow arrows, Figure 3.12, B,I,P). Conversely endomucin stains venous 
endothelium (245) and was therefore used to identify veins. At E17.5, sub-epicardial vessels 
showed strong expression of endomucin (yellow arrows, Figure 3.12, E,M,S) while mid-
myocardial vessels showed weak endomucin expression (purple arrows, Figure 3.12, F,N,T). 
E17.5 heart sections stained with anti-CD105 and anti-SM22α or anti-endomucin antibodies 
(Figure 3.12) revealed that endoglin was strongly expressed in venous ECs in the sub-epicardial 
region (yellow arrows, Figure 3.12), but expressed at significantly reduced levels in ECs of 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.5. Expression of Endoglin in Postnatal Mice Hearts  
Mouse heart development continues for 3wks in postnatal life (45). During this time the 
myocardium volumes increases significantly which in turn triggers the growth of the coronary 
vasculature (257). Interestingly, in post-natal and adult rodent hearts, arteries are still observed 
in the intra-myocardial space and veins are more superficially located in the sup-epicardial 
region (258).  
To study the expression of endoglin at the final stages of heart development, coronal heart 
sections from P21 mice (n=3), were stained with rat anti-CD105 and anti-SM22α antibodies. A 
tiled immunofluorescence image showed a typical P21 mice heart with thick ventricular 
myocardium with mature coronary vessels (Figure 3.13A). Mean fluorescent intensity analysis 
revealed strong endoglin expression in capillaries and in large sub-epicardial veins, identified 
by a flattened morphology and a thin vSMCs layer (Figure 3.13, I&P). In contrast, low endoglin 
expression was observed in highly muscularised intra-myocardial vessels (A to I, Figure 3.13). 
This endoglin expression pattern was similar to the one observed at E17.5 (Figure 3.12). 
Presumed EPDCs seen during the embryonic period (section 3.2.3, Figure 3.10) were not 
observed at P21. 
To confirm this differential expression of endoglin in arteries, veins and capillaries, sister 
sections of P21 hearts were also stained with anti-endomucin and goat anti-CD015 antibody. 
Only sub-epicardial veins and intra-myocardial arteries were considered for quantification 
purposes. Mean endoglin fluorescence intensity analysis of high-power images of veins in the 
sub-epicardium showed strong expression of both endoglin and endomucin (yellow arrows, L-
N Figure 3.13) while the intra-myocardial vessels (with big lumen) were negative for 
endomucin and expressed low levels of endoglin (purple arrows, Q-S Figure 3.13). Capillaries 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.6. Expression of Endoglin in Adult Mice Hearts 
In adults, expression of endoglin was reported in the coronary capillaries (128, 216), but arterial 
and venous expression in the adult heart has not yet been established. 
To distinguish between arteries and veins, coronal sections of 14-week hearts (n=3) were 
stained with anti-endomucin antibody (Figure 3.14) to identify veins. . In addition to this, 
several morphological characteristics are utilised to differentiate between arteries and veins. 
For instance arteries are known to be located deeper in the myocardial layer of mouse heart 
while veins are present in the sub-epicardial layer (258). Arteries also have thicker SMC layer 
compared to veins (259). Another distinct feature of arteries is presence of elastin, which is not 
found in veins (259). Therefore, a vein was only selected for quantification if it was: (i) located 
in the sub-epicardial region and had a visible lumen, (ii) showed no elastin auto-fluorescence 
and (iii) had thin or no vSMCs layer and are stained positive for endomucin (yellow arrows, 
Figure 3.14). To select an artery, the following criteria were used: (i) present in intra-myocardial 
space with visible lumen, (ii) presence of elastin auto-fluorescence in vessel wall and (iii) either 
possessed a thick vSMCs layer or was negative for endomucin (purple arrow, Figure 3.14).  
Next, coronal sections of 14-weeks hearts were stained with anti-CD105 and anti-SM22α or 
anti-endomucin antibodies. In a healthy adult mouse heart, expression of endoglin was observed 
to be restricted to the CD31 positive endocardium and ECs of coronary arteries, veins & 
capillaries (Figure 3.15), similar to P21 hearts (section 3.2.5, Figure 3.13) and the presumed 
EPDCs were absent, as expected.  
Whole heart tiled immunofluorescence images showed a typical adult mouse heart with thick 
myocardium and a rich coronary vascular network (Figure 3.16, A&D). Mean endoglin 
fluorescent  analysis of high-power images showed strong endoglin expression in the ECs of 
sub-epicardial non-muscularised and endomucin positive veins (yellow arrows, Figure 3.15) 
and capillaries (white arrows, Figure 3.15) compared to muscularised intra-myocardial arteries 
(purple arrows, Figure 3.15). There was approximately 50% reduction in the endoglin 
expression in the veins of adult hearts observed (Figure 3.13R) compared to P21 subepicardial 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.1. Endoglin in Coronary Endothelial Cells 
Prior to coronary vasculature development, endoglin expression is only observed in the 
endocardium of the heart (128, 137, 161). During this study, the expression of endoglin was 
consistently observed in the endocardium of all hearts analysed from embryo to adult. In 
addition, the coronary ECs (coECs) were observed to express endoglin from E11.5 (Figure 3.3) 
onwards throughout development (E13.5, Figure 3.4; E15.5, Figure 3.5 and E17.5, Figure 3.6), 
in post-natal (P21, Figure 3.13) and adult (Figure 3.15) mice hearts.  
In the early stages of coronary vasculature development (E13.5, Figure 3.4 and E15.5, Figure 
3.5), endoglin expression in all coECs was observed to be similar (Figure 3.16). These vessels 
could potentially be capillaries. As the development continues, the coronary vessels start to 
differentiate into arteries and veins. In this study, the earliest stage arterial and venous ECs 
could be differentiated was at E17.5 (Figure 3.12). As the ECs differentiate, the expression of 
endoglin in the arterial ECs in the mid-myocardial region was observed to decline (Figure 3.16). 
In contrast, endoglin expression in veins and capillaries remains high during coronary vessel 
development and begins to decline once heart development is complete [P21, (Figure 3.16)]. In 
adult heart, ECs express lower levels of endoglin but the endoglin expression in coronary veins 
and capillaries was still observed to be almost double than coronary arteries (Figure 3.16). 
 
 
Figure 3.16: Dynamic Expression of Endoglin in Coronary ECs throughout development and in adult 
hearts. The expression of endoglin begins at similar level in all the coronary ECs at the beginning of coronary 
vasculature development (E11.5 to E15.5). However, as the ECs start to express arterial markers (E17.5), endoglin 
expression starts to decline in these arterial ECs, whereas in ECs of veins and capillaries, endoglin expression 
increases during the active phase of coronary vasculature development. Once the vasculature development is 
almost complete (P21), a decline in endoglin expression was observed in venous and capillaries ECs. In adult mice 
(14wks), the lowest amount of endoglin expression was observed in ECs, however, at this stage the expression of 
endoglin was still almost double in the venous and capillaries ECs compared to the arterial ECs. 
Consistent with previous publications, quiescent arterial ECs in this study were observed to 
express low level of endoglin expression (215, 216). However, coronary veins expressed similar 
levels of endoglin as the surrounding capillaries. It is not clear why quiescent ECs of veins 
express higher levels of endoglin compared to arterial ECs. In the study by Laake et al. (216), 
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it was observed that mice heterozygous for endoglin expression showed reduced angiogenesis 
in the peri-infarct region of the heart. This reduced angiogenic response could be due to lack of 
endoglin not in all ECs but specifically due to loss of endoglin in venous ECs. During coronary 
vasculature development, the majority of coronary ECs arise from the sinus venosus ECs [(43, 
44) and (discussed in section 1.3.2)], so potentially during an injury due to MI, coronary veins 
initiate the developmental like process again. Evidence from a recent publication by Dubé et 
al. (260), support this hypothesis. During development, the sinus venosus is a transient 
structure, however in adults, the coronary sinus veins act as the similar source. Using pulse-
chase genetic lineage tracing in PdgfCre-ERT2; Rosa26ReYFP mice, Dubé et al. (260) showed, after 
a MI the heart structure changes to developing hyper-trabeculated state and the new vessels 
originate from coronary sinus and endocardium (260).  
To test this hypothesis, it might be useful to study the angiogenic remodelling after a MI in 
mice lacking endoglin in venous ECs. To knockdown endoglin in venous ECs, a cre-loxP 
system would be a best approach but unfortunately a quiescent venous ECs specific Cre (e.g. 
driven by the EphB4 promoter) is not yet available for adult mice (261). Furthermore, it might 
also be useful to observe if other organs also display a similar endoglin expression pattern i.e. 
lower in arteries than in veins. For instance, in the study by Mahmoud et al. (141), endoglin 
expression was observed in the endothelium of the pulmonary veins and venules of adult mice. 
In contrast, endoglin expression was only observed in the ECs of arterioles but not in the ECs 
of pulmonary arteries (141). 
3.3.2. Endoglin in Cardiac Mesenchymal Cells 
During embryonic development (E13.5 to E17.5), mesenchymal cells were also observed to 
express endoglin, previously shown in valvular mesenchymal cells (128, 239, 240), but here 
for the first time in EPDCs. Both valvular mesenchymal cells and presumed EPDCs expressed 
significantly lower levels of endoglin compared to endocardium and sub-epicardial 
endothelium (Figure 3.17). Consistent with their known dynamics, as initial epicardial cells 
undergoing EMT to generate mesenchymal cells at E13.5, that later differentiated into vSMCs 
or fibroblasts, these presumed EPDCs were only observed from E13.5 to E17.5 with the highest 
numbers present at E15.5 (Figure 3.10). However, in future studies it would be beneficial to 
confirm these cells as EPDCs by staining heart sections with a EPDCs specific markers 




Figure 3.17: Endoglin is strongly expressed in the coronary ECs compare to a weaker expression in the 
mesenchymal cells. Endoglin is highly expressed in the coronary endothelium of E13.5, E15.5 & E17.5 
developing hearts. In comparison to ECs, a significantly weaker endoglin expression was observed in the presumed 
EPDCs at respective ages (E13.5: 0.480±0.072, n=3, p = 0.0019; E15.5: 0.373±0.0267, n=3, p = <0.0001 and 
E17.5: 0.357±0.0145, n=3, p = <0.0001). Data shown as mean±SEM and analysed using two tailed unpaired t-
test (** p <0.01 and **** p <0.0001). 
In conclusion, this chapter provides a comprehensive description of endoglin expression in 
developing and adult heart. Endoglin expression in presumed EPDCs suggests it may have a 










Chapter 4. Role of Endoglin and 






In the previous chapter, I analysed the relative expression of endoglin in three cell types during 
heart development: endocardial ECs, vascular ECs and mesenchymal cells, including presumed 
EPDCs. In this chapter, I investigate the role of endoglin and TGFβR2 in EPDCs during 
development of the coronary vessels. 
As described in section 1.3.1, the epicardium is the outer layer of the heart and by E10.5 whole 
heart is covered by epicardial cells (53). The epicardium is not in direct contact with the 
myocardium but separated by sub-epicardial space filled with ECM which is rapidly populated 
by EPDCs derived via EMT of epicardial cells (46). These EPDCs then start to invade the 
myocardium around E12.0 (54) and differentiate, primarily into vSMCs and fibroblasts (54, 70-
75) with minor contribution towards ECs (43, 44, 73, 78, 79). 
4.1.1. Endoglin and TGFβ Signalling in EMT 
The role of some of the TGFβ ligands & their receptors have been studied in the epicardium 
using different Cre-loxP mouse lines [discussed in section 1.5.2 and summarised in Table 1.2]. 
TGFβ signalling is important during EMT of epicardial cells (60, 62, 68). For instance, 
epicardial cells fail to undergo TGFβ induced EMT in vitro after epicardial specific knockdown 
of Alk5 (16). However, the role of the type 2 receptor (Tgfbr2) and endoglin in epicardial cells 
has not yet been evaluated in vivo.  
Sridurongrit et al. (60) showed that epicardial specific Alk5 knockout (Alk5-KOepi) using the 
Gata5-Cre led to impaired myocardial growth due to defective SMCs support of the coronary 
vessels (60). They also observed that the epicardium was not attached properly over the 
myocardium and there were increased numbers of capillaries in the myocardium in Alk5-KOepi 
mutants compared to controls during late embryonic cardiac development (E17.5 and E18.0) 
potentially due to lack of larger muscularised vessels. In vitro analysis also showed that the 
EPDCs EMT process was disturbed in Alk5-KOepi mutants (60). During the signalling process 
ALK5 binds specifically with TGFβR2 (263, 264). Therefore, knockdown of TGFβR2 in 
epicardial cells could potentially results in a phenotype similar to Alk5-KOepi mutants. I tested 
this hypothesis in this study by using Wt1Cre-ERT2 mouse line to knockout Tgfbr2 specifically in 
epicardial cells and EPDCs.   
The TGFβ co-receptors type 3, endoglin were also shown to be necessary during the process of 
EMT in AV cushions. In chicks, endoglin protein and mRNA expression is present in the 
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endothelium (stage 16) and AV canal mesenchymal cells (stage 17) and OFT cushions (242). 
In mouse, expression of endoglin has been reported in the endothelium and AV cushions at 
E12.5 (137, 161). Analysis of E10.5 heart after global deletion of endoglin in mice showed 
hypocellular cardiac cushions (127, 128, 161). However, detailed analysis of these embryos 
was not possible as embryos die by mid-gestation.  
In vitro studies using chick AV explants showed blocking endoglin with siRNA led to reduction 
in EMT markers including RhoA, slug and β-catenin as well as reduction in proliferative 
markers such as cyclin B2 and Id1. They also reported a significant reduction number of 
mesenchymal cells in AV explants (242). In the same study, a similar phenotype was observed 
in AV explants treated with siRNA and ALK5 specific inhibitor. This study further indicates 
that endoglin interacts with ALK5 to promote EMT as well as mesenchymal cell proliferation 
(242).  
In another study by Nomura-Kitabayashi et al. (239), the role of endoglin in AV mesenchymal 
cells was studied in vivo in mice using chimeric endoglin knockout mice. They show that in 
chimeric endoglin knockout mice, very few endoglin negative endocardial cell underwent EMT 
and migrated into AV cushions at E10.5 compared to WT embryos. They further confirmed this 
role endoglin in vitro using AV canal explant culture on hydrated collagen gel (239) and showed 
reduced number of mesenchymal cells in endoglin null AV canal explants (63). They suggested 
that endoglin is potentially required to initiate EMT as the endoglin null endocardial cell 
interaction with surrounding cells was hindered (239). Furthermore, qPCR analysis of endoglin 
null hearts tissue showed significantly reduced levels of EMT promoter gene Snai1 (239). Snai1 
is a transcription factor required for EMT (Figure 1.10) activated by TGFβ mediated signalling, 
so it is possible endoglin promotes EMT by promoting Snai1 expression in EPDCs. 
As seen in chapter 3, mesenchymal cells present in the myocardium express endoglin (Section 
3.2.3, Figure 3.10) and are presumed to be epicardial in origin (EPDCs) for two reasons. Firstly, 
the location of these cells is similar to that of EPDCs (73, 265). Secondly, in vitro studies 
showed that human adult epicardial cells express endoglin in culture after EMT (64).  
In the study by Bax et al. (64), cultured adult EPDCs after EMT attain a spindle like structure 
(similar to SMCs) and 73% were observed to express endoglin (64). Bax et al. (64) also showed 
the absence of endoglin led to a significant increase in epicardial markers (β-catenin, E-cadherin 
and VCAM-1) but did not block TGFβ mediated EMT. In this study, they suggested that 
endoglin is not directly involved during the EMT process but might play a role later in the 
mesenchymal cells  or during EPDCs differentiation to cardiac cell types (64). 
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To date, no study has examined the expression and functional role of endoglin in EPDCs in 
vivo, which is the goal of this part of the current study. Considering the importance of endoglin 
in mesenchymal cell, migration proliferation and differentiation (64, 239, 242), it is possible 
similar process would be affected in the absence of endoglin in EPDCs in vivo (discussed in 
section 1.3.1.2). To study this, Wt1Cre-ERT2 was used in combination with endoglin floxed mice 
(Engfl/fl) (266) to allow specific depletion of endoglin in Wt1Cre-ERT2 epicardial cells and EPDCs 
along with Rosa26eYFP reporter mice (267) for lineage tracing. 
4.2. Results 
4.2.1. Wt1Cre-ERT2 Optimisation and Lineage Tracing 
To investigate the role of endoglin and Tgfβr2 in EPDCs during cardiac development in vivo 
the epicardial specific Cre transgenic mouse line Wt1Cre-ERT2 was used (81). The Wt1Cre-ERT2 is a 
widely used as an epicardial specific inducible Cre mouse line. To activate Cre-ERT2, 
tamoxifen is injected at specific a dose and time point. Zhou and Pu (253), also suggested that 
different reporter line could affect the recombination efficiency of Wt1Cre-ERT2 (Table 4.1). To 
ensure the Wt1Cre-ERT2 mice line was as effective as possible in activating Cre and could be used 
to target epicardial cells and their derivative EPDCs I first optimised Cre activation for Wt1Cre-
ERT2 mouse line using a Rosa26eYFP reporter mouse line both in C57Bl/6 background mice. 
Table 4.1: Combinations of Wt1Cre-ERT2 with different Cre-Activated Rosa26 Reporters from different 
genetic background [adapted from (253)] 
Reporter Observations Pitfalls 
Rosa26Lz-Orkin 
Inefficient Cre recombination 
after tamoxifen injection. 
Low labelling efficiency. 
Rosa26Lz-Soriano 
Moderately efficient Cre 
recombination with one dose of 
tamoxifen between E9.5-E11.5. 
Endothelial labelling if induced Tam treatment 
performed at E14.5 or P4. Late gestational Tam 
toxicity and failure to yield live pups. 
Rosa26mTmG 
Moderately efficient Cre 
recombination with one dose of 
tamoxifen between E9.5-E11.5. 
Endothelial labelling if induced Tam treatment 
performed at E14.5 or P4. Late gestational Tam 
toxicity and failure to yield live pups. 
 
4.2.1.1. Wt1Cre-ERT2 Optimisation 
The Wt1Cre-ERT2 mouse line has been extensively studied and when Cre is activated with 
tamoxifen between E9.5 to E11.5, the activation is specific to the epicardium as most of the 
Wt1 expressing cells are located in the proepicardium and epicardium but not in the 
myocardium (81, 253). Therefore, to test the Wt1Cre-ERT2 activation labelling efficiency and 
reproducibility, Wt1Cre-ERT2 was activated in three different ways in pregnant females using 1mg 
tamoxifen (tam) dose per injection (Figure 4.1). The three groups were: (i) two subcutaneous 
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(subcut) tamoxifen injections on E9.5 and E10.5; (ii) three subcut tamoxifen injections from 
E9.5 to E11.5 and (iii) three intra-peritoneal (IP) tamoxifen injections from E9.5 to E11.5.  
 
Figure 4.1: Analysis of Wt1Cre-ERT2 activity using Rosa26eYFP reporter. (A) To test different doses and sites of 
tamoxifen injections to activate Wt1Cre-ERT2, a male mouse with heterozygous expression of Wt1Cre-ERT2/+ and 
homozygous expression of Rosa26eYFP/eYFP was crossed with a Rosa26eYFP/eYFP female mouse. In the presence of 
tamoxifen Cre-ERT2 is activated and removes a stop sequence which in turn leads to expression of eYFP in all 
Wt1 positive cells and their daughter cells. (B) Wt1Cre-ERT2 is activated by tamoxifen injection in three different 
strategies: (i) two subcut injection at E9.5 & E10.5 (pink arrows); (ii) three subcut injections from E9.5 to E11.5 
(light blue arrows) and (iii) three IP injections from E9.5 to E11.5 (orange arrows). The embryos were harvested 
from all three different groups are E15.5 stage of development. 
The embryos from all three groups were harvested at E15.5 stage of development, fixed in 4% 
PFA, embedded in paraffin (section 2.2.1) and sectioned into sister sections (section 2.4.1). 
These sections were then stained using anti-GFP antibody to detect eYFP protein following 
IHC-DAB protocol (Section 2.5.2) and imaged using bright-field setting on M2 axio-imager 
(section 2.10.2). A minimum of three embryos from the same litter were stained for each group 
to test intra-litter variability and 5 sections per embryo were imaged. The quantification of data 
was done using the event function of Zen 2012 software. Analysis of low power tiled images 
of whole hearts showed strong expression of eYFP in epicardial cells of all three groups (Figure 




Figure 4.2: Strong eYFP expression was observed in the epicardium and in the EPDCs after activation of 
Wt1Cre-ERT2. IHC-DAB tiled images of E15.5 hearts stained with anti-GFP antibody to detect eYFP protein 
(brown). Activation of Wt1Cre-ERT2 via (A) 2 Subcut (E9.5 and E10.5, n=9), (B) 3 Subcut (E9.5 to E11.5, n=3) and 
(C) 3IP (E9.5 to E11.5, n=3) tamoxifen injections (1mg/injection) led to similar levels of expression of eYFP in 
epicardial (black arrows) and EPDCs (red arrows) in three groups. (D) No primary antibody staining control. 
Abbreviations: epi – epicardium; EPDCs – Epicardially Derived Cells; IP – Intraperitoneal; IVS - Interventricular 
Septum; LV - Left Ventricle; RV - Right Ventricle and Subcut – Subcutaneous. Scale Bar: A to C = 200µm and D 
= 50µm. 
Next, the number of GFP labelled EDPCs (eYFP+ve EPDCs) were compared between the three 
groups. Quantification of higher power images of the free ventricle walls (RV and LV) showed 










































































































































































































































































































































































































































































































































































































































































































































To compare all three groups, the density of eYFP+ve EPDCs was calculated per FOV from 
higher power images. The eYFP+ve EPDCs density was calculated from four FOV per section 
(Boxed regions 1, 3, 4 & 6, Figure 4.4) and three sections with four chamber view were analysed 
from each heart. Each section analysed were at least 50µm apart to avoid duplicate cell 
counting.  
 
Figure 4.4: Cartoon image of transverse section of an embryonic heart section. For quantification, higher 
power images were taken from free wall of RV and LV around the dotted white boxed region. Abbreviation: RA 
– Right Atria; RV – Right Ventricle; LA – Left Atria; LV – Left Ventricle and IVS – Inter Ventricular Septum. 
The quantification showed similar density of eYFP+ve EPDCs per FOV in all three groups 
(Figure 4.3 and summarised in Table 4.2). Thus, activation of Wt1Cre-ERT2 using any of three 
strategies leads to a similar number of YFP labelled epicardially derived cells. During this 
study, I also analysed Wt1Cre-ERT2 negative embryos for each group (n=3/ group) to ensure the 
Wt1Cre-ERT2 specificity. Analysis of Wt1Cre-ERT2 negative embryos showed no eYFP expression 
in any cell types (Figure 4.3, C-E), confirming the no Wt1Cre-ERT2 activity in the absence of cre.  
Table 4.2: The activation of Wt1Cre-ERT2 using three different tamoxifen regimes (2 Subcut, 3 Subcut & 3 
IP) showed a similar density of eYFP positive EPDCs at E15.5.  
 2 Subcut Tam on 
E9.5 & E10.5 
3 Subcut Tam from 
E9.5 to E11.5 
3 IP Tam from 
E9.5 to E11.5 
N 9 3 3 
No. of Litters 3 1 1 
Total No. of eYFP+ve EPDCs 
per FOV 
27 ± 2 27 ± 3 29 ± 3 
Total No. of Nucleated Intra-
myocardial Cells per FOV 
165 ± 5 183 ± 9 199 ± 25 
Proportion of eYFP+ve EPDCs 
per myocardial cell 
16% ± 1% 15% ± 1% 16% ± 4% 
Total No. of eYFP+ve 
Epicardial Cells per FOV 
60 ± 4 




Total No. Nucleated 
Epicardial Cells per FOV 
79 ± 4 
Proportion of Epicardial Cells 
that are eYFP+ve  
75% ± 2% 
Heart Development Normal 
VSD in 2 out 6 hearts 
(1 cre+ve & 1 cre–ve) 
Normal 
The above analysis was performed on 4 FOV per section and 3 sections were analysed per heart.  
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Moving forwards, the ‘2-subcut’ injection method for Cre activation was chosen for following 
reasons: (i) all three groups showed similar eYFP labelling efficiency (Table 4.2); (ii) IP 
injections risk injection of tamoxifen directly into the uterus; (iii) higher doses of tamoxifen 
can cause developmental defects due tamoxifen toxicity (268, 269). In the current study, VSD 
was observed in 2 out of 6 hearts (1 cre+ve and 1 cre-ve) from the 3 subcut tam injection group 
(Table 4.2), which was potentially due to tamoxifen toxicity. In contrast, no developmental 
defects were observed in the other two groups.  
To ensure the 2 subcut method led to efficient epicardial labelling a quantitative analysis was 
performed. The percentage epicardial labelling efficiency was calculated by counting total 
number of epicardial cells and eYFP+ve epicardial cells (identified as cells displaying thin 
morphology on the surface of the heart). The analysis showed an average of 75% of epicardial 
cells were eYFP+ve after 2 subcut tam injections (Table 4.2). This is moderately high efficiency 
and has been considered sufficient for most fate mapping studies (253).  
4.2.1.2. Wt1Cre-ERT2: Lineage Tracing 
As mentioned in Section 1.3.1.2, epicardial cells significantly contribute to smooth muscle and 
fibroblasts cell population in the developing heart via EMT of EPDCs (54, 70-75) but only a 
minor contribution towards coronary ECs (43, 44, 73, 78, 79) and cardiomyocytes (78, 80, 81). 
Before addressing the role of endoglin in EPDCs, I first established the EPDCs contribution 
towards these different cell types (SMCs, fibroblasts, ECs and cardiomyocytes) at E17.5 using 
lineage tracing and my optimised protocol to activate Wt1Cre-ERT2.  
Three Wt1Cre-ERT2; Rosa26eYFP positive embryonic hearts were analysed at E17.5 from two 
different litters. The E17.5 embryonic hearts were fixed in 0.2% PFA, embedded in OCT 
(section 2.2.2) and sectioned into sister sections (section 2.4.2). The sections were then 
subjected to optimised double immunofluorescence staining described in section 2.5.4 using 
the antibodies shown in Table 4.3 and imaged using fluorescence setting in M2 axio-imager 
microscope. Two different anti-GFP antibodies (to detect eYFP protein) were used during the 
current study due to compatibility issues with the SMCs and fibroblasts marker. The images 
were taken from six different regions of free ventricle walls (Figure 4.4), from five different 





Table 4.3: Antibodies used to for lineage tracing of EPDCs after activation of Wt1Cre-ERT2 using the 
optimised protocol. Antibodies details are summarised in Table 2.8. 
Antibody Target protein Raised In Specificity within Heart 
Anti-GFP GFP Chicken/ Rabbit YFP Positive EPDCs 
Anti-CD31 PECAM1 Rat ECs & Endocardium (244) 
Anti-SM22α TAGLN Rabbit vSMCs (246-248) & Mesenchymal Cells (249) 
Anti-Vimentin Fibroblasts Chicken Fibroblasts and Mesenchymal Cells (270) 
Anti-MF20 Cardiomyocytes Mouse Cardiomyocytes (271-274) 
Anti α-Actinin Cardiomyocytes Mouse Cardiomyocytes (275) 
 
To analyse the contribution of EPDCs towards different cardiac cells, co-localisation between 
anti-GFP and cell specific markers were analysed. The immunofluorescence analysis showed 
differentiation of eYFP+ve EPDCs into vSMCs (Figure 4.5, A-C, white arrows), fibroblasts 
((Figure 4.5, E-G, white arrows) and ECs ((Figure 4.5, I-K, white arrows) as expected (section 
1.3.1.2). At E17.5, a few low Sm22α expressing mesenchymal cells were also observed (Figure 
4.5, A-C, yellow arrows). During this study, to verify the contribution of epicardial cells 
towards cardiomyocytes, heart sections were stained with two different cardiomyocyte markers, 
MF20 ((Figure 4.5,  M-O) and α-Actinin (data not shown). However, none of the 
cardiomyocytes were observed to be from Wt1+ve epicardial origins.  
I next calculated percentage contribution of eYFP+ve EPDCs towards these cardiac cell types 
(Table 4.4). As expected, the majority of EPDCs were observed to differentiate into vSMCs 
(17% ±1.15) or fibroblasts (22% ±2.33). While, 6% ±1.33 of EPDCs differentiated into EC (3% 
of total ECs). This data is consistent with previous publications showing majority of vSMCs 
and fibroblasts arise from epicardial cells (54, 70-75) while only a minor amount differentiate 
into ECs (43, 44, 73, 78, 79). In contrast to the previous studies (78, 80, 81), no contribution 
towards cardiomyocytes was observed. At E17.5, 38% ±2.40 EPDCs appeared to be 
undifferentiated according to the marker panel used (Table 4.3). These undifferentiated EPDCs 
are predicted to eventually differentiate into cardiac cell types (vSMCs, fibroblasts or ECs) as 
the heart development continues into post-natal life. This percentage contribution of EPDCs 
towards different lineages (Table 4.4) was next used as the baseline to determine whether this 











































































































































































































































































































































































































































































































































































































































Table 4.4: EPDCs differentiation into Cardiac Cell Types at E17.5 
Cell Type 
Percentage of EPDCs Differentiating 
to Cardiac Cell Types 
vSMCs 17% ± 1.15 
Mesenchymal Cells (SM22α) 17% ± 2.03 
Fibroblasts 22% ± 2.33 
ECs 6% ± 1.33 
Cardiomyocytes 0% ± 0 
Undifferentiated EPDCs 38% ± 2.40 
 
4.2.2. Expression of Endoglin in EPDCs in vivo 
To knockout endoglin in epicardial cells the Engfl/fl; Wt1Cre-ERT2; Rosa26eYFP mouse line was 
used (Figure 4.6B) and Wt1Cre-ERT2 was activated using the optimised protocol (2 subcut tam 
injections at E9.5-E10.5). Embryos were harvested at E15.5 for analysis as most of the endoglin 
expressing presumed EPDCs were observed at this stage of development (Figure 3.11). 
 
Figure 4.6: Mouse lines used to study and knockdown the expression of endoglin in epicardium and EPDCs 
in vivo. (A) To verify the expression of endoglin in EPDCs in vivo, embryos were harvested at E15.5 using the 
Wt1Cre-ERT2/+; Rosa26eYFP/eYFP mouse line. (B) To knockout endoglin gene in Wt1+ve cells, Engfl/fl; Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP mouse line was used. In both lines a Cre-negative female was mated with a Cre-positive male to 
avoid possible effects of Cre activation on the pregnant mother, and limit Cre activity to the developing embryos. 
Wt1Cre-ERT2 was activated by injecting tamoxifen at E9.5 and E10.5 via subcut route (in scruff) and embryos were 
harvested at E15.5. 
The E15.5 embryonic hearts were fixed in 0.2% PFA, embedded in OCT, sectioned into sister 
sections and stained using double immunofluorescence protocol with rat anti-CD105 and 
chicken anti-GFP antibodies. In each immunofluorescence experiment, the control (Wt1Cre-
ERT2/+; Rosa26eYFP/eYFP) and epicardial-specific inducible endoglin knockout (Engfl/fl; Wt1Cre-
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ERT2/+; Rosa26eYFP/eYFP, Eng-iKOepi) hearts were stained simultaneously and were compared 
with each other. Once stained, images were taken from free RV & LV wall per section (1-6 
boxed region, Figure 4.4) from 5 sections imaged per embryo and 3 embryos were analysed per 
group. To validate the expression of endoglin in EPDCs in vivo, z-stack imaging was performed 
using fluorescence setting on M2 axio-imager microscope with an apotome at x63 
magnification. The z-stack imaging allows confirmation of the expression of a marker in a cell 
in all three planes (X-Y, X-Z and Y-Z, Figure 4.7A). This helps to verify that expression of 
both makers (GFP and CD105) are expressed by same cell and not by two different cells either 
stacked on top of each other or next to each other (Figure 4.7B). To remove any observer bias 
during quantification, data was blinded prior to analysis.  
The z-stack image analysis on control embryos (Wt1Cre-ERT2/+; Rosa26eYFP/eYFP) at E15.5 
confirmed that EPDCs do express endoglin in vivo Figure 4.8) consistent with in vitro study 
(64). However, not all EPDCs were observed to express endoglin in vivo. In contrast to Bax et 
al. (64), who reported 73% EPDCs in vitro expressed endoglin, only an average of 13% ±2 
EPDCs were observed to express endoglin (n=3 hearts, n=114 ±8.327 EPDCs per heart) in vivo. 
In agreement with Bax et al. (64), endoglin expression was only observed in the EPDCs and 
not in the epicardial cells. 
 
Figure 4.7: A cartoon and an example image of a z-stack. (A) A cartoon of a z-stack showing a cell (cream 
circle) in the 2D plane (X-Y) and the in the 3D plane, X-Z and Y-Z. (B) Example of eYFP+ve EPDCs (green) 
showing expression of eYFP in all three planes X-Y, X-Z and Y-Z planes thus confirming the expression of eYFP 
in one single EPDCs and not two adjacent cells. This process was repeated for 728 endoglin expressing EPDCs 











Figure 4.8: EPDCs express endoglin in vivo. Immunofluorescent stained section of E15.5 Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP mouse heart stained with chicken anti-GFP antibody (green) to mark EPDCs and rat anti-CD105 
antibody (red) to detect endoglin positive cells. Counter stained with DAPI to detect nuclei. (A) High power (x63) 
image of endoglin & eYFP positive EPDCs (yellow arrow) and endoglin negative eYFP positive EPDCs (white 
arrows, n=3). (D-F) Split channel z-stack image of an EPDC positive for endoglin (A, white box 1). (G-I) Split 
channel z-stack image of an EPDC negative for endoglin (A, white box 2). (B) No primary and (C) no antibody 




Next, I studied the effect of endoglin knockdown in EPDCs. To study this, embryos were 
harvested at E15.5 stage of development from Engfl/fl; Wt1Cre-ERT2/+; Rosa26eYFP/eYFP mice. The 
external morphology and shape of both control (Figure 4.9 A-B, n=3) and Eng-iKOepi mutant 
(Figure 4.9 C-D, n=3) hearts was similar. However, analysis of E15.5 coronal sectioned hearts 
stained with chicken anti-GFP and rat anti-CD105 antibodies showed a reduced number of 
EPDCs in Eng-iKOepi mutants compared to control embryo hearts (Figure 4.9 E-F). The 
quantification using the event function of Zen 2012 software showed a 28% reduction in EPDCs 
number in Eng-iKOepi mutants compared to control embryos (Figure 4.9G). A summary of 
quantification is shown in Table 4.5.  







Reduction in Eng-iKOepi 
P value 
No. of hearts 3 3 n/a n/a 
Total No. of eYFP+ve EPDCs ± 
SEM per FOV 
29 ± 2 21 ± 2 28% 0.0249 
Total No. of eYFP+ve Eng+ve 
EPDCs ± SEM per FOV 
4 ± 0.3 2 ± 0.3 50% 0.0474 
Percentage of Eng+ve EPDCs ± 
SEM per FOV  
13% ± 2 11% ± 1 15% 0.3232 
Total No. of Nucleated myocardial 
cells ± SEM per FOV 
145 ± 2 142 ± 4 2% 0.5899 
Percentage of EPDCs ± SEM per 
myocardial cell 
20% ± 1 15% ± 1 25% 0.0197 
Percentage of eYFP+ve Eng+ve 
EPDCs ± SEM per myocardial cell 
3% ± 0.2 2% ± 0.1 33% 0.0133 
 
Next, a 50% reduction in the number of double positive CD105+ve; eYFP+ve EPDCs was 
observed in Eng-iKOepi embryos compared to controls (Figure 4.9H). The most likely reasons 
for only ~50% (and not 100%) endoglin knockdown in Eng-iKOepi could be due to incomplete 
Cre-LoxP recombination of the floxed Endoglin allele. However, even this partial knockdown 
did affect the number of EPDCs. Therefore, the effect of epicardial specific knockdown on 
EPDCs contribution to coronary vessels was investigated. 
As controls and Eng-iKOepi mutant hearts were collected from different mouse litters, hind 
limbs from the embryos were collected to confirm the similar stage of development (Figure 
4.10). Hind limbs from both control and Eng-iKOepi were observed to be at a similar stage of 
development within and between litters. The hind limb morphology was also cross referenced 













Figure 4.9: Endoglin knockout in the EPDCs led to a significantly reduced number of EPDCs in Eng-iKOepi 
mutants compared to age matched controls. Normally developed frontal and dorsal view of E15.5 (A-B) control 
(n=3) and (C-D) Eng-iKOepi mutant (n=3) embryonic hearts. E15.5 (E) control and (F) Eng-iKOepi heart sections 
stained with chicken anti-GFP antibody (green), rat anti-CD105 (red) and DAPI (blue) showing reduced number 
of EPDCs (white arrows) in Eng-iKOepi mutant compared to age matched control hearts. (G) Endoglin knockout 
led to significant reduction in density of EPDCs in Eng-iKOepi mutant per FOV (14.54±0.989, n=3) compared to 
controls (19.81±0.994, n=3, p = 0.0197) embryonic hearts. (H) Significantly reduced density of Eng+ve EPDCs 
were observed in Eng-iKOepi mutant per FOV (1.623±0.097, n=3) compared to age matched controls 
(2.636±0.221, n=3, p = 0.0137) embryonic hearts. Data shown as mean±SEM and analysed using two tailed 










Figure 4.10: Staging control and Eng-iKOepi mutant embryos using hind limb development. To confirm the 
developmental age of embryos from both mouse lines (Wt1Cre-ERT2/+; Rosa26eYFP/eYFP and Engfl/fl; Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP) hind limbs were collected and compared. The hind limbs of both (A) control and (B) Eng-iKOepi 
were observed to be at a similar stage of development. Scale bar: A-B – 1mm. 
4.2.3. Effect of Epicardial Specific Endoglin Knockdown on Coronary 
Vessel Development 
As reported in numerous publications (43, 44, 78, 79)  and observed during this study Figure 
4.5), EPDCs contribute towards ECs, vSMCs and fibroblasts of the developing heart. The 
reduction in the number of EPDCs due to lack of endoglin could lead to vasculature related 
defects which in turn could have a detrimental effect on development of the myocardium. 
Therefore, to analyse if the epicardial specific knockdown of endoglin causes any coronary 
vasculature defects, embryos were collected at E17.5 from Engfl/fl; Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP mice. Littermate embryos without Wt1Cre-ERT2/+ were used as controls. The 
E17.5 stage of development was selected for two reasons: (i) it allows analysis of the coronary 
vasculature at a late stage of embryogenesis and (ii) as the pregnant mice were injected with 
tamoxifen to activate Cre which inhibits labour, by harvesting embryos at E17.5 any labour 
induced complications were avoided.  
The freshly dissected E17.5 embryonic hearts were imaged (section 2.10.1), fixed in 4% PFA 
at 4°C O/N and then embedded in paraffin wax (section 2.2.1). The embryos were next 
sectioned into sister sections (section 2.4.1) and stained using the optimised double 
immunofluorescence protocol (section 2.5.3). During this staining due to incompatibility 
between rat anti-CD31 antibody and the embedding protocol, isolectin B4 (lectin) was used as 
the endothelial marker alongside Sm22α to mark vSMCs. Once stained, images were taken at 
x10 and x40 magnification using the fluorescence setting on M2 axio-imager microscope. A 
minimum three sections were analysed per embryo and around 3 to 5 images were taken from 
the free RV & LV wall.  
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The external morphology of the E17.5 heart was observed to be similar in both control (n=5) 
and Eng-iKOepi mutants (n=6; Figure 4.11, A&B). Next the whole heart width was calculated 
using the line function of Zen 2012 software, which was also observed to be similar between 
the two groups (Figure 4.11C).  
 
Figure 4.11: Normal heart morphology of control and Eng-iKOepi mutant embryos at E17.5. Normal frontal 
& dorsal view of E17.5 (A) control (Engfl/fl; Rosa26eYFP, n=5) and (B) Eng-iKOepi (Engfl/fl; Wt1Cre-ERT2; Rosa26eYFP, 
n=6) embryonic hearts. (C) There was no difference between the width of control (1192±42.20, n=5) and Eng-
iKOepi (1220±47.26, n=6; p = 0.6741) embryonic hearts. Data shown as mean±SEM and analysed using two tailed 
unpaired t-test. Scale Bars: A-B & D,E – 1mm. 
Next, the myocardium width was calculated following the method described by MacDonald et 
al. (276). Briefly, to measure myocardial width x10 tiled images of coronal heart sections were 
selected (middle of the heart). Three sets of measurements were taken from each of the six sites 
from free RV and LV wall (1-6 boxed region, Figure 4.4; 3x6 measurements in total per heart 
section). The average of these measurements was then normalised dividing it by the heart width 
of each section (276). This process was repeated for a minimum of 5 sections per heart. The 
control (n=3) and Eng-iKOepi mutant (n=3) hearts displayed similar morphological structure 
(Figure 4.12, A&E) and myocardial width analyses showed no difference between the two 
groups (Figure 4.12L, p value = 0.4362). 
To analyse the effect of reduced number of EPDCs on development of coronary vessels in 
E17.5 hearts, 3 to 5 images from each ventricle free wall were taken at x40 magnification from 
immunofluorescence stained hearts (section 2.10.2). To compare ECs density in the 
myocardium, the threshold function of ImageJ software was used to calculate lectin stained 
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percentage area. While to compare the number of (Sm22α positive) muscularised vessels in 
control and Eng-iKOepi embryo hearts, manual counting was performed on vessels (identified 
by a distinct lectin+ve endothelium layer) using the event function of Zen 2012 software.   
The analysis of isolectin B4 staining showed no difference in the density of isolectin B4 staining 
in myocardial tissue of control (n=3) and Eng-iKOepi mutant (n=3) embryonic hearts (Figure 
4.12, B,F,J). This was expected as only 6% of EPDCs were observed to differentiate into ECs 
and this contributed only 3% of total ECs (Table 4.4). The number of muscularised vessels were 
also observed to be similar in both wax embedded control (n=3) and Eng-iKOepi mutant (n=3) 
embryonic hearts Figure 4.12, white arrows). 
After thorough analysis of the above data, it was concluded that EPDCs do express endoglin in 
vivo and knockdown of endoglin using Wt1Cre-ERT2 did lead to significant reduction in the 
number of EDPCs but it did not lead any detectable structural or vasculature related defects in 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.4. Effect of Epicardial Specific Tgfbr2 Knockdown on Coronary Vessels 
Development  
To further investigate the role of TGFβ signalling in EPDC differentiation and especially in 
light of data showing an important role for ALK5 [i.e. TGFβR1, (60)], I analysed the role of 
epicardial specific Tgfrb2 knockdown (Tgfbr2-iKOepi) using Tgfbr2fl/fl; Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP mice. Wt1Cre-ERT2 was activated by two subcut tam injections at E9.5 & E10.5 
(Figure 4.13) and embryos were harvested at E17.5 for structural & vasculature analysis.    
 
Figure 4.13: Epicardial Specific Tgfbr2 knockout using Wt1Cre-ERT2 mouse line. To knockout Tgfbr2 gene in 
Wt1+ve cells, Tgfbr2fl/fl; Wt1Cre-ERT2; Rosa26eYFP/eYFP mouse line was used. During experiment, a Cre-negative 
female was mated with a Cre-positive male to avoid possible effects of Cre activation on the pregnant mother, and 
limit Cre activity to the developing embryos. Wt1Cre-ERT2 was activated by injecting tamoxifen at E9.5 and E10.5 
via subcut route (in scruff) and embryos were harvested at E17.5. 
Tgfbr2 is ubiquitously expressed (277-281) but due to lack of a suitable antibody (host lab data), 
during this study confirmation of Tgfbr2 knockdown in epicardial cells and EPDCs was done 
using genomic PCR. DNA was extracted from heart sections of Tgfbr2-iKOepi mutants 
(Tgfbr2fl/fl; Wt1Cre-ERT2; Rosa26YFP/YFP) and litter-mate controls (Tgfbr2fl/fl; Rosa26YFP/YFP) using 
the protocol described in section 2.3.2. The concentration of extracted DNA from each sample 
was measured using nanodrop and summarised in Table 4.6.  
Table 4.6: Concentrations of DNA in Tgfbr2-iKOepi and littermate control embryonic heart sections.  
ID Avg. DNA Conc. (ng/µl) DNA Volume (µl) Final DNA Conc. (ng) 
1 39.33 5.10 200.60 
2 17.04 9.20 156.79 
3 15.95 9.20 146.69 
4 32.24 6.20 199.90 
5 81.47 2.50 203.66 
6 45.97 4.40 202.25 
7 13.93 9.20 128.16 
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ID Avg. DNA Conc. (ng/µl) DNA Volume (µl) Final DNA Conc. (ng) 
8 21.14 9.20 194.47 
9 26.82 7.50 201.13 
10 27.12 7.40 200.65 
 
Next, PCR was performed using Cre, Tgfbr2-iKOepi and Myo primers (Table 2.4; Figure 
4.14A). Following activation of Wt1Cre-ERT2 by tamoxifen, exon 4 is removed from the Tgfbr2fl/fl 
gene leading to a frameshift mutation (Figure 4.14, B&C). This recombination was confirmed 
in Tgfbr2-iKOepi embryos using P3b and P5b primers (Figure 4.14D, ~450bp).  Details of DNA 
concentrations for each sample are summarised in Figure 4.14.  
 
 Figure 4.14: Confirmation of the presence of Tgfbr2-iKOepi recombined gene in epicardial and epicardially 
derived cells from tissue sections. (A) To detect the presence of Wt1-Cre gene, Cre PCR was performed using 
cre forward and cre reverse primers. To confirm the presence of template DNA in the samples myo gene is used 
as a control. To detect myo gene, myo forward and myo reverse primers were used. (B) Schematic of a floxed 
Tgfbr2 allele showing the location of P3b and P5b primers. In a WT mice the PCR product is >1Kb so could not 
be amplified. (C) However, in the presence of an active cre causes a frameshift mutation so exon 5 is located 
immediately after exon 3. This genetic mutation can be confirmed by using P3b forward primer and P5b reverse 
primer (PCR product ~450bp). (D) The recombined Tgfbr2 gene was detected in all Cre+ve samples confirming 
Cre activity while no bands were detected in Cre negative as expected. Myo provided a positive control to show 
sufficient genomic DNA template was present to support a PCR reaction. 
To analyse the effect of epicardial specific Tgfbr2 knockdown on cardiac and coronary 
development freshly dissected E17.5 hearts were imaged (section 2.10.1) and measured using 
the line function of Zen 2012 software but showed no difference between control (n=5) and 
Tgfbr2-iKOepi mutants (n=5; Figure 4.15).  
To investigate vasculature related defects in Tgfbr2-iKOepi mutants, OCT embedded E17.5 
Tgfbr2-iKOepi mutants and littermate control hearts were sectioned into sister sections and 
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subjected to double immunofluorescence staining using rat anti-CD31 and rabbit anti-Sm22α 
antibodies. The sections were then imaged at x10 and x40 magnification using fluorescence 
setting on M2 axioimager microscope. Three sections were images per heart and 6 images were 
taken from free RV & LV wall per section (Figure 4.4).  
 
Figure 4.15: Epicardial Specific Tgfbr2 knockout using Wt1Cre-ERT2 did not have any effect on development 
of the mouse heart. The external morphology of E17.5 embryonic hearts was similar in both controls (A-B) and 
Tgfbr2-iKOepi (D-E) embryos (n=5/ group). (C) Quantification using Zen 2012 showed no difference between the 
myocardial width of control (1227.0±27.81, n=5) and Tgfbr2-iKOepi mutant (1189.0±13.43, n=5, p = 0.2476) 
embryonic hearts. Data shown as mean±SEM and analysed using two tailed unpaired t-test (* p < 0.05). Scale 
Bars: A-B & D-E – 1mm. 
In whole view images of control (n=5) and Tgfbr2-iKOepi mutant (n=5) embryonic hearts no 
gross developmental heart defects or changes in myocardial width measurements were observed 
(Figure 4.16). I next analysed the vasculature of control and Tgfbr2-iKOepi mutant embryonic 
hearts in x40 magnification images. The quantification of CD31 staining using threshold 
function of ImageJ software showed a similar percentage area stained in both controls (n=5) 
and Tgfbr2-iKOepi mutant (n=5) hearts (Figure 4.16, B,F,J). The manual counting of Sm22α 
positive muscularised vessels using event function of Zen 2012 software also showed no 
difference between controls (n=5) and Tgfbr2-iKOepi mutant (n=5) hearts (Figure 4.16, white 
arrows).  
The analysis of the above data clearly showed that knockdown of Tgfbr2 in epicardial and 
epicardially derived cells using Wt1Cre-ERT2 does not lead to any clear developmental (structural 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3. Discussion   
The aim of this study was to understand the importance of endoglin and Tgfβr2 in epicardium 
and epicardially derived cells in vivo during coronary development. To this end, Wt1Cre-ERT2 
was used to knockdown these genes in epicardial and epicardially derived cells. 
4.3.1. Specificity of Wt1-CreERT2  
There is some debate regarding the specificity of Wt1-Cre. Theoretically, in order to use cre–
loxP technology to accurately trace cell fate, the promoter that drives the cre recombinase 
should only be expressed in the precursor cell population but not in the descendent cell 
population. In case of endogenously active Wt1-Cre mouse line, expression of Wt1 is reported 
not only in the epicardial cells but EPDCs as well and in the ECs (82). Therefore, inducible 
Wt1Cre-ERT2 mouse line (used during this study) is preferred over Wt1-Cre mouse line. 
Furthermore, it is suggested that the recombination efficiency can be influenced by multiple 
tamoxifen doses, route of tamoxifen delivery and genetic background (outbred or inbred) of 
mice (253). There are also slight concerns regarding recombination efficiency of Wt1Cre-ERT2 
(82, 253).  
Zhou and Pu (253) showed that activation of Wt1Cre-ERT2 between E9.5 to E11.5, is quite specific 
to epicardium. They activated Wt1Cre-ERT2 by a single tamoxifen injection at E10.5 (2.5 to 
3.75mg) via gavage route has showed a moderately high efficiency (70.2±10.4%) labelled 
epicardial cells (81, 253). This efficiency was said to be enough for lineage tracing the fate of 
epicardial and epicardially derived cells. Higher Cre activation could be achieved by increasing 
the tamoxifen dose or multiple tamoxifen injections but too much tamoxifen can also lead to 
embryonic lethality or congenital defects due to tamoxifen toxicity (253). They also showed 
that gavage route is preferable to IP injections as it has lower risk of tamoxifen toxicity. 
Furthermore, they also observed rare GFP+ve ECs when Wt1Cre-ERT2 was activated at E10.5 but 
suggested these to be epicardially derived ECs (253).  
Therefore, during the current study, I first optimised the dose and site of tamoxifen injection to 
activate WT1Cre-ERT2 and showed that 2 subcut tam injection at E9.5 and E10.5 gave 
reproducible moderately high (~75%) WT1Cre-ERT2 recombination, similar to Zhou and 
colleagues [~70%, section 4.2.1.1, (78, 253)].  
Using lineage tracing I showed that the majority of EPDCs differentiated into vSMCs and 
fibroblasts (Figure 4.5 and Table 4.4) consistent with the previous studies (54, 78, 253, 282). 
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Around 3% of ECs were observed to have an epicardial origin (Figure 4.5 and Table 4.4), 
consistent with the work suggesting minor epicardial cells towards ECs population of the heart 
(43, 44, 79, 253). However, in contrast to previous studies (78, 80, 81) no epicardially 
originating cardiomyocytes were observed during this study (Figure 4.5 and Table 4.4). 
Compared to previous studies where only qualitative analysis is performed, I show the exact 
percentage contribution of Wt1Cre-ERT2 positive cells into different cardiac cell types. However, 
using this Cre line ~25% of epicardium remains unlabelled consistent with previous publication 
(253) therefore, the percentage analysis is likely to be an underestimate of epicardial 
contribution towards the cardiac cell types. Another limitation of the work described in this 
chapter is the microscope used was epi-fluorescence microscope with apotome. Apotome does 
help to remove out of focus light however imaging with confocal would give superior resolution 
to cell specific signal. 
4.3.2. Role of Endoglin in EPDCs 
TGFβ pathway has been shown to be vital during EMT and knockdown of any of its ligands or 
receptors have detrimental effects [discussed in 4.1.1, (60, 62, 68)]. One of the main objectives 
of this study was to study the expression of endoglin in EPDCs in vivo. Using z-stack imaged 
E15.5 embryonic hearts sections from Wt1Cre-ERT2/+; Rosa26eYFP/eYFP mice I confirmed that 
EPDCs do express endoglin in vivo (Figure 4.8). However, in contrast to the  73% of EPDCs 
expressing endoglin in vitro  (64) only 13% EPDCs were observed to express endoglin in vivo 
(Figure 4.9). Knockdown of endoglin in these EPDCs using the Engfl/fl; Wt1Cre-ERT2/+; 
Rosa26eYFP/eYFP mouse line, led to a significant reduction (28%) in total number of eYFP+ve 
EPDCs in Eng-iKOepi mutants compared to age matched controls (Figure 4.9). However, this 
reduction in EPDCs number did not affect the cardiac development. Furthermore, no difference 
in the vasculature was observed between E17.5 Eng-iKOepi mutant and littermate control hearts 
(Figure 4.12). The lack of defect in ECs density is expected as only 3% of ECs arise from 
EPDCs however no effect on the muscularised vessels number and heart was surprising 
considering a 28% reduction in EPDCs number. This could potentially be due to only a partial 
(~50%) endoglin knockdown in EPDCs. 
It is still possible that this reduction in eYFP+ve EPDCs number Figure 4.9) could cause a subtle 
effect on the vasculature and the myocardium postnatally. To analyse this, embryos would need 
to be fostered and analysed at later stages of development potentially around P10 or end of heart 
development around P21.  
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An additional approach would be to analyse the effect of endoglin depletion on gene expression 
in EPDCs. Using a laser dissection microscope or cell sorting, eYFP+ve cells could be collected 
and subjected to qPCR to analyse the effect of endoglin knockdown on EMT associated genes, 
such as those studied in AV explant studies (242) for example RhoA, β-catenin or Fibulin-2. 
Another factor to consider for any future studies would be to check percentage endoglin 
knockdown in each embryo/ pup. As tam would have been given to a pregnant female and not 
all embryos would have received it in even proportions, this could have an impact on the 
phenotype. This could either be done by western blot on protein lysates extracted from GFP+ve 
EPDCs or by analysing endoglin mRNA using qPCR. 
It would also be useful to analyse whether the cause of reduced EPDCs number I observed in 
endoglin mutants was due to lack of proliferation or increased apoptosis of Eng-ve EPDCs using 
pHH3 and an apoptosis marker such as caspase 3/ Ki67.  
During the current study, due to tissue constraints caused by poor mating, it was not possible 
to look at the effect of epicardial specific endoglin knockdown on the EPDC-derived cardiac 
fibroblast population. This would be useful to address in a future study. However, major issue 
with fibroblasts is lack of single cell specific marker potentially due to the multiple origin/ 
functional roles (283). In this study, I used anti-vimentin to mark fibroblasts but in future studies 
it might be wise to use an additional fibroblast marker such as anti-FSP1.  
4.3.3. Role of TGFβR2 in Epicardium and EPDCs 
During EMT TGFβ1 is a major driver of the process and signals through a receptor complex of 
TGFβR2 and ALK5 (Figure 1.17). Loss of ALK5 in epicardial cells (Alk5-KOepi) leads to: (i) 
defective myocardial development; (ii) problems with vSMCs recruitment; (iii) improper 
attachment of epicardium; (iv) increased capillary density and (v) EPDCs failed to undergo 
EMT (60). Similar defects were expected from Tgfbr-iKOepi mutants. To study this, Tgfbr-
iKOepi mutant and litter-mate control embryos were harvested at E17.5 stage of development.  
However, in contrast to Alk5-KOepi mutants, the analysis of E17.5 Tgfbr-iKOepi mutant and 
littermate control hearts did not display any defects in morphology Figure 4.15 and Figure 
4.16). Furthermore, no differences in the vasculature of Tgfbr-iKOepi mutant and littermate 




This lack of phenotype in E17.5 Tgfbr-iKOepi mutants could be due multiple reasons. For 
instance, in the study by Sridurongrit et al. (60), constitutively active Gata5-Cre was used to 
knockdown Alk5 in epicardial cells compared to Wt1Cre-ERT2 used in the current study to 
knockout Tgfbr2. The Gata5-cre is activated in epicardium around 9.25 while Wt1Cre-ERT was 
activated at E9.5 in this study. Gata5-Cre is also shown to be expressed not only in the 
epicardium but in the myocardium as well (284). Therefore, loss of Alk5 in myocardium as well 
as epicardium could lead to loss of signalling required for EMT to form EPDCs, reduced or no 
production of ECM formation which could affect vessels development. The reduced number of 
mature vessels may also explain the myocardium related defects.  
Another reason for lack of a phenotype in Tgfbr-iKOepi mutants could be that TGFβR2 has a 
level of redundancy (285). Dudas et al. (285) showed that knockdown of Alk5 in neural crest 
cells led to severe craniofacial defects in contrast to neural crest specific Tgfbr2 knockdown 
(286). They speculated that the role of ALK5 role during craniofacial development is non-
redundant compared to TGFβR2 and that ALK5 can be activated combining with some other 
type 2 receptor of the TGFβ family if TGFβR2 is not available (285).  
In conclusion, the current study demonstrated that knockdown of endoglin led to reduction in 
total number of EPDCs in Eng-iKOepi mutants at E15.5 but does not cause any structural or 
vasculature related defects in E17.5 Eng-iKOepi mutants. Similarly, knockdown of Tgfbr2 in 
epicardial and epicardially derived cells did cause any structural or vasculature related defects 
at E17.5. The TGFβ signalling pathway in EPDCs could have a negligible dependence on 
endoglin and continue to signal in the absence of TGFβR2 (Figure 4.17), explaining the lack of 
a detectable coronary vessel phenotype in the absence of each of these genes. To confirm the 
effect on TGFβ signalling, further in vivo studies using a TGFβ signalling reporter line (SBE-
luc mice) would need to be carried out. The SBE-luc mice are transgenic mice in which 
expression of luciferase is promoted when SMAD2/3 signalling cascade is activated (287). This 
mouse line in combination with Wt1Cre-ERT2 and Engfl/fl or Tgfbr2fl/fl mouse line would allow 
evaluation of the functional role of these receptors (in terms of SMAD2/3 signalling in vivo) in 




Figure 4.17: Summary of TGFβ signalling in EPDCs in the presence and absence of Endoglin or TGFβR2. 
(A) Normal TGFβ signalling in EPDCs in the presence of endoglin and TGFβR2. Endoglin potentially promotes 
TGFβ signalling through the ALK5/TGFβR2 receptor complex. ALK5 phosphorylates SMAD2/3 which then 
combines with SMAD4 and moves to the nucleus to activate gene expression related to proliferation and 
differentiation of EPDCs. (B) My results showed that knockdown of endoglin in EPDCs potentially affects the 
epicardial EMT, reduced proliferation or increased apoptosis of EPDCs post EMT but it did not cause any 
problems with EPDCs differentiation. (C) Analysis of the current results showed that knockdown of TGFβR2 in 
EPDCs did not lead to any defects, potentially due to activation of ALK5 via a different type 2 receptor. It is 










Chapter 5. Role of Endoglin in 
Endothelial Cells during Development and 





To address the role of endoglin in endothelial cells I have taken three different approaches. 
First, in the heart, ECs start to express endoglin from early development of new vessels (chapter 
3), but its function in coronary endothelial cells during heart development has not yet been 
investigated and forms the first part of this chapter.  
Second, endothelial endoglin is also essential to maintain vessel calibre and integrity (section 
1.5.1). Mutations in the endoglin gene lead to HHT1, which is associated with AVMs (section 
1.6, see also Figure 1.21) (178). The mouse models of HHT1 generated in my host laboratory 
showed AVM formation in the developing neonatal retina when endoglin is depleted from the 
ECs (188). This phenotype is thought to be due to an imbalance between the pro-angiogenic 
factors in the developing retina and BMP9 pro-quiescent signalling, such that in the absence of 
endoglin excess angiogenesis occurs and vessels enlarge to generate AVMs. In the second part 
of this chapter, I used the neonatal retinal model to test whether additional BMP9 can over-ride 
this signalling defect (in the absence of endoglin) to rescue the AVM phenotype. In addition, I 
investigated whether loss of endoglin in veins (but not arteries) leads to AVM formation.  
Finally, little is known about the role of endoglin in quiescent vessels in adult life.  Therefore, 
in this chapter I address the role of endoglin in quiescent vessels in the adult vasculature. 
5.1.1. Endoglin in Coronary Vessel Development 
Studies to investigate the effect of endoglin knockdown in ECs during the different waves of 
coronary vessel angiogenesis during heart development (Figure 1.15) have not been possible to 
date because global knockout of endoglin is embryonic lethal at E10.5 (137, 161, 288). 
Furthermore, even using a conditional endothelial specific Cre line (VE-CadCre-ERT2) with Cre 
activation at later stages of development (E11.5 to E13.5), the analysis of the role of endoglin 
in coronary vessel development was prohibited due to rapid foetal lethality at E13.5 and E14.5 
(Figure 5.1, unpublished data, Arthur Lab). This is likely because loss of endothelial endoglin 
in the foetus leads to similar defects in the placental vasculature seen following loss of ALK1 




Figure 5.1: Depletion of Endoglin using VE-CadCre-ERT2 even at later stages led to rapid embryonic lethality 
(unpublished data, Arthur Lab). (A) To knockdown Endoglin in endothelial cells (ECs), Engfl/fl mice were used. 
In the presence of an active Cre, the first LoxP site and exon 5 are removed leading to formation of a truncated 
endoglin protein. During this study, VE-CadCre-ERT2 was used to knockdown Endoglin in ECs. (B) In this study, 
VE-CadCre-ERT2 is activated either by 2 (Strategy 1, pink arrows) or 3 (Strategy 2, orange arrows) IP injections of 
tamoxifen (dose: 1mg/injection) and embryos were harvested at E13.5 or E14.5 respectively. Whole view images 
of normally developed E13.5 (C) and E14.5 (E) control embryos. While knockdown Endoglin led to rapid lethality 
of embryos at E13.5 (D, in strategy 1) and E14.5 (F, in strategy 2). Scale bars: C-F = 1mm. 
To address this limitation in this project, a new arterial specific Cre, Dll4in3Cre-ERT2 (with low 
expression in the placenta) was used to study the role of endoglin in coronary arterial ECs 
during foetal development (in collaboration with Sarah de Val, University of Oxford). 
Endogenous Dll4 is highly expressed in various arterial endothelium including aorta, yolk sac 
arteries, and coronary arteries during development (290, 291).  
To generate this Dll4in3Cre-ERT2 Cre line, initially an in silico search of the Dll4 gene showed 
that the third intron of Dll4 (Dll4in3) contained a highly conserved enhancer sequence (233). 
This sequence was cloned upstream of a LacZ reporter gene and used to generate a reporter 
mouse to evaluate Dll4in3 expression prior to generating a Cre line. Dll4 enhancer expression 
was observed in dorsal aorta in E9.0 and E15.0 embryos. At E15.0, the expression of Dll4in3 
only occurs in a small subset of placental vessels, minimising the impact of the corresponding 
Cre line on the placental vasculature. The expression of the enhancer is also seen in coronary 
arteries at P6 (233). This Dll4 enhancer sequence (Dll4in3) was cloned upstream of Cre-ERT2 
(de Val, unpublished work) and inserted into the mouse genome to produce the transgenic 
Dll4in3Cre-ERT2 mouse which was then imported to our mouse facility (Figure 5.2). The 





Figure 5.2: Dll4in3Cre-ERT2 cloned sequence and its insertion into mouse genome. A 937bp fragment of a highly 
conserved enhancer of Dll4 gene (Dll4in3) is cloned upstream of the Cre-ERT2 Recombinase gene. This sequence 
is then randomly inserted into a mouse genome to form a transgenic mouse line.  
The next aim of this study was to use this novel Dll4in3Cre-ERT2 line to understand the role of 
endoglin during early development of coronary arteries. I hypothesised that lack of endoglin in 
arteries would lead to reduced proliferation of arterial ECs and delayed or lack of mature 
vessels. This was addressed in the results section 5.2.1 below.  
5.1.2. Endoglin and the Developing Retinal Vasculature 
The reason for formation of AVMs in HHT patients is not clear but preclinical models show 
that endothelial knockdown of endoglin alone does not result in formation of AVMs. An 
additional angiogenic stimulus is required (182, 188, 292). This indicates that endothelial 
endoglin is required for normal angiogenesis. As discussed in the section 1.5.1, endoglin has 
high affinity towards BMP9 and BMP10 ligands (130, 134) and promotes signalling via ALK1 
receptor in ECs (Figure 5.3A). Furthermore, antibody mediated deletion of BMP9 and BMP10 
via a trans-mammary route led to formation of AVMs in P6 neonate retinas (293). This along 
with previous studies strongly suggest that the AVM phenotype observed in neonatal retinas of 
HHT1 (endoglin-deficient) mice was potentially due to lack of BMP9/10 mediated signalling 
(Figure 5.3B). I therefore hypothesised that treatment with active BMP9 would prevent the 
formation of AVMs in Eng-iKO neonatal retinas by bypassing the role of endoglin to activate 
ALK1 signalling (Figure 5.3C). To address this hypothesis, the effect of intra-ocular (IO) BMP9 
treatment on retinal AVM formation was tested in HHT1 mice and is addressed in results 




Figure 5.3: BMP9 mediated signalling in ECs via ALK1 and endoglin mediated signalling. (A) In 
normal/control retinas, during the angiogenesis process, endoglin promotes BMP9 ligand recruitment/binding to 
the BMPR2 which then combine with ALK1 type 1 receptor to induce ECs proliferation via SMAD mediated 
signalling. (B) However, in Eng-iKOEC retinas ALK1 mediated signalling is inhibited leading to imbalanced 
angiogenesis. (C) I hypothesise, that in the presence of abundant active BMP9 ligands, ALK1 mediated signalling 
is promoted leading to ECs proliferation.  
In a recent study by Jin et al. (294), they showed that arteries are the origin for AVM formation. 
They showed that in the absence of endoglin, arterioles enlarge and over time expand to merge 
with veins to form AVMs (294). In this chapter, I analysed the effect of endoglin knockdown 
specifically in venous and capillary ECs on AVM formation, using a venous ECs specific 
ApjCre-ER mouse line (44). The expression of the apelin receptor Apj has been shown in venous 
ECs during embryonic development (43, 44). I hypothesised that endoglin knockdown only in 
venous ECs would either prevent or delay AVM formation and address this in results section 
5.2.5.  
5.1.3. Endoglin and Quiescent Adult Vasculature 
Finally, in my host laboratory, knockdown of endoglin in quiescent adult ECs (Eng-iKOqEC) in 
mice has been shown to lead to HOHF (Figure 5.4). In HOHF, heart failure is coupled with 
increased cardiac output and this pathology occurs due to reduced vascular resistance which 




Figure 5.4: Knockdown of Endoglin in ECs lead to High Output Heart Failure. Magnetic resonance imaging 
showed increased cardiac output (A) and reduced ejection fraction (B) in Eng-iKOqEC mice (data courtesy Dr. 
Simon Tual-Chalot).  
Aortic telemetry analysis showed reduced aortic pressure in Eng-iKOqEC mice whilst cardiac 
conductance catheter analysis showed decreased end systolic LV blood pressure, indicating 
reduced systemic vascular resistance (unpublished data, Arthur Lab). Further experiments to 
analyse the cause of HOHF phenotype showed normal haemoglobin levels and normal dilation 
of aorta in Eng-iKOqEC mice, eliminating anaemia and vascular tone as the cause of HOHF 
(unpublished data, Arthur Lab). I therefore hypothesised that the reduced vascular resistance 
leading to HOHF in Eng-iKOqEC mice could be due to AVMs in the systemic circulation. In 
this chapter (section 5.2.6) I sought to address this question using microbeads to detect 
arteriovenous shunting. 
5.2. Results 
5.2.1 Optimisation of Dll4in3Cre-ERT2 activation  
Dll4in3Cre-ERT2 is a new arterial specific Cre mouse line. To determine an optimal dose of 
tamoxifen to activate Cre-ERT2, Dll4in3Cre-ERT2 mice were crossed with Rosa26eYFP reporter 
mice (230) so that expression of eYFP protein could be used to track all Dll4in3-Cre positive 




Figure 5.5: Optimisation of Dll4in3Cre-ERT2 activation. (A) Cre mediated deletion of stop sequence from the 
eYFP gene in Rosa26 floxed stop eYFP reporter mice leads to expression of eYFP protein in all Dll4in3-Cre 
positive cells. (B) Experiment design used to activate Dll4in3Cre-ERT2 using 1mg tamoxifen/injection (subcut) at 
different time points. Each dotted coloured arrow represents a different time points used to activate the Cre-ERT2 
while the same colour continuous arrow represents the day embryos were harvested. 
As the development of coronary vessels begins around E11.5 from the sinus venous (43, 44), 
the arterial markers are probably not yet expressed, I first activated Dll4in3Cre-ERT2 by two 
tamoxifen injections at E12.5 and E13.5 (orange arrows, Figure 5.5B). The embryos were 
harvested at E15.5 and embedded in paraffin wax (protocol described in section 2.4.1). Next, 
to visualise eYFP expression, embryos were sectioned and stained with rabbit anti-GFP 
antibody following the IHC-DAB staining protocol (section 2.5.2). The analysis of eYFP 
stained images showed very few eYFP positive coronary arteries in the myocardium (Black 
arrow, Figure 5.6A) but strong expression was observed in the aortic endothelium (red arrows, 
Figure 5.6F) and right coronary artery (yellow arrow, Figure 5.6F). 
To analyse if later activation of Dll4in3Cre-ERT2 would yield better labelling of coronary arteries, 
Dll4in3Cre-ERT2 was activated by injecting tamoxifen at (i) E14.5, (ii) E15.5 and (iii) E15.5 & 
E16.5 (Figure 5.5B). The embryos were harvested at E16.5 or E17.5 and were embedded in 
paraffin wax, sectioned and stained with rabbit anti-GFP antibody as before. In all three 
scenarios, very few coronary arteries expressed eYFP protein (black arrows, Figure 5.6, B-D). 
However, positive expression of Dll4in3-Cre was observed in the pulmonary artery (blue 
arrows, Figure 5.6 G&H) and in aorta (red arrows, Figure 5.6I). As Dll4in3-Cre was only 




















































































































































































































































































































































































































































































































































5.2.2 Effect of Endothelial Specific Endoglin Knockdown on Coronary 
Vessel Development in the Foetal and Neonatal Heart 
In this section, the role of endoglin in ECs during the third wave of coronary vessel development 
(Figure 1.15) was analysed using the Engfl/fl; VE-CadCre-ERT2 mouse (Figure 5.7). The expression 
of VE-CadCre-ERT2 was first mapped using Rosa26eYFP reporter mice (230) using a previously 
optimised protocol (i.e. subcut 0.5mg tamoxifen injection at P2 and P4; Figure 5.7). Following 
this, pup hearts were harvest at P7, fixed in 1% PFA, embedded in OCT, sectioned and stained 
with rat anti-CD31 to detect ECs and chicken anti-GFP antibody to detect eYFP protein 
expression. 
 
Figure 5.7: Mapping the expression pattern of VE-CadCre-ERT2 in neonate mouse hearts using Rosa26eYFP 
reporter mice. Activation of VE-CadCre-ERT2 by Subcut tamoxifen injection (0.5mg/injection) at P2 and P4 leads 
to deletion of stop sequence from the eYFP gene, leading to expression of eYFP in all VE-Cad-Cre positive cells 
and daughter cells, hence confirms activation of Cre-ERT2.    
Overview images of stained P7 hearts showed strong expression of eYFP in coronary vessels 
(Figure 5.9, A-C). Qualitative analysis of x20 magnification images showed eYFP expression 
in coronary arteries, coronary veins and many capillaries (Figure 5.9, E-G). However, a few 
capillaries were observed to be negative for eYFP expression interspersed throughout the 
myocardium (white arrows, Figure 5.9, E-G). These VE-Cad-Cre negative capillaries could 
possibly be lymphatic vessels. However, this would need confirmation by staining with a 
lymphatic vessels marker such as LYVE1 (298). 
As the majority of coronary vessel ECs expressed eYFP, showing efficient Cre activation 
endoglin was next depleted in these cells using the Engfl/fl mouse (Figure 5.8). To knockdown 
endoglin in ECs, tamoxifen (0.5mg/injection) was injected on day P2 and P4 as before. On day 
P7, pups were weighed and humanely killed by cervical dislocation. The beating pup hearts 
were harvested following the protocol describe in section 2.1.3. The freshly dissected hearts 
were weighed and imaged using MZ6 Leica microscope. Next, hearts were fixed in 1% PFA, 
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embedded in OCT, coronally sectioned into sister sections and subjected to double 
immunofluorescence staining to analyse the vasculature.  
 
Figure 5.8: Endothelial specific Endoglin knockdown using Engfl/fl; VE-CadCre-ERT2 mouse line. In Engfl/fl 
mouse line, exon 5 and 6 of Endoglin gene are flanked by LoxP sequences. In the presence of an active Cre, LoxP 
site along with exon 5 and 6 are removed from the gene leading to formation of truncated endoglin protein. In the 
current experiment, VE-CadCre-ERT2 was used to knockdown endoglin in all VE-CadCre-ERT2 positive cells. To 









































































































































































































































































































































































































































































































































































































































The body weight (both male and female pups) of control (n=38) and Eng-iKOEC (n=28) mice 
were similar (Figure 5.10C). However, the size and weight of Eng-iKOEC hearts was 
significantly higher than controls. This difference was maintained when heart weight was 
normalised to body weight showing a 61% increase in heart size compared to controls (Figure 
5.10D). This shows that loss of endothelial endoglin led to heart enlargement potentially due to 
cardiac hypertrophy or dilation.  
 
Figure 5.10: Endothelial specific Endoglin knockdown using VE-CadCre-ERT2 led to development of enlarged 
hearts in P7 Eng-iKOEC mice compared to controls. Whole-view images of (A) a control and (B) an enlarged 
Eng-iKOEC heart. (C) The body weight of both controls (2.774±0.097, n=38) and Eng-iKOEC (2.686 ± 0.115, 
n=28; p = 0.5601) mice was observed to be similar. (D) In contrast, heart weight (normalised to body weight) of 
Eng-iKOEC (0.0089±0.0004, n=28) mice was significantly higher compared to controls (0.0055±0.0001, n=38; p 
= <0.0001). Data shown as mean±SEM and analysed using two tailed unpaired t-test (**** p < 0.0001). Scale 
bar A&B = 2mm. 
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I next analysed the effect of endothelial endoglin knockdown on coronary vascular 
development. To study this, coronal sister sections of the above P7 control (n=3) and Eng-
iKOEC (n=3) hearts were stained using immunofluorescence staining with rat anti-CD105, 
rabbit anti-Sm22α and goat anti-podocalyxin (EC marker). Once stained, 3 to 4 images (x20 
magnification) were taken from the free ventricular wall (RV and LV) as described in Figure 
5.11. Endoglin knockdown efficiency and vascular density were calculated by quantification of 
percentage stained area of CD105 and podocalyxin staining using the threshold function of 
ImageJ software. In addition, to compare the effect of endothelial specific endoglin knockdown 
on the density of muscularised vessels (Sm22α positive), manual counting was performed 
following the method described in Chapter 4 (section 4.2.3) using the event function of Zen 
2012 software. 
 
Figure 5.11: Cartoon image of coronal P7 heart section. For quantification, higher power images were taken 
from free RV and LV wall around the dotted black boxed region. Abbreviation: RA – Right Atria; RV – Right 
Ventricle; LA – Left Atria; LV – Left Ventricle; IVS – Inter Ventricular Septum. 
Image analysis showed expression of endoglin in large (red arrows, Figure 5.12A) and small 
vessels (yellow arrows, Figure 5.12A) in controls. The quantification of percentage stained 
CD105 area showed a significant endoglin knockdown (~61%) in Eng-iKOEC hearts compared 
with controls (Figure 5.12K). However, number of muscularised vessels (Figure 5.12L) and 
podocalyxin staining density (Figure 5.12M) per FOV was similar in Eng-iKOEC hearts 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Next, the cardiac structure was analysed, coronal heart sections of P7 control (n=3) and Eng-
iKOEC (n=3) mice were stained with fluorescein labelled wheat germ agglutinin (WGA) and rat 
anti-CD105 antibody to investigate CM hypertrophy. Once stained, three images were taken 
from free RV and LV region of the heart (boxed region, Figure 5.11) using fluorescence setting 
on M2 axio-imager at x40 magnification. These images were taken from a minimum of three 
sections per heart and each of these sections was at least 100µm apart to avoid duplicate imaging 
of same cell.  
Analysis of CD105 staining showed ~40% endoglin knockdown in 2 out 3 Eng-iKOEC hearts 
and over 90% knockdown in the third heart. In order to evaluate whether there were differences 
between the myocardial regions with and without endoglin expression in Eng-iKOEC hearts, a 
mosaic analysis was performed: CM cell area was measured in Eng-ve areas and compared with 
Eng+ve regions within the same heart using spline contour function of Zen 2012 software. The 
analysis showed a significant increase in the area of CM in the Eng-ve region of Eng-iKOEC 
mice (Figure 5.13 F-H) compared to controls (Figure 5.13 A-C, p value = 0.050). The area of 
CM in the Eng+ve region of Eng-iKOEC mice was similar to area of CM in the Eng-ve region 
(Figure 5.13, J-L, p value =0.999). These CM in the Eng+ve region of Eng-iKOEC mice also 













































































































































































































































































































































































































































































































































































































































































































































































Total heart width of Eng-iKOEC heart sections (using x10 tiled images mid-coronal sections in 
4 chamber view, Figure 5.14B) was observed to be significantly higher than control hearts 
(Figure 5.14A). I next analysed if these enlarged hearts had any difference in wall thickness by 
measuring width of free ventricular walls from a minimum of 3 sections per heart.  There was 
a non-significant trend towards slightly reduced ventricular wall thickness of both right (~8%) 
and left (~16%) free walls in Eng-iKOEC hearts compared to controls (Figure 5.14F). This 
suggests that these hearts have eccentric cardiac hypertrophy with enlarged ventricle chambers. 
Eccentric cardiomyopathy is characterised by occurrence of increased chamber volume in 
response to chronic volume overload without a significant change in myocardial wall thickness 
(299). 
As no coronary vasculature related defects were observed, the cause of this enlarged cardiac 
phenotype could be due to a systemic vasculature defect, potentially due to reduced vascular 
resistance due to formation of AVMs in the systemic vasculature. As a previous study in my 
host laboratory using the same mouse line showed formation of AVMs in the neonatal retina of 
Eng-iKOEC mice (188) I repeated this analysis in a small group of neonates. The postnatal retina 
model provides a powerful tool to study pathological angiogenesis during vascular development 
in vivo. In the first week after birth, the retinal vasculature expands towards the periphery of 
the retina and by P8 the entire surface of retina is covered with a 2D primary vascular plexus 
with an alternating pattern of arteries and veins (easily distinguished as arteries are thinner than 
veins, and capillaries are less dense around arteries) providing a valuable structure to study 











Figure 5.14: Endothelial specific Endoglin knockdown led to an enlarged heart. Immunofluorescence stained 
P7 coronal heart sections, stained with rat anti-CD105 (green) and goat anti-podocalyxin (red, to detect ECs) 
antibodies. Counterstained with DAPI to mark nuclei (blue). Tiled overview images of (B) an Eng-iKOEC heart 
showing an enlarged and slightly dilated ventricles compared to littermate (A) control hearts. (C) No primary and 
(D) no antibody staining controls. (E) Quantification showed that overall the Eng-iKOEC hearts were significantly 
wider (3015.00±49.10, n=3) compared to controls (2709.00±55.21, n=3; p = 0.0144). (F) The myocardial width 
analysis of RV and LV free wall showed a similar width between Eng-iKOEC (RV: 365.20±27.44, n=3 and LV: 
571.30±59.99, n=3) and control (RV: 396.60±13.67, n=3; p = 0.3641 and LV: 681.30±33.88; n=3; p = 0.1856) 
hearts. Data shown as mean±SEM and analysed using two tailed unpaired t-test (* p < 0.05). Abbreviation: RA – 
Right Atria; RV – Right Ventricle; LA – Left Atria; LV – Left Ventricle; IVS – Inter Ventricular Septum. Scale bar: 




5.2.3 Effect of Endothelial Specific Endoglin Knockdown on the Neonatal 
Retinal Vasculature 
To investigate the presence of retinal AVMs in P7 mice, control and Eng-iKOEC retinas were 
harvested according to the protocol described in section 2.1.3. These retinas were then stained 
using rat anti-CD105 antibody and isolectin GS-IB4 (to mark ECs) using the wholemount 
immunofluorescence staining protocol described in section 2.5.5. Next, whole-view retinal 
images were taken using M2 axio-imager microscope. To measure vascular progression, the 
ratio of length of each retina petal (Figure 15.5, grey line) and expanding vasculature (Figure 
15.5. yellow line) was calculated from the centre of the retina using the line function of Zen 
2012 software (Figure 5.15). 
 
Figure 5.15: Cartoon of neonate retina showing vasculature structure and progression. The development of 
the retinal vasculature begins at the centre for the retina with alternating pattern between arteries (red) and veins 
(veins). The vasculature progression was measured by calculating a ratio of expanding vasculature length (yellow 
line) over the radius of the retina (black line). 
The vasculature in control retinas (n=6) showed the typical pattern of alternating arteries and 
veins (Figure 5.16, A-F) with normal progression of the vascular plexus towards the retinal 
periphery (red & blue arrows, Figure 5.16, A-F). In contrast, AVMs were observed in 67% (4/6) 
of P7 Eng-iKOEC retinas (yellow arrows, Figure 5.16, G-L) with an average of 3 AVMs per 
retina. In addition there was delayed vascular progression (blue & red arrows, Figure 5.16, G-
L) and hypervascularisation (white arrows, Figure 5.16, G-L) of the retinal plexus; consistent 
with previously published data (188).  
Furthermore, and as previously observed in the current study, the hearts of all the P7 Eng-iKOEC 
(n=28) mice were enlarged compared to controls (n=38). As mentioned before, retinas were 
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selected to analyse the systemic vasculature because of the unique vasculature development in 
2D format (300). However, it does not mean that AVMs are only expected in the retinas. AVMs 
can form in other organs such as brain, lungs and liver, and the retina merely serves as a 
representative tissue. For example, deletion of endothelial endoglin in neonates showed AVMs 
in brain as well as in retinas (294). However, this would need further confirmation by analysing 
other organs such as brain, liver and gut using different imaging techniques for instance latex 
injection in LV. 
In conclusion, the current study shows a novel cardiac phenotype in Eng-iKOEC neonates that 
could be due to the presence of systemic AVMs, such as those seen in the retinas, leading to 
reduced vascular resistance. If AVMs could be prevented by using a therapeutic intervention 
and this could also rescue the cardiac phenotype, this would help to confirm the cause of the 







Figure 5.16: Endothelial specific Endoglin knockdown led to development of AVMs in P7 Eng-iKOEC retinas. 
Immunofluorescence stained P7 retinas with isolectin GS-IB4 (green, to mark ECs) and rat anti-CD105 antibody 
(red). Split channel (A-C) overview and (D-F) digital zoomed (white box) images of control of retina showed 
normally developed retina vasculature with alternate arteries and vein pattern as well as normal retina vasculature 
progression (red & blue arrows). Split channel (G-I) overview and (J-L) digitally zoomed (white box) images of 
an Eng-iKOEC retina showed presence of AVMs (yellow arrows), hypervascularisation (white arrows) and delayed 
retina vasculature progression (red & blue arrows). Abbreviations: a – artery; AVMs – Arteriovenous 




5.2.4 To investigate the effect of exogenous BMP9 treatment on AVM 
formation in Eng-iKOEC mice – A Pilot Study 
As discussed in section 5.1.2, absence of BMP9/10 signalling led to formation of AVMs in 
retinas (192, 293). During the signalling cascade, BMP9/10 signals via endoglin and ALK1 
pathway (Figure 5.3). Therefore, in this section, I investigated whether exogenous BMP9 
treatment could be used to reduce retinal AVM development in Engfl/fl; VE-CadCre-ERT2 mice. 
The VE-CadCre-ERT2 was activated by tamoxifen injection at P2 and P4 via subcut route (Figure 
5.8). Following this, active BMP9 ligand (3µl of 1.5mg/ml, right eye) and 3µl PBS (left eye) 
was injected via IO route on day P4 or P5 following the protocol described in section 2.6. 
Retinas were harvested on day P7, stained with isolectin GS-IB4 and imaged using the M2 
axio-imager to detect AVMs.  
The P7 retinas treated with IO injection of either BMP9 or PBS at P4 showed very poor 
morphology (data not shown) potentially due to the injury caused by the needle (27G). This 
hindered any data analysis on this group. While for IO injection at P5, the retinal vascular 
morphology was slightly better. To study the effect of BMP9 treatment, several parameters 
were analysed including retina vasculature progression, width of veins and AVMs following 
the methods described by Mahmoud et al. (188). Briefly, the vein width was calculated by 
taking 5 measurements along the vein (red lines, Figure 5.16C) using the line function of Zen 
2012 software. Two to six veins were analysed per retina. The vein width was then normalised 
to controls within each litter. Similarly, to calculate AVM width, 3 measurements were taken 
(red lines, Figure 5.16E) from all the AVMs in the Eng-iKOEC retinas.  
Analysis of P7 retinas showed a slight delay in the vascular progression at baseline (untreated) 
Eng-iKOEC mice compared to controls (Figure 5.17B). A similar result was observed in groups 
with IO injection of BMP9 and PBS (Figure 5.17B). The veins in the baseline Eng-iKOEC 
retinas were also observed to be wider compared to controls, consistent with previous work 
(188). However, after treatment with BMP9 the venous vessels diameter was still observed to 
be wider compared to controls (Figure 5.17D). Surprisingly, an increase in the number of 
AVMs (~2.8 fold in PBS treated and ~3.5 fold in BMP9 treated) and width of AVMs (~1.8 fold 
in PBS treated and ~2.0 fold in BMP9 treated) was observed in IO injected Eng-iKOEC 
compared to untreated Eng-iKOEC mice (Figure 5.17). This dramatic increase in the number of 
AVMs even in the PBS injected group suggests that the injection itself might have acted as a 
second trigger (186-190) which led to an enhanced angiogenic stimulus. This could be masking 




Figure 5.17: Intraocular exogenous treatment of BMP9 did not rescue the AVMs phenotype in P7 Eng-
iKOEC. Immunofluorescence stained P7 retinas with isolectin GS-IB4 (Lectin, green). (A) Example of an Eng-
iKOEC mice retina petal, showing relative progression of retinal vasculature (red arrow) towards the retina 
periphery (blue arrow). The control retinas from the two litters used in this analysis appeared to be at a different 
stage in retinal vascular development suggesting they were slightly different ages (+/- half a day). Therefore, 
vascular progression and vein width from Eng-iKOEC retinas were normalised to their litter mate controls. (B) 
Quantification showing a delayed relative vasculature progression (Eng-iKOEC over controls) in all baseline 
(untreated, 0.8948±0.053, n=6; p = 0.3484), PBS (0.7970±0.027, n=4; p = 0.0294) and BMP9 (0.7933±0.030, 
n=3) treated Eng-iKOEC retinas compared to respective control retinas (baseline n=6; IO P5 PBS, n=3 and P5 IO 
BMP9, n=2). (C) Example of a retina vein showing approximate sites of measurements to calculate vein width 
(red lines). (D) Quantification showed a non-significant trend towards wider veins in retinas of baseline (untreated, 
1.318±0.098, n=6; p = 0.1375), PBS injected (1.466±0.123, n=4; p = 0.0687) and BMP9 treated Eng-iKOEC 
retinas (1.562±0.168, n=3) compared to respective littermate control retinas (baseline n=6; IO P5 PBS n=3 and 
P5 IO BMP9 n=2). Data shown as mean±SEM and analysed using two-way ANOVA (* p < 0.05). Abbreviations: 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.5 Effect of Venous Endothelial Specific Endoglin Knockdown on AVM 
formation in Neonates using ApjCre-ER 
The study by Jin et al. (294) showed that AVMs potentially originate from arteries following 
loss of endothelial endoglin. However, endoglin expression is greater in veins than arteries and 
there is a significant increase in vein width in Eng-iKOEC retinas, pointing to a venous role for 
endoglin. Therefore, in this section, I analysed the role of endoglin in venous ECs using ApjCre-
ER.  
In retinas, the expression of Apj is reported as early as P3 (301, 302) however, the earliest ApjCre-
ER expression has only been shown in the sinus venosus of E9.5 hearts (44). Therefore, the first 
aim of the current study was to establish the venous specificity of ApjCre-ER in neonatal retinas. 
To investigate this, ApjCre-ER was activated at different time-points by injecting tamoxifen (0.5–
0.6mg per injection) via subcut route (Figure 5.19A). To report the ApjCre-ER activity, 
Rosa26mTmG reporter mice were used. The Rosa26mTmG is a dual Cre reporter, which in the 
absence of an active Cre leads to expression of red fluorescence (mT) in a cell while in the 
presence of an active Cre, the polyadenylation (pA) sequence is removed and expression of 
eGFP (mG) is observed in all Cre positive cells and their daughter cells [(235), (Figure 5.19B)]. 
To test ApjCre-ER activity after activation via injection of tamoxifen at different time points 
(Figure 5.19A), neonatal hearts and retinas were harvested on day P8 following protocols 
described in section 2.1.3. Next, dissected retinas images were taken and then retinas were 
flattened following the protocol described in section 2.10.2 and stored at -20°C until required. 
Harvested hearts were imaged (section 2.10.1), fixed in 1% PFA, embedded in OCT and stored 





Figure 5.19: Optimisation of ApjCre-ER activation using Rosa26mTmG reporter mice. (A) Experiment design 
showing different time-points used (red arrows) to activate ApjCre-ER by subcut tamoxifen injection [0.5mg (P2 & 
P4) or 0.6mg (P5 & P6) per injection]. From all the different groups, retinas and hearts were harvested at P8 (green 
arrow). (B) Activation of Cre was reported using Rosa26mTmG, a dual fluorescence reporter mouse. In the absence 
of Cre, cells express a red fluorescence (membrane tomato, mT), while in the presence active ApjCre-ER (after 
tamoxifen injection) the polyadenylation (pA) sequence is removed leading to expression of eGFP (mG) in all 
ApjCre-ER positive and daughter cells.  
The activation of ApjCre-ER at P2 led to expression of eYFP in all the vessels (arteries, veins and 
capillaries) of P8 retinas (Figure 5.20A-C). This was expected as at P2 arterial and venous 
differentiation has not yet occurred, therefore Apj-Cre expression is not yet specific to veins. 
Furthermore, this result also suggests that the primitive capillary plexus at P2 expresses Apj-
Cre. Similarly, tamoxifen activation of ApjCre-ER at P4 showed strong expression of ApjCre-ER in 
all veins and capillaries (Figure 5.20D-F). However, there was reduced arterial expression of 
ApjCre-ER as observed by low eGFP expression at the base of the arteries (white arrows, Figure 
5.20D-F) suggesting arterial differentiation potentially begins by P4. Activation of ApjCre-ER at 
late P5 (Figure 5.20G-I) and P6 (Figure 5.20J-L), led to eGFP expression only in veins and 
capillaries while arteries retained expression of red fluorescence (Figure 5.20G-L). This 
established appropriate timings of ApjCre-ERT2 activation (late P5 onwards) for venous specific 
endoglin depletion and is consistent with the lack of arterial expression of Apj protein observed 
in the P5 retinas in previous studies (301, 302).  
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Next, venous specific ApjCre-ER expression was analysed in P8 hearts harvested from ApjCre-ER; 
Rosa26mT/mG mouse line after injection at P6. Hearts were sectioned and subjected to 
immunofluorescence staining using chicken anti-GFP and rat anti-CD31 antibodies. The 
sections were then imaged using fluorescence setting on M2 axio-imager microscope. To 
identify arteries and veins following criteria were used. A coronary vessel was presumed to be 
a vein if: (i) the vessels was present in the sub-epicardial region and (ii) lacking a thick SMCs 
coat (identified by presence of nuclei in centric circles around the endothelial cells, Figure 5.21, 
pink arrows). In contrast, a vessel was presumed as an artery if it was present in deeper in the 
myocardium and had an evident thick SMC layer (recognised by concentric DAPI only 
staining).  
Analysis of x20 images showed GFP expression (Apj-Cre positive and/ or daughter cells) in 
the coronary veins of P8 post-natal hearts as observed by anti-GFP staining (Figure 5.21, B,E,H) 
while presumed coronary arteries were negative for GFP expression (Figure 5.21, C,F,I) 
indicating venous specificity for Apj-Cre. However, a uniform mosaic pattern of GFP 
expression was observed in capillaries, although the majority of capillaries were GFP+ve 
(yellow arrows, Figure 5.21). The Apj-Cre negative capillaries could be lymphatic vessels, but 







Figure 5.20: Activation of ApjCre-ER by tamoxifen injection at P5 or P6 showed GFP expression in veins and 
capillaries of P8 retinas. Expression of enhanced GFP (mG, green) indicates Cre activity in the blood vessels of 
the retina and expression of red fluorescence (mT) indicates the absence of active Cre. In retinas, vasculature is 
developed in a unique format with arteries and veins developing in alternate pattern (Figure 5.15). (A-C) ApjCre-ER 
activation by subcut tamoxifen (0.5mg/injection) injection on P2 (n=1) leads to expression on eGFP in all arteries, 
veins and capillaries. (D-F) Activation of ApjCre-ER at P4 (n=1) showed expression of eGFP in all veins, capillaries 
and in most of the arteries except for near the centre of the retina (white arrows). In contrast, activation of ApjCre-
ER at (G-I) late P5 (n=4) and (J-L) late P6 (n=3) showed the expression of eGFP in veins and capillaries while red 
fluorescence was observed in the arteries (white arrows). Abbreviations: a – arteries; v – veins; mT – membrane 






Figure 5.21: Activation of ApjCre-ER at P6 by tamoxifen leads to GFP reporter expression in coronary veins 
and capillaries but not arteries of P8 hearts. Immunofluorescence stained P8 heart with chicken anti-GFP 
(green), rat anti-CD31 (red) antibodies and counterstained with DAPI to mark nuclei (blue). (A) Overview image 
of a P8 ApjCre-ER heart showed expression of GFP in coronary vasculature. Qualitative analysis on high power split 
channel images of (B,E,H) RV and (C,F,I) LV free wall showed expression of GFP in a coronary vein (v) and 
majority of the capillaries (yellow arrows, n=2). While coronary artery (a, pink arrows) and a few capillaries (white 
arrows) were observed to be negative for GFP expression (n=2). (D) No primary and (G) no antibody staining 
controls. Abbreviations: RA – Right Atria; RV – Right Ventricle; LA – Left Atria; LV – Left Ventricle; IVS – 




The next question was to address the effect of endoglin depletion in the veins and venous 
derived capillaries. To maximise endoglin depletion two tamoxifen injections were used to 
activate ApjCre-ER:  late afternoon on day P5 (0.6mg subcut) and 24h later at P6 (0.6mg; Figure 
5.22A). These timings are much later than the work described earlier in this chapter when VE-
CadCre-ERT2 was activated by tamoxifen injection at P2 and P4 (Figure 5.8). In order to use VE-
CadCre-ERT2 retinas as a comparator (i.e. endoglin knockdown in all ECs) VE-CadCre-ERT2 was 
activated using the same protocol (subcut tamoxifen on late P5 and P6, 0.6mg/day, Figure 
5.22B).  Hearts and retinas were then harvested from both mouse lines at two time points (P8 
and P11) to compare the effect of total EC (Eng-iKOEC) and venous EC (Eng-iKOV) endoglin 
knockdown on cardiac hypertrophy and retinal vascular development.  
 
Figure 5.22: Mouse models used to study the effect of venous ECs specific Endoglin knockdown. (A) 
Activation of ApjCre-ER by subcut tamoxifen injection on late P5 and P6 (dose: 0.6mg/ injection) leads to 
knockdown of Endoglin and expression of eGFP in all Apj-Cre positive cells. (B) To compare the effect of venous 
specific Endoglin knockdown using ApjCre-ER vs. Endoglin knockdown in all ECs using VE-CadCre-ERT2 on AVMs 
formation, VE-CadCre-ERT2 was also activated by subcut tamoxifen injection at late P5 and P6 (dose: 0.6mg/ 
injection). This leads to knockdown of endoglin in all VE-Cad-Cre positive cells.  
The body weight of all pups (Cre-negative controls, Eng-iKOEC and Eng-iKOV) was similar at 
P8 as well as at P11 (Figure 5.23 E&F). The heart weight of Eng-iKOEC pups showed no 
difference at P8 but did increase significantly (~52%) at P11, compared to controls (Figure 
5.23). A similar cardiac phenotype was observed in the Eng-iKOV pups with no difference in 






Figure 5.23: Endothelial specific Endoglin knockdown using VE-CadCre-ERT2 and ApjCre-ER lead to enlarged 
hearts in both males and females at P11 Eng-iKOEC and Eng-iKOV mice compared to controls. Overview 
images of an enlarged P11 Eng-iKOEC (B) and Eng-iKOV (D) hearts compared to the littermate controls (A,C). 
(E) The body weight of P8 (3.844±0.178, n=9) and P11 (3.667±0.186, n=3) controls was observed to be similar 
to P8 (3.900±0.188, n=7; p >0.9999) and P11 (3.433±0.273, n=3; p >0.9999) Eng-iKOEC pups. (F) No difference 
in the heart weight (normalised to body weight) was observed in P8 Eng-iKOEC (0.0056±0.0002, n=7) compared 
to P8 controls (0.0055±0.0002, n=9; p >0.9999). However, a significant increase in heart weight was observed in 
P11 Eng-iKOEC hearts (0.0090±0.0011, n=3) compared to P11 controls (0.0056±0.0004, n=3; p = 0.0008) and to 
P8 Eng-iKOEC hearts (p <0.0001). (G) A similar pattern was observed in Eng-iKOV hearts. The body weight of 
controls (P8: 4.10±0.182, n=5 and P11: 3.71±0.257, n=7) and Eng-iKOV (P8: 4.50±0.173, n=3; p >0.9999 and 
P11: 4.42±0.364, n=5; p = 0.4313) mice were similar. (H) The heart weight (normalised to body weight) analysis 
showed no difference in P8 Eng-iKOV (0.0057±0.0003, n=3) compared to controls (0.0057±0.0002, n=5; p 
>0.9999). However, a significant increase in the heart weight was observed in P11 Eng-iKOV hearts 
(0.0083±0.0007, n=5) compared to P11 controls (0.0061±0.0003, n=7; p = 0.0097) and to P8 Eng-iKOV (p = 
0.0140) hearts. Data shown as mean±SEM and analysed using two-way ANOVA (* p < 0.05; ** p < 0.01; *** p 
< 0.001 and **** p <0.0001). Scale bar A-B = 2mm. 
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To analyse if the above cardiac phenotype was due to AVMs in the systemic vasculature as 
observed earlier (Figure 5.16), P8 and P11 retinas from both Eng-iKOEC and Eng-iKOV were 
analysed for presence of AVMs along with their respective controls. At P8, whole view tiled 
images retinas were taken. However, from P8 onwards the expansion of retina vasculature 
progresses deeper into the retina leading to two parallel interconnected vascular planes by P11 
[(Figure 5.24), (300)]. Therefore, to investigate primary and secondary plexus of P11 retinas, 
z-stack images of the primary and secondary plexus were taken at x20 using M2 axio-imager 
microscope. Once imaged, in-depth coding was applied to colour code different layer of tissue 
according to its depth from the focus point. This enables each layer of retina vasculature to be 
observed in 2D plane. 
 
Figure 5.24: Cartoon of retina vasculature development in mice [adapted from (300, 303)]. New born mice 
retinas are avascular. (A) In the first week of retina vasculature development, the vascular plexus starts to migrate 
from the middle of the retina (P3) and progress towards the periphery of the retina (P5). By P8, the whole surface 
of the retina is covered by primary vascular plexus. (B) In the next week of retina development, the vessels start 
to develop in 3D plane with the formation of deeper plexus or secondary plexus by P12. (C) Finally, in the third 
week of post-natal development deeper plexus are formed to form mature three-layered retina vasculature. 
The control retinas from both lines at P8 and P11 showed normally developing retina 
vasculature expressing higher levels of endoglin in veins compared to arteries (Figure 5.25 A-
D & I-L). The Eng-iKOEC retinas showed successful endoglin knockdown in arteries, veins and 
capillaries as well as occurrence of retinal AVMs in both P8 (Figure 5.25 E-F, white arrows) 
and P11 (Figure 5.25 G-H, white arrows) retinas. The in-depth coding images analysis of P11 
retinas showed that the AVMs observed in both Eng-iKOEC and Eng-iKOV retinas (Figure 5.26) 
were formed in both primary and secondary plexus layers of the retinas (white arrows, Figure 
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5.25C-F). This shows despite delayed or venous EC specific endoglin knockdown, AVMs still 
persist to form in both primary and secondary plexus layer.  
In Eng-iKOV retinas, consistent with the expression of ApjCre-ER observed earlier (Figure 5.20 
G-L), endoglin knockdown was only observed in the veins and capillaries but not in the arteries 
of P8 and P11 retinas (Figure 5.25 M-P). However, in contrast to P8 Eng-iKOEC retinas, only a 
mild AVM phenotype was observed in P8 Eng-iKOV retinas (Figure 5.25 M-N, white arrows). 
While at P11, AVMs were observed in Eng-iKOV retinas (Figure 5.25 O-P, white arrows) 
similar to the Eng-iKOEC retinas. Again, these AVMs in Eng-iKOV retinas were also observed 
in the primary and secondary plexus layer however, it does not rule out smaller AVMs in 














































































































































































































































































































































































































































































































































































































































































































































Figure 5.26: In-depth coding showed the AVMs observed in P11 Eng-iKOEC and Eng-iKOV retinas had 
developed in the primary plexus. (A) Isolectin GS-IB4 stained and (B) in-depth coding image of a control retina 
showing normal retina vasculature with major vessels formed in the primary plexus layer (first layer, reddish 
orange) interconnected through capillaries (green/yellow) with an extensive vascular network forming in the 
second layer (blue). Images of Eng-iKOEC (C-D) and Eng-iKOV (E-F) showing forming of AVMs (white arrows) 
in the primary plexus layer (red/orange). Abbreviations: a – artery; AVMs – Arteriovenous malformations and v – 
veins. Scale bars: A-F = 50μm. 
By P8 as expected (300, 303), the retinal vasculature has reached the periphery of the retina in 
all controls (Figure 5.25, A&I) and endoglin knockout pups (Figure 5.25, E&M). The analysis 
of vein width showed a significant increase in the vein width of both P8 (~11%) and P11 (~45%) 
Eng-iKOEC veins compared to their respective controls (Figure 5.27I). This was consistent with 
the results observed earlier using the standard endoglin knockout strategy (Figure 5.10D). A 
similar phenotype was observed in the Eng-iKOV mice: in P8 retinas, veins were ~14% wider 
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while by P11 veins were ~53% wider compared to their respective controls (Figure 5.27J). 
During this analysis, only the veins in the primary plexus were analysed. 
No statistically significant difference was observed between the number of AVMs per retina in 
Eng-iKOEC and Eng-iKOV retinas at either P8 or P11 (Figure 5.27K). However, the probability 
of AVM formation was much higher in P8 Eng-iKOEC retinas (~57%) compared to Eng-iKOV 
(~33%) retinas. In contrast, at P11 this ratio was reversed as all Eng-iKOV retinas (7/7) had 
AVMs while only 4 out 6 Eng-iKOEC retinas had AVMs.  
At P8, no statistical difference was observed between Eng-iKOEC and Eng-iKOV AVMs width, 
although there was a trend towards wider AVMs in Eng-iKOEC (Figure 5.24L). But by P11 this 
difference was lost due to growth of AVMs in P11 Eng-iKOV retinas, such that they were 
significantly wider than P8 Eng-iKOV retinas (Figure 5.24L).  
A summary of these results compared with early deletion of endoglin in all EC using VE-CadCre-
ERT2 (activated at P2 and P4) are shown in Table 5.1. This shows that, lack of endothelial 
endoglin (in all ECs) in the first week of neonatal life leads to development of enlarged hearts 
(Figure 5.10 and Figure 5.23) and AVMs (Figure 5.16 and Figure 5.25) in retinas, and likely 
also in other organs. The same phenotype was observed after venous ECs specific endoglin 
knockdown (Figure 5.23 and Figure 5.25). This suggests that endoglin in veins plays a crucial 
role in normal vascular development.  
Table 5.1: Data summary of heart and retinal phenotype in pups with endoglin knockout in all ECs (Eng-
iKOEC) and venous & capillary ECs (Eng-iKOV) 
Age at time of Cre 
activation 
P2 & P4 P5 & P6 
Genotype Eng-iKOEC Eng-iKOEC Eng-iKOV 
Age at time of analysis P7 P8 P11 P8 P11 
No. of Retinas 
analysed 
6 14 6 6 7 
Avg. No. of AVMs per 
Retina ±SEM 
3.0±1.0 2.0±0.7 2.0±0.7 0.3±0.2 3.4±0.7 
Probability of AVMs 
incidence per retina 
67% 57% 67% 33% 100% 
Avg. AVMs Width (in 
µm) ±SEM 
20.12±3.75 21.01±1.19 28.68±5.02 15.88±0.18 30.47±2.51 
Avg. Veins Width (in 
µm) ±SEM 
32.93±3.36 27.58±0.70 30.46±3.67 26.61±1.62 33.18±2.72 
Percentage increase in 
vein width compared 
to controls 























Figure 5.27: Endoglin knockdown using VE-CadCre-ERT2 and ApjCre-ER leads to development of wider veins 
and AVMs in P8 and P11 retinas. Immunofluorescence stained P11 retinas with isolectin GS-IB4 (green) 
showing normal retina vasculature in controls (A,C,E,G). In contrast, wider veins (v) and AVMs (red arrows) 
were observed in Eng-iKOEC (B,F) and Eng-iKOV (D,H) retinas. (I) Quantification showed similar width of veins 
in P8 Eng-iKOEC retinas (27.58±0.697, n=14) compared to P8 controls (P8: 24.91±0.574, n=17; p = 0.4093). 
However, by P11 the veins were observed to be significantly in Eng-iKOEC retinas (30.46±3.668, n=6) compared 
to P11 controls (P11: 20.98±0.912, n=6; p = 0.0010). (J) Vein width quantification of Eng-iKOV retinas also 
showed a similar pattern with no difference in the vein width of P8 controls (23.31 ±0.843, n=9) and Eng-iKOV 
(26.61±01.616, n=6; p = 0.8475) retinas while, a significant increase in vein width was observed in P11 Eng-
iKOV retinas (33.18±2.720, n=7) compared to P11 controls (21.71±0.770, n=13; p = <0.0001). The vein width 
analysis also showed the presence of significantly wider veins in P11 Eng-iKOV compared to P8 Eng-iKOV retinas 
(p = 0.0466). (K) The average number of AVMs per retina in P8 Eng-iKOEC (1.857±0.695, n=14) was almost 
double that in Eng-iKOV (0.333±0.211, n=6; p = 0.8577). The average number of AVMs were still observed to 
be similar to in P11 Eng-iKOEC retinas (1.833±0.749, n=6) while, in contrast a significant increase in number of 
AVMs were observed in P11 Eng-iKOV (3.375±0.755, n=8; p = 0.0288) retinas. (L) Quantification of AVMs 
width analysis showed a trend towards wider AVMs in P8 Eng-iKOEC retinas (21.01±1.191, n=8) compared to P8 
Eng-iKOV AVMs (15.87±0.182, n=2) retinas. By P11, no difference in the retina AVMs width was observed 
between Eng-iKOEC (28.68±5.016, n=4) and Eng-iKOV (30.47±2.512, n=7; p >0.9999) retinas. Data shown as 
mean±SEM and analysed using one-way ANOVA (* p < 0.05; ** p < 0.01 and **** p <0.0001). Abbreviations: 














5.2.6 Effect of Endoglin Knockdown in Adult Quiescent Endothelial Cells 
using VE-CadCre-ERT2 
As mentioned above, endoglin knockdown in adult quiescent ECs leads to development of 
HOHF (Figure 5.4) due to reduced vascular resistance potentially caused by formation of AV 
shunts in the pulmonary or systemic vasculature (unpublished data, Arthur Lab). To investigate 
this, 10-12week old adult mice from Engfl/fl; VE-CadCre-ERT2 mouse line were treated with 2mg 
tamoxifen per day (IP) for 5 consecutive days (Figure 5.28) to deplete endoglin in quiescent 
ECs (Eng-iKOqEC). To control for any tamoxifen related effects from these analyses, control 
(Engfl/fl) mice were also treated with tamoxifen following the same protocol. The organs from 
Eng-iKOqEC and control mice were harvested 5wks after the first tamoxifen injection for all 
experiments.  
 
Figure 5.28: Endoglin knockout in adult quiescent ECs using VE-CadCre-ERT2. In adult mice to knockout 
endoglin, VE-CadCre-ERT2 was activated by IP injections of tamoxifen (dose: 2mg/injection) for 5 consecutive days. 
To analyse the effect of endoglin knockdown, organs were harvested 5wks after the first tamoxifen injection. 
Knockdown of endothelial endoglin in adult mice led to development of enlarged hearts (Figure 
5.29A&B). This phenotype was observed in both male and female Eng-iKOqEC mice. Analysis 
of heart weight showed significantly enlarged male (~47%) and female (~34%) hearts of Eng-
iKOqEC mice compare to their respective controls. This difference was maintained when heart 
weight was normalised to body weight (Figure 5.29D). This phenotype was similar to the 






































































































































































































































































































































































































































































































































































































































































































































































































I analysed the expression and knockdown of endoglin in arteries, veins and capillaries of lungs, 
liver and heart in Eng-iKOqEC mice to establish the model. To perform this analysis, organs 
harvested from both Eng-iKOqEC and control mice, were fixed in 1% PFA, embedded in OCT 
and sectioned in sister sections. These sections were then stained with rat anti-CD31 and goat 
anti-CD105 antibodies and imaged at x40 magnification using fluorescence setting on M2 axio-
imager. Individual cell staining intensity was measured using spline counter function of Zen 
2012 software (Figure 3.5). The identification of arteries and veins in these organs was 
performed by using morphological characteristics described in Figure 5.30.  
In control mice showed strongest endoglin expression in coronary veins, pulmonary arteries, 
pulmonary veins and liver central veins (Figure 5.31, C,E,G&K), while lower expression was 
observed in coronary arteries and liver portal veins (Figure 5.31, A &M). The lowest endoglin 
expression in control mice was observed in hepatic arteries (Figure 5.31I, white arrow).  
In Eng-iKOqEC, varying levels of endoglin knockdown was observed in all vessels. A significant 
reduction in endoglin expression was observed in coronary veins, pulmonary arteries 
pulmonary veins and liver central (Figure 5.31, D,F,H&L). While a non-significant reduction 
in endoglin expression was observed in coronary arteries and portal veins (Figure 5.31, B&N). 
In hepatic arteries, no apparent reduction in endoglin expression was observed in Eng-iKOqEC 







Figure 5.30: Morphological characteristic used to identify arteries and veins in heart, lungs and liver. In the 
heart, (A) a vessel was presumed to be a coronary artery if it was present in the mid-myocardium, showed a 
presence of elastin auto-fluorescence (A’ inset, orange arrows) and thick SMCs layer [recognised by presence of 
concentric nuclei round the vessels (red arrows)]. (B) In contrast, a vessel was presumed to be a coronary vein, if 
it was present in the sub-epicardial space, lack elastin and obvious SMCs layer. In the lungs, (C) a vessel was 
identified as pulmonary arteries if it was present next to a bronchioles (bo) and presence of elastin auto-
fluorescence (orange arrows). (D) However, if a vessel was present away from bronchioles, showed presence of 
SMCs [recognised by presence of concentric nuclei round the vessels and auto-fluorescence (red arrows)] and was 
devoid of elastin, it was presumed to be a pulmonary vein. In the liver, (E) hepatic artery (ha) was present in a trio 
with bile duct (negative for CD31) and portal vein (pv). (F) While central vein (cv) was located away from the trio 
showed in E. Abbreviations: a – artery; v – vein; bo – bronchioles; pv – pulmonary vein; ha – hepatic artery; bd 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Next, to analyse if heart enlargement is associated with CM hypertrophy, the above control and 
Eng-iKOqEC hearts sections stained with WGA to measure CM area. The CM area was 
measured using Zen 2012 software from only transversely cut CMs of both Eng-iKOqEC and 
controls. This analysis showed a significantly higher CM area of both right (~47%) and left 
(~79%) ventricle CM of Eng-iKOqEC compared to their respective controls (Figure5.26G).  This 
result confirms CM hypertrophy following endothelial endoglin depletion and indicated the 
continued importance of endoglin expression even in quiescent ECs. 
 
Figure 5.32: Depletion of Endoglin in adult quiescent ECs using VE-CadCre-ERT2 leads to cardiac hypertrophy. 
WGA stained (white) control (A) and Eng-iKOqEC (B) mice transverse heart sections showing cardiomyocyte (CM) 
hypertrophy in Eng-iKOqEC mice. (C) Quantification of WGA staining showed significantly increased area of Eng-
iKOqEC CM in RV (285.9±31.34, n=3; p = 0.0137) and LV (277.6±29.02, n=3; p = 0.0477) compared to respective 
controls (RV: 194.0±8.90, n=3; LV: 155.1±3.14, n=3). Data shown as mean±SEM and analysed using two tailed 




5.2.6.1 Effect of Endoglin knockdown in Adult ECs on AVM formation  
As seen during the neonatal study, this cardiac phenotype could be due to AVMs in the systemic 
vasculature (Figure 5.16) These AVMs can occur in any part of the body, however HHT1 
patients are more prone to AVMs in lungs and brain [(section 1.6), (182)]. To detect 
arteriovenous shunts (AVS), Eng-iKOqEC (Figure 5.28) and control mice were injected with 
fluorescently labelled microspheres. To detect pulmonary AVMs, 15µm3 microspheres (red 
beads) were injected into the venous circulation (Figure 5.33, red arrow) as these are readily 
trapped in the pulmonary capillaries (141). While to analyse the presence of AV shunts in the 
systemic circulation beads were injected into the left ventricle, also larger (45µm3) green 
florescent microspheres (green beads, Figure 5.33, green arrow) were used as smaller beads 
passed through natural endogenous AV shunts even in control mice, such as those between 
hepatic artery and portal veins (304).  
 
Figure 5.33: Injection of fluorescently labelled microsphere to investigate the presence of AVMs in 
pulmonary or systemic circulation [adapted from (305)]. To investigate presence of AVMs in lungs, 15µm3 
red fluorescent microspheres were injected via tail vein and to study the presence of AVMs in systemic vasculature, 




To check that the red 15um3 beads were consistently trapped in the lungs in control mice, 200µl 
of 106 beads per ml was injected via tail vein in three control female mice. The organs were 
harvested and prepared following the protocol described in section 2.7.3 and imaged using filter 
set 31 on M2 axio-imager microscope. The red beads were efficiently trapped in the lungs 
(Figure 5.34A) with no beads in the brain, liver and kidneys of control female mice (n=3) 
(Figure 5.34, F-H). The examination of left lung slices showed even distribution of beads 
throughout the left lung lobe (Figure 5.34, B-E). In Eng-iKOqEC female mice (n=6), a similar 
phenotype was observed with all the red beads trapped in the lungs (Figure 5.34I), with an even 
distribution in lungs slices (Figure 5.34, J-M). Similarly, no beads were observed in the other 
organs of Eng-iKOqEC mice (Figure 5.34, N-P). A summary of this data is showed in Table 5.2. 
Together, this current data confirms that lack of endothelial endoglin did not cause any vascular 
shunting of greater than 15µm diameter in lungs. 
Table 5.2: Results summary of tail vein injection of 2x105 (200µl) 15µm3 red fluorescently labelled 
microspheres in control and Eng-iKOqEC female mice  
No. Genotype Gender 
Beads 
Brain Liver Lungs Left Lung Slices Kidneys 
1 Control F No No 
Yes 
***** 
Even Distribution No 
2 Control F No No 
Yes 
***** 
Even Distribution No 
3 Control F No No 
Yes 
***** 
Even Distribution No 
1 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 
2 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 
3 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 
4 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 
5 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 
6 Eng-iKOqEC F No No 
Yes 
***** 
Even Distribution No 






Figure 5.34: Knockdown of Endoglin in quiescent ECs using VE-CadCre-ERT2 did not lead to formation of 
AVMs in the lungs. 15µm3 red fluorescence beads injected via the tail vein were efficiently trapped in the lungs 
[whole view lungs (A,L) and transverse 100µm thick slices of left lungs (B-E, J-M) of both controls and Eng-
iKOqEC mice. No beads were observed in the brain (F,N), liver (G,O) and kidneys (H,P) of control and Eng-iKOqEC 
mice. Abbreviations: RL – right lung; LL – left lung; B – bronchioles. Scale bar: A-P = 1mm. 
To detect AVMs in the systemic circulation, various volumes of (50 to 300µl) 45µm3 green 
beads (5 x 105/ml) were injected via LV and allowed to circulate for one minute under terminal 
anaesthesia following the protocol described in section 2.7.2.  In all cases very few beads 
reached the lung in control females, but large numbers of beads reached the lung in control 
males. Male mice are larger than female mice so the shunting of 45um3 beads from the arterial 
to the venous side in control males could potentially be due to larger vessels in males compared 
to females. However, this would need further analysis to confirm. 
 A volume of 100µl containing 5.5x104 green beads injected via LV was selected for testing in 
a larger group (n=8) control female mice. The organs and lungs slices were prepared as before 
(section 2.7.3) and imaged using filter set 10 on M2 axio-imager microscope. Results showed 
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a fairly consistent pattern of green beads entrapment in brain, liver, kidneys and intestine. A 
high number of beads were trapped in major vessels of brain (Figure 5.35A), liver (Figure 
5.35B, white arrows) and arteries in intestine (Figure 5.35D) with an even spread throughout 
both kidneys (Figure 5.35C). Only one control liver was observed with a lower number of beads 
in all organs suggesting failure in the injection (Control 7, Table 5.3). In the lungs of all the 
control mice, only a small number of green beads were observed (Figure 5.35, E&F, yellow 
arrows). These could potentially have reached the lungs due to presence of natural endogenous 
shunts in the liver (304). 
Repeating the experiment in Eng-iKOqEC mice (n=7), gave a similar pattern of green beads 
trapped in brain (Figure 5.35G), kidneys (Figure 5.35I) and intestine (Figure 5.35J). In contrast, 
green beads were observed in the vessels present in the periphery of the liver (red arrows, Figure 
5.35H) and a significantly increased number of beads reached the lungs (Figure 5.35, K&L and 
Figure 5.35M) indicating presence of AV shunts greater than 45µm diameter in the systemic 
circulation. To compare the number of beads reaching lungs in controls and Eng-iKOqEC mice, 
total number of beads were counted using event function of Zen 2012 software from the tiled 
images of all left lung slices. The quantification using unpaired t-test showed a 98% increase 
in the number of beads reaching the left lung of Eng-iKOqEC female mice compared to controls 
(Figure 5.35M, p value = 0.0023). A summary of this data is shown in Table 5.3.  
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Table 5.3: Results summary of 45µm3 green fluorescently labelled microspheres (5.5x104) entrapment in 
organs of female controls and Eng-iKOqEC mice injected via left ventricle. 
No. Genotype Gender 
Presence of Beads 
Brain Liver Kidneys Lungs Left Lung Slices 





















































































































































Key: * – lowest beads density; ***** – highest beads density 
 
In conclusion, the analysis of red beads showed that endoglin knockdown in quiescent ECs does 
not lead to any pulmonary vascular abnormalities (Figure 5.34 and Table 5.2). In contrast, green 
beads injected into the systemic circulation via LV readily reach the lungs in Eng-iKOqEC 
female mice (Figure 5.35 and Table 5.3) demonstrating the presence of arteriovenous shunts in 
the systemic circulation of (Figure 5.31). However, further experiments potentially using 








Figure 5.35: Knockdown of Endoglin in quiescent ECs using VE-CadCre-ERT2 cause systemic vasculature 
related abnormalities. Most of the 45µm3 green fluorescence beads injected via the left ventricle were observed 
to be trapped in the brain (A), liver (B), kidneys (C) and intestine (D) of control mice. While a few beads were 
observed to reach the lungs [yellow arrows; whole view (E) & transverse 100µm thick slice of left lung (F)] of 
control mice. In contrast, numerous beads were observed in Eng-iKOqEC mice lungs [whole view (K) & transverse 
100µm thick slice of left lung (L)]. The pattern of beads in brain (G), kidneys (I) and intestine (J) of Eng-iKOqEC 
mice was observed to be similar to controls. However, in liver the beads were observed near the periphery (red 
arrows, H) while in controls these trapped in the in middle (white arrows, B). (M) Quantification showed 
significantly higher number of 45µm3 green beads trapped in Eng-iKOqEC mice (2560.00±717.40, n=7; p = 
0.0023) compared to control (33.00±14.99, n=8) mice. Data shown as mean±SEM and analysed using two tailed 






5.3.1 Endoglin in coronary ECs during cardiac development 
5.3.1.1 Endoglin in ECs during embryonic heart development 
To investigate the role of endoglin in ECs of the developing coronary vessels, a new inducible 
arterial ECs specific Cre (Dll4in3Cre-ERT2) mouse model was used. This part of the work would 
provide further insights into the development of coronary vessels which in turn could be utilised 
to design better treatment strategies for patients with coronary vasculature related defects. 
Unfortunately, activation of Dll4in3Cre-ERT2 at different time-points did not label many coronary 
arteries in developing embryos (Figure 5.6). This could be potentially due to following reasons: 
(i) poor Cre recombinase efficiency, (ii) long gap between the loxP sites (306-308), (iii) lack of 
stability or efficiency of the small enhancer sequence (Dll4in3-Cre-ERT2) (309) or else (iv) 
depending on the location of enhancer sequence in the genome, it could also be affected by 
chromatin condensation. This poor Cre recombination postnatally due to long gap in between 
loxP sites is unlikely as the same reporter is widely used including in this thesis (chapter 4 & 
5). In a publication by Turlo et al. (310), a similar issue was observed with poor β1 integrin 
knockdown using Sm22αCre-ER in one mouse strain. It was observed that the knockdown was 
unsuccessful due to the presence of a Cre recombinase episomal product (small circular DNA 
product formed from the excised sequence) in slowly proliferating cells (310). It is possible that 
arterial ECs proliferate at a slower rate compared to venous ECs, to analyse this, embryo 
sections would need to be stained with a proliferation, arterial and venous markers such as 
pHH3, Jagged1 and Endomucin respectively. To analyse the presence of the episomal product, 
qPCR was used in the study by Turlo et al. (310) by custom designed primer sequences against: 
(i) recombined loxP sites; (ii) unrecombined sequence and (iii) another set against the excised 
DNA sequence (episomal product). In the presence of successful recombination, there would 
be minimal amount of product in latter two. However, in this study, due to these disappointing 
results no further experiments were performed using this mouse line.  
5.3.1.2 Endoglin in ECs during postnatal heart development 
I next investigated the role of endothelial endoglin during the third phase of coronary 
development in the first week of postnatal life (122). Activation of VE-CadCre-ERT2 on day P2 
and P4 showed knockdown of endoglin in all cardiac blood vessels except for a few capillaries 
(Figure 5.9) and development of enlarged hearts by P7 (Figure 5.10) along with CM 
hypertrophy (Figure 5.13) and enlarged ventricle chambers (Figure 5.14). It is possible that 
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these mice develop eccentric cardiomyopathy caused by chronic overload due to systemic 
vasculature defects (discussed below). However, no abnormalities were observed in the 
coronary vasculature of Eng-iKOEC mice at P7 (Figure 5.12). It is possible that there could be 
still some subtle defects which are not visible in the 2D imaging plane of heart tissue sections. 
To analyse this, 3D reconstruction would need to be performed on serially sectioned heart 
tissue.   
Another possible reason for the lack of observed coronary vascular defects could that the 
development (third wave) of vessels in the trabeculae starts earlier than reported by Tian et al. 
(122), potentially intra-embryonically. In a future study, it might be beneficial to activate VE-
CadCre-ERT2 immediately after birth (P0 and P1) to investigate the effect of endoglin knockdown 
on coronary vasculature. Mahmoud et al. (188) reported that endoglin knockdown in ECs led 
to increased EC proliferation. Therefore, it would also be informative in future studies to 
analyse the effect on endothelial cell proliferation using markers such as pHH3 or BrdU and 
apoptosis using Caspase 3. Furthermore, it might also be useful to isolate coronary ECs from 
controls and Eng-iKOEC mice; and check the levels of phosphorylated smad1/5/8 and smad2/3 
as well as proteins including Pai1, Id1, and PDGF using techniques such as western blots or 
qPCR or both. This will help to reveal which proteins are affected downstream of TGFβ/BMP9 
signalling pathway in heart.  
In the current model, AVMs were suspected as causal for the eccentric cardiac hypertrophy 
phenotype as loss of endothelial endoglin leads to AVMs in neonatal retinas of Eng-iKOEC mice 
(188) and I confirmed this phenotype in P7 Eng-iKOEC mice (Figure 5.16). These mice could 
also be developing HOHF similar to that observed in Eng-iKOqEC adult mice (Figure 5.4). 
However, further experiments to study cardiac function would be required to calculate cardiac 
output and ejection fraction of control and Eng-iKOEC neonatal mice.  
Another parameter to check would be cardiac fibrosis, a common histological parameter 
observed in multiple heart diseases (311). To analyse this, the heart sections would need to be 
stained with masson trichrome or Sirius Red, which would allow quantification of cardiac 
fibrosis. It might also be beneficial to analyse the impact of endoglin knockdown on angiogenic 
factors which could be downstream of TGFβ/BMP signalling. To analyse this, an angiogenesis 
antibody array kit (e.g. from R&D systems, cat. no. ARY015) with various angiogenic factors 
could be used with lysates of whole organs or if possible, with isolated ECs from AVMs prone 
organs such as lungs, liver and brain from control and Eng-iKOEC mice. This would aid in 
showing possible angiogenic factors which could be working downstream of TGFβ/BMP 
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signalling. The selected factors then further quantified either using qPCR or western blots and 
could generate new therapeutic targets in patients with vascular related illness/ disorders.  
5.3.2 BMP9 mediated rescue of AVM phenotype 
The standard treatment for severe AVMs is embolization, performed under general anaesthesia 
to block the vessels while most of the small AVMs are generally left untreated (194, 195). 
However, these embolized vessels could reopen again in future (194). Therefore, delivery of a 
pharmaceutical molecule could definitely aid in development of better treatment strategy. 
During the current study, I tested the effect on AVMs formation after exogenous BMP9 
treatment in vivo.  
During the TGFβ/BMP signalling, endoglin is required to help to bind the BMP9/10 ligand to 
BMPR2 (130, 134). Therefore, in the absence of endoglin, availability of ligands BMP9/10 
would be reduced which could potentially cause AVMs in retinas along with delayed vascular 
progression and wider veins [(188) Figure 5.16]. However, IO injection of BMP9 on day P4 or 
P5 in Eng-iKOEC mice did not rescue the AVMs phenotype in P7 Eng-iKOEC retinas (Figure 
5.16) but the IO injection itself exacerbated the AVM phenotype (Figure 5.18). This was 
potentially because a 27G needle was used to inject BMP9 and PBS which led to a severe injury 
in the eyes such that many retinas had very poor morphology. In a study by Hombrebueno et 
al. (312), they showed IO injection of normal saline in 3 months led to upregulation of multiple 
inflammatory genes including VEGF. It is possible in the current study, IO injection led to 
increased Vegf expression providing the angiogenic stimuli leading to an aggravated phenotype 
(Figure 5.18). In any future studies it might be beneficial to use a smaller gauge potentially 33G 
Hamilton syringe. This might provide better morphology potentially due to reduced injury  
If IO injection still does not work due to morphological issue; systemic delivery (IP injection) 
could be tested however, much higher doses of BMP9 would be needed. Long et al. (313) using 
immunoprecipitation and immunoblotting showed that BMP9 signals via canonical signalling 
pathway in combination with BMPR2 in vitro and prevents tumour necrosis factor α (TNFα) 
induced ECs apoptosis. Mutations in BMPR2 are shown to be associated with pulmonary 
arterial hypertension (PAH) (314, 315). Long et al. (313), also showed that 6 month old 
Bmpr2+/R899X mice develop PAH as observed by increased right ventricular systolic pressure 
(RVSP) and enhanced muscularisation of pulmonary arteries. Interestingly, treatment of these 
mice with exogenous BMP9 by IP injection (75ng dose daily for 4wks) reversed these PAH 
symptoms by reducing in RVSP to WT levels as well as reduction in the enhanced vascular 
muscularisation phenotype (313). If the HHT phenotype is due to lack of BMP9/10 signalling 
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(192, 293), it is possible similar treatment with BMP9 would also reduce the AVM phenotype 
in HHT1 mice to generate a protective response (i.e. prevent AVM formation). Further studies 
would be required to determine if BMP9 could also revert established AVMs.  
5.3.3 Origin of AVMs: Arterial, Venous or Both 
AVMs are abnormal direct connections between arteries and veins (Figure 1.21). However, the 
origin of these AVMs is still unclear. Jin et al. (294), suggested that AVMs originate from 
arteries. However, I analysed the effect of endoglin knockdown in venous ECs and capillaries 
on AVMs formation. The activation of ApjCre-ER using tamoxifen at P5 was the earliest time-
point that allowed specific activation in veins and capillaries of the retinas (Figure 5.20).  
Mirroring these Cre activation times (P5 & P6) in the VE-CadCre-ERT2 mouse model generated 
AVMs and enlarged veins in P8 and P11 Eng-iKOEC retinas (Figure 5.25). The probability of 
AVM formation in Eng-iKOEC retinas was ~67% after Cre activation at P2&P4 (similar to that 
observed by in Mahmoud et al. (188)). Later depletion of endothelial endoglin (at P5&P6), a 
comparable incidence of retinas with AVMs was observed (~57% at P8 and ~67% at P11). 
Furthermore, these AVMs as well as additional AVMs likely present in the systemic circulation 
also led to development of enlarged heart in P11 mice (Figure 5.23B). This strongly suggests 
that endothelial endoglin is required for normal cardiovascular development. I next compared 
these results with venous ECs specific endoglin knockdown using ApjCre-ER. Interestingly, a 
similar phenotype was observed in both P8 and P11 hearts (Figure 5.23) and retinas (Figure 
5.25). However, in the current preliminary study slight differences were observed in the P8 
phenotype of Eng-iKOV compared to Eng-iKOEC retinas. The AVMs formation probability was 
considerably lower in P8 Eng-iKOV retinas (~33%) compared to P8 Eng-iKOEC retinas (~57%). 
The AVMs in the Eng-iKOV were also ~24% thinner compared to Eng-iKOEC mice. If 
confirmed in larger numbers of mice this finding suggests that AVMs in Eng-iKOEC develop 
earlier than in Eng-iKOV mice and enlarge over time potentially due to increased EC 
proliferation and blood flow through the AV connection (188, 316).  
To test any difference in EC proliferation, P8 and P11 retinas from both mouse lines would 
need to be first injected then stained with BrdU. Furthermore, the effect of venous ECs specific 
endoglin knockdown could also be studied on vessel muscularisation in retinas (using αSMA 
antibody). As reduced BMP9/10 signalling could be causing this effect it might useful to 
compare the angiogenic factor profile in retina ECs from VE-CadCre-ERT2, venous and arterial 
ECs from ApjCre-ER mice using an angiogenesis antibody protein array. The ECs from P8 control 
and Eng-iKOEC retinas could be extracted using Dynabeads conjugated with anti-PECAM1 
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antibodies (317). However, to isolate venous ECs from littermate control and Eng-iKOV P8 
retinas, Dynabeads would need to be used with antibodies such as anti-apj [located on cell 
surface (318)] or anti-endomucin. An alternative approach would be to isolate ECs from Eng-
iKOV (and controls) using FACS, as ApjCre-ERRosa26mT/mG mice express eGFP in all Cre-
recombined cells. These ECs could then be subjected to angiogenesis antibody array kit to 
discover any common angiogenic factors potentially crucial for formation of AVMs, which 
could then be quantified either using western blots or qPCR.  
In conclusion, this study shows a clear HHT1 phenotype in a novel mouse line. More 
importantly, this study indicates the importance of endoglin in veins and capillaries for 
maintaining vascular homeostasis.  
5.3.4 Endoglin in Vascular Maintenance in Adult Mice 
HOHF is a rare complication in HHT patients and in most cases is associated with liver AVMs 
(170-172). HOHF could also be caused due to anaemia or vasodilation or loss of systemic 
vascular resistance (295-297) . Lack of endoglin in quiescent endothelial cells using VE-CadCre-
ERT2 consistently led to development of HOHF (Figure 5.4). In my host laboratory, analysis of 
aortic pressure showed that loss of endothelial endoglin led to reduced systemic vascular 
resistance. This reduced vascular resistance was not due to anaemia as Eng-iKOqEC mice had 
normal haematocrit. Another cause of HOHF could be AV shunts in the pulmonary and 
systemic circulation. I therefore analysed Eng-iKOqEC mice to study the presence of AVMs. 
In Eng-iKOqEC mice, 5wks after first tamoxifen injection, enlarged hearts (Figure 5.29) were 
observed with CM hypotrophy (Figure 5.32) similar to neonate phenotype (Figure 5.10 and 
Figure 5.13). In addition, strong endoglin expression was observed in coronary veins, 
pulmonary veins, central veins and pulmonary arteries compared to arterial ECs coronary, 
hepatic arteries and portal veins (Figure 5.31). This was a novel discovery, potentially 
suggesting that ECs of these vessel proliferate at higher rate as during angiogenic phase, 
proliferating ECs express strong levels of endoglin (144). In Eng-iKOqEC mice, a varying level 
of endoglin knockdown was observed all the vessels except hepatic arteries (Figure 5.31). As 
mentioned above, this poor recombination could be linked with low proliferating cells (310). 
This hypothesis would need to be verified either by staining for proliferative marker pHH3 on 
sister sections of the above mice or harvesting fresh organs from BrdU injected mice and then 
stain for BrdU. 
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The analysis of pulmonary AVMs using 15µm3 red fluorescent beads injected via tail vein 
showed normal pulmonary vasculature in control and Eng-iKOqEC with all the red beads trapped 
only in the lungs (Figure 5.34). In addition to this, oxygen saturation analysis in Eng-iKOqEC 
mice showed no difference in comparison to controls (unpublished data, Arthur Lab). Taking 
this data together confirmed lack of pulmonary AVMs in Eng-iKOqEC mice. This is contrast 
with 33% risk of pulmonary AVMs in HHT1 patients (319). This difference could be potentially 
due to lack of a second angiogenic stimulus (e.g. lung infection) or somatic mutations which 
potentially lead to formation of pulmonary AVMs in patients (187-190).  
Analysis of the systemic circulation using 45µm3 green fluorescent beads injected via LV 
showed a significantly higher number of green beads in Eng-iKOqEC lungs compared to controls 
(Figure 5.35, E,K&M). This indicated the presence of AVMs or enlarged AV connections in 
the systemic circulation. The distribution pattern of green beads was similar in brain, kidneys 
and intestine of control and Eng-iKOqEC mice (Figure 5.31). However, in liver the beads were 
observed in the central hepatic vasculature in control while in Eng-iKOqEC mice, beads were 
trapped in the periphery of the liver (Figure 5.31B&H). Further analysis in the Arthur laboratory 
using beads showed a 50:50 occurrence of central or peripheral location of beads in the liver in 
both controls and Eng-iKOEC mice. This could be due to variation in the size of endogenous 
shunts between hepatic artery and portal vein (304). Further work using latex (which when 
injected into the aorta is normally retained in the arterial side of the circulation unless AV shunts 
are present) showed consistent large AVMs in the pubis symphysis region of Eng-iKOqEC mice 
(Figure 5.36). This finding confirmed the initial hypothesis that reduced vascular resistance was 
caused by AVMs in the systemic circulation leading to HOHF.  
 
Figure 5.36: Endothelial Endoglin knockdown in adult ECs leads to development of AVMs in pubis 
symphysis. (A) Image of pubic symphysis region of control (n=11) showed normally developed vasculature 
visualised using injection of latex (blue) via aorta. (B) Image of Eng-iKOqEC pubic symphysis showed enlarged 
vessels and AVMs (n=9). Data courtesy of Dr. Simon Tual-Chalot. 
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This work showed that continued expression of endoglin in ECs is crucial for maintaining 
normal adult vasculature. However, the mechanism behind this is still unknown. In a recent 
publication by Jin et al. (294), it was observed that neonate mice lacking endothelial endoglin 
develop AVMs in brain and retina. They also observed high level of Vegfa expression in the 
brain lysates from Eng-iKO mice potentially induced due to hypoxia (294). Furthermore, in 
vivo inhibition of VEGFR2 or PI3K (a downstream target of VEGF induced signalling) led to 
reduction in expansion of these AVMs (294). In addition to this, HHT patients also have 
increased VEGF levels in their serum/plasma (320, 321). Therefore, VEGF signalling could be 
playing an important role in the current cardiac and AVMs phenotype. Furthermore, during the 
current study in vivo inhibition of VEGF signalling via treatment with anti-VEGFR2 antibody 
(DC101, 1wk after first tamoxifen injection) showed normal vessel development in the pubic 
symphysis region of Eng-iKOqEC mice that partially rectified the cardiac phenotype 
(unpublished data, Arthur lab).   
In light of this new evidence from the adult and neonatal mice studies, it is possible endoglin 
not only promotes EC proliferation during angiogenesis but also helps to maintain ECs in 
quiescent state by influencing VEGF signalling. The expression of both endoglin (144) and 
VEGF (13, 14, 16, 107) is reported in proliferating ECs and both are upregulated during hypoxia 
(216, 217, 322-325). Perhaps, in proliferating ECs, hypoxia promote expression of endoglin 
which then stimulate Vegf signalling pathway via BMP9/ALK1 mediated signalling cascade 
(Figure 5.37A). When the hypoxic trigger is lifted, these ECs enter a quiescent/ vessels 
maturation phase. It is widely known that the endoglin keeps a balance between ALK1 and 
ALK5 pathway (123) so potentially, endoglin supresses VEGF signalling pathway via ALK5 
mediated pathway (Figure 5.37B). However, in the absence of endoglin, this balance is 
disturbed leading to enhanced VEGF signalling leading to increased EC proliferation and 
AVMs (Figure 5.37C).  
To test this hypothesis, primary endothelial cells could be used from Engfl/fl; Rosa26Cre-ERT2 
mice. Half of the cells would be subjected to endoglin knockdown using 4-hydroxy tamoxifen 
and seeded to a desired cell density. Cells from both groups (control and Eng-iKOu), would be 
cultured in either hypoxic or normoxic conditions. At the end of incubation time, one hypoxic 
batch of cells would be returned to normoxia to simulate an in vivo scenario. Once cells from 
all three batches are collected, they would need to be analysed for levels of signalling proteins 
involved in BMP9 (e.g. endoglin, Smad1/5/8, pSmad1/5/8, Sma2/3, pSmad2/3, ID1 and Pai-1) 
and VEGF (e.g. Vegfa, Vegfr1, Vegfr2, pI3K and pERK) signalling using either qPCR, western 





Figure 5.37: Summary of TGFβ/BMP9 signalling in quiescent endothelial cells in the presence and absence 
of endoglin. (A) In quiescent ECs, endoglin potentially supresses VEGF signalling probably indirectly via ALK5 
pathway. (B) However, in the absence of endoglin, this balance is disturbed leading to enhanced VEGF signalling 
which in turn cause hyper-proliferation leading to vascular abnormalities such as AVMs.   
In conclusion, at the end of this study, the role of endoglin in coronary vasculature development 
is still elusive and would need a better genetic tool to study it during embryogenesis. However, 
this study did highlight various novel aspects of endoglin in ECs. In neonatal proliferating ECs, 
loss of endoglin not only leads to the formation of AVMs (188) but also cause an enlarged heart 
in Eng-iKOEC mice. This phenotype occurs after complete loss of endoglin using VE-CadCre-
ERT2, as well as in the venous and capillary ECs specific endoglin knockdown using ApjCre-ER. 
This strongly indicates that even a partial imbalance of endoglin is detrimental for vascular 
development. Furthermore, similar phenotype occurs in adult quiescent ECs which shows that 
continuous endoglin expression is still crucial in quiescent ECs for maintenance of normal 









Chapter 6. Role of Endoglin in CDC 





In this chapter I describe my investigations of the role of endoglin in cardiac stem cells used in 
pro-angiogenic cell therapy following myocardial infarction (MI). As described in section 1.7, 
a normal healthy heart has a high energy demand and to keep with energy demand every CM 
is in the close vicinity of a capillary (45, 46). Blockage of a coronary artery leads to MI (201) 
and severity of MI depends on the coronary artery involved. The CM death post-MI is inevitable 
and to reduce CM loss, acute MI patients are subjected to PPCI also known as angioplasty to 
restore the blood supply to the affected region (203). Occurrence of MI results in a cascade of 
cellular responses to initiate heart repair in three phases: (i) inflammatory, (ii) proliferative and 
(iii) maturation (Figure 1.20). The process of angiogenesis occurs during the second phase 
while arteriogenesis occurs during the third phase. These two processes are critical for cardiac 
healing but are generally insufficient at the endogenous level to protect the CM death (218). 
During angiogenesis, endoglin promotes BMP9 signalling via the ALK1 pathway (Figure 1.17) 
and following MI, increased endoglin expression is observed in the infarcted region (216, 217). 
Furthermore, following MI in mice with heterozygous deletion of endoglin there was reduced 
angiogenesis along with significant reduction in stroke volume, cardiac index and ejection 
fraction compared to control mice (216). To improve cardiac healing post-MI various stem cells 
are being exploited and promising results are observed using CDCs (discussed in section 1.7.2). 
 Cardiospheres Derived cells in Therapeutic Angiogenesis Post-MI 
CDCs are a mixed population of cells generated from cultured heart tissue biopsies and express 
various cell specific markers including mesenchymal markers (Eng/CD105) and stem cell 
markers (c-kit1, SCA-1) (326). Various studies have tested CDCs for their regenerative 
potential for heart repair post-MI [reviewed in (220)]. The beneficial effects of CDCs are 
primarily derived via a paracrine mechanism (Figure 1.22). Injection of CDCs in post-MI hearts 
showed beneficial effects including improved heart function and reduction in scar size 3 weeks 
after MI (225, 327). In the current study I analysed the importance of endoglin expression in 




 Role of Endoglin in CDCs: Pilot study 
In my host laboratory, CDCs were cultured from heart biopsies taken from Engfl/fl; RosaCre-ERT2; 
CAG-GFP mice (150) following the protocol described in Section 2.8 (Figure 6.1). CDCs 
cultured from this line allows depletion of endoglin in all cardiac cells in the presence of 4 
hydroxy tamoxifen (4-OH tam).  
 
Figure 6.1: Derivation of murine CDCs [Images courtesy of Dr. Rachael Redgrave]. (A-C) Schematic 
showing stages of CDC culture. Briefly, heart tissue from Engfl/fl; Rosa26Cre-ERT2 neonatal mice is cut into small 
explants and plated onto fibronectin. Explant outgrowth cells (A,D) are cultured for approximately 2 weeks and 
consist of a layer of stromal-like cells (yellow arrows) over which small, phase-bright cells (white arrows) grow. 
(B,E) All cells are harvested and re-plated onto poly-d-lysine in a growth factor rich media. Over 1-week cells 
begin to aggregate and form spherical clusters or cardiospheres (E, red arrows). (C) Loosely adherent 
cardiospheres are then re-plated onto fibronectin-coated flasks and expanded as a monolayer of cardiospheres-
derived cells (F). Scale bars B-F = 100µm. 
My colleague Dr Rachael. Redgrave showed using flow cytometry that over 70% CDCs express 
CD105 (Figure 6.2A) with a few CDCs express CD45 consistent with their non-haematopoietic 
origins. To confirm endoglin knockdown in Eng-iKO CDCs, cells with and without tamoxifen 
treatment at P1 were seeded in chamber slides and stained with rat anti-CD105 antibody (Figure 
6.2C-E). Quantification showed that, 93%±3 of control CDCs express endoglin while 23%±5 
Eng-iKO CDCs express endoglin (data analysed by Dr. Rachael Redgrave). In other words, 




Figure 6.2: Characterisation of endoglin expression in CDCs and knock-down [Images & data courtesy of 
Dr. Rachael Redgrave]. (A) Over 70% of CDCs express endoglin, as shown by representative FACS analysis. 
(B) To induce Endoglin knockdown in vitro, CDCs are treated with 2µM of 4-hydroxy tamoxifen for 4 days to 
activate Rosa26-Cre-ERT2. Representative anti-CD105 immuno-fluorescence images of (C) control CDCs (no 
tamoxifen) showed high expression of endoglin (red), whereas (D) Eng-iKO CDCs (tamoxifen-treated) showed a 
marked reduction in endoglin levels. Nuclei are stained with DAPI. (E) No primary staining control. Scale bars: 
C-E = 50µm. 
To investigate whether endoglin is required for the pro-angiogenic properties of CDCs I 
performed experiments that built on pilot data (Figure 6.3) gathered in my host laboratory. This 
preliminary work, from Dr Redgrave’s PhD thesis, used CDCs from a small number of mice 
(n=2-4) and the results suggested that knockout of endoglin in CDCs prior to intra-myocardial 
injection post-MI led to reduced angiogenesis at 4 weeks post-MI compared to CDCs without 
endoglin knockout (328).  
The purpose of my study was firsty, to expand this pilot study MI and sham groups. Therefore, 
group sizes were calculated based on identifying a difference in vessel density at a significance 
of p ≤0.05 with 80% power using UBC online tool (329) and minitab software. Following the 
power calculations, the groups ‘n’ numbers were increased as follows: (i) MI+PBS from n=4 
to n=8; (ii) MI+CDC-Ctl from n=4 to n=8 and (iii) MI+CDC-Eng-iKO from n=4 to n=7. The 
sham group were increased to a minimum of 3. The second aim of my study to investigate the 





Figure 6.3: Effect of endoglin knockout on CDC mediated heart repair, pilot data results [Image courtesy 
of Dr. Racheal Redgrave (328)]. Incidence of MI (B) lead to reduction in the density of vessels in the infarcted 
zone compared to Sham hearts (A). Transplantation of WT CDCs lead to increased angiogenic response in 
infarcted zone (D). However, this pro-angiogenic response of CDCs was lost after depletion of endoglin (E). (C) 
Quantification showed a significant increase in angiogenesis in the infarcted zone after transplantation of Control 
CDCs (0.088±0.003, n=4) in post-MI hearts compared to MI+PBS (0.073±0.002, n=4; p = <0.0010) and 
MI+CDC-Eng-iKO (0.075±0.001, n=4; p = <0.001) group. Abbreviations: CDC – Cardiospheres Derived Cells; 
Eng-KO – Endoglin knockout; PBS – Phosphate Buffer Saline; MI – Myocardial Infarction and WT – Wild Type. 
Data analysed using one-way ANOVA (** p < 0.01). Scale bar: A,B,D,E = 50μm. 
6.2. Results 
6.2.1. Experimental setup and optimisation of CD31 quantification  
 In order to expand the pilot study group sizes, approximately 12-weeks old C57Bl/6 male mice 
were given MI by permanent ligation of the LAD. Following MI, two intra-myocardial injection 
of either PBS or control or Eng-iKO CDCs [(5x105cells/10µL), prepared by Dr. Darroch Hall 
during surgeries] was administered by Dr. Rachael Redgrave. The chest was then closed, and 
mice were allowed to recover. For sham mice, the same surgery was performed without a 
coronary ligation and without any intra-myocardial injections. After 4 weeks, mice from all 
four groups were humanely killed and hearts were fixed in 0.2% PFA. These hearts were then 
embedded in OCT and transversely cut into sister sections (Figure 6.4, A&B). The sections 
were then subjected to immunofluorescent staining and in each immunofluorescence 
experiment, heart sections from all groups were included to reduce variability due to different 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To quantify vessel density and maturation in post-MI hearts, images were taken from the infarct 
border zone of the mid-infarct region (Figure 6.4A). By definition, the infarct border is the 
region of the heart where infarcted myocardium meets the viable myocardium (Figure 6.4, 
C&D) recognised by auto-fluorescent CM. The trans-border region used for this analysis was 
approximately 0.25mm on either side of the infarct border (Figure 6.4B).  
For quantification, 5 sections from the mid-infarct region were selected from MI mice (Figure 
6.4A) and imaged at x20 magnification using a M2 axio-imager microscope. To minimise 
imaging of the same vessels, each of the five sections selected were at least 200µm apart. In the 
case of the sham mice, 8 images were taken from a similar region of heart (free LV wall). To 
quantify vessel density (by CD31 staining), the same white and black balance was set for each 
of the x20 images. These images were then converted into tiff format to quantify vessel density 
by measuring the percentage of CD31 positive stained area using the threshold function of 
ImageJ software. This process was repeated for all images taken from the 5 different heart 
sections per heart. Furthermore, to remove observer bias, data was blinded prior to 
quantification and data analysed by two independent observers (Esha Singh and Dr. Rachael 
Redgrave). 
6.2.2. Pro-angiogenic effect of CDCs is Endoglin Dependent 
The transverse sections of 4-weeks post-MI hearts were stained with rat anti-CD31 antibody. 
Table 6.1, shows the average vessel density calculated using ImageJ function for each heart, 
from all four groups (Sham (n=3), MI+PBS (n=4), MI+ CDCs-Ctl (n=4), and MI+CDCs-Eng-
iKO (n=3)). 
Table 6.1: Summary of ImageJ area analysis of CD31 stained heart sections 4 weeks post-MI and cell 
delivery. Images were taken along the trans-border zone region (mid-ventricle) of MI hearts at x20 and in similar 
region of Sham hearts (in arbitrary units). Each cell of the table represents an individual mouse heart and is an 
average of at least 26 images. Grey coloured cells represent the pilot data from Dr Redgrave and white cells 
represent the hearts analysed as part of this thesis. 




128858.93 74897.07 98407.07 77504.05 
114915.41 66911.68 89356.37 63493.55 
123863.18 64039.52 79256.82 64390.78 
112354.05 53506.87 63995.71 60438.52 
119420.80 62009.60 79509.13 86889.46 
 57739.70 94724.89 78939.00 
 57680.38 79111.33 62989.58 












Quantification of the CD31 staining on the new hearts showed similar results to those from the 
pilot experiment (Figure 6.3). A significant reduction in vessel density was observed at the 
trans-border zone region of all the MI group hearts (Figure 6.5, B,D&E) compared to sham 
hearts (Figure 6.5A). However, transplantation of control CDCs post MI led to a significant 
increase in the vessel density of these heart (Figure 6.5D) compared to PBS injected group 
(Figure 6.5B). This pro-angiogenic effect of CDCs was lost upon depletion of endoglin as 
shown by reduced angiogenesis in MI+CDC-Eng-iKO group (Figure 6.5E).  
As the results from the current study and pilot study were similar (Table 6.1), both data sets 
were combined and are shown in the form of scatter plot in Figure 6.5G with pilot data coloured 
in black and current data in different colours according to group type. Quantification analysis 
of the merged data showed a decrease in CD31 vessel area in all groups compared to sham. 
These decreases were 48% in ‘MI+PBS’, 29% in ‘MI+CDC-Ctl’ and 41% in ‘MI+CDC-Eng-
iKO’. Comparing the MI groups with one another, transplantation of control CDCs led to a 37% 
increase in vessel density compared to MI+PBS group, whilst transplantation of Eng-iKO 
CDCs only led to a 14% increase in vessel density compared to MI+PBS group. Taken together 
this data shows that, intra-myocardial injection of CDCs led to a significant increase in the 
CD31 vessel density in the ischemic border-zone. This effect of CDCs was endoglin dependent. 
6.2.3. Endoglin Promotes Vessel Maturation in the Infarct Border Zone 
Many studies have shown that endoglin promotes recruitment of vSMCs, which are required 
for vessel maturation (129, 330-333). As the pro-angiogenic effect of CDCs in 4-weeks post-
MI hearts was endoglin dependent, the effect of control and Eng-iKO CDCs on vessel 
maturation was examined. Sister sections from the mid-infarct region of all the MI hearts 
(Figure 6.4A) and similar regions from sham hearts were stained with anti-CD31 and anti-
αSMA antibodies. Images were taken as described earlier in section 6.2.1.  
I first analysed the vascular remodelling in the infarcted zone of MI hearts. As a result of MI, 
blood vessels are damaged, therefore to cope with the increased energy demand viable vessels 
dilate and eventually muscularised during the scar maturation phase to form collateral vessels 
(Figure 1.22). These vessels are formed in response to stress induced by MI (334). Analysis of 
the low power tiled images from all MI groups showed a thin left ventricle 4 weeks after MI 
(Figure 6.6, B-D) compared to healthy compact myocardium in sham hearts (Figure 6.6A). 
Digitally zoomed images of infarcted zone of MI hearts (Figure 6.6, F-H & J-L) revealed 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To analyse the role of CDCs on vessel muscularisation at the border zone, x20 magnification 
images were taken across the trans-border zone region (Figure 6.4, C-F) of the MI hearts and 
similar region in sham hearts. Visual inspection showed a high number of large vessels in the 
transborder zone region of all MI group hearts that were covered with a thick layer of aSMA 
positive vSMCs (Figure 6.7B-D, white boxes). In contrast, there were very few large 
muscularised vessels in the sham hearts (Figure 6.7A, white arrows). This was confirmed by 
manual counting on x20 images using event function of Zen 2012. During manual counting, 
each vessel identity was also confirmed by the presence of CD31 staining of the vascular 
endothelium.  
Using the manual counting method, the average numbers of vessels per FOV from 5 different 
heart sections were compared across the four different groups. As before, analysis was blinded 
to treatment to remove observer bias. This analysis showed a high number of muscularised 
vessels in the transborder zone region of MI mice (Figure 6.8 B-D & F-H, white arrows) 
compared to sham hearts (Figure 6.8 A&E, white arrows). In MI hearts, the transborder region 
is populated with large muscularised vessels (Figure 6.7B-D) while in sham hearts, 
muscularised vessels distribute evenly across the heart (Figure 6.7A) and were not enriched in 
the equivalent region.  
Visual inspection of the MI hearts, suggested that most muscularised vessels occurred at the 
border zone of  the ‘MI+CDC-Ctl’ group (Figure 6.8 C&G) compared to ‘MI+PBS’ (Figure 6.8 








Figure 6.7: Whole-view tiled image of 4-weeks sham and MI hearts showing the analysis area. Adult sham 
and MI heart sections stained anti-αSMA antibody to mark SMCs (red) and counterstained with DAPI (blue). (A) 
Whole-view image of sham hearts, showing even distribution of muscularised vessels throughout the heart section 
and region of heart used for quantification (white boxes). (B-D) In MI hearts, transborder region (white boxes) 
used for quantification, showed the presence of multiple muscularised vessels. Abbreviations: IVS – Inter 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Statistical analysis confirmed a significant increase in the average number of muscularised 
vessels in the trans-border zone region of ‘MI+CDC-Ctl’ groups compared to ‘MI+PBS’ (p = 
0.0217) and ‘Sham’ (p = 0.0109, Figure 6.8) groups. This positive effect of control CDCs on 
vessel stabilisation was lost in ‘MI+CDC-Eng-iKO’ group (p = 0.0011). A summary of this 
quantification is showed in Table 6.2.  
Table 6.2: Summary of the average number of muscularised/αSMA positive vessels in the trans-border zone 
4wks post-MI with and without CDCs, with and without endoglin KO. Images were taken along the trans-
border zone region (mid-ventricle) of MI hearts at x20 and in similar region of Sham hearts. Only the vessels 
stained positive for both CD31 and αSMA were counted. Each cell of the table represents an individual mouse 
heart and is an average of at least 25 images. Grey coloured cells represent the hearts from pilot study and white 
colour cell represent the hearts analysed during the current study. 
  SHAM MI Only MI + CDC-Ctl MI + CDC-Eng-iKO 
Average Number 
of αSMA positive 
vessels per FOV  
7.80 8.63 15.52 14.83 
9.83 11.39 11.17 7.92 
8.88 9.44 22.00 6.50 
 12.25 17.00 6.08 
 12.10 19.29 10.89 
 12.33 9.75 10.00 
 10.82 18.24 7.00 
  11.92 14.41  
Average ± SEM 8.83 ±0.58 11.11 ±0.49 15.92 ±1.45 9.03 ±1.18 
 
However, as observed earlier in the study, CDCs promote neovascularisation in transborder 
zone in post-MI hearts (Figure 6.5); so, it is possible that this direct comparison of vessels 
number potentially be showing a false positive effect of control CDCs on muscularisation. 
Therefore, to confirm this phenotype I calculated density of muscularised vessels per FOV 
(average number of muscularised vessels/ average CD31 stained area x 100). A summary of 
this data is shown in the Table 6.3. 
Table 6.3: Summary of density of muscularised vessels per FOV in the trans-border zone 4-weeks post-MI 
hearts with and without CDCs, with and without endoglin KO. The number of muscularised vessels was 
normalised using the mean CD31 stained area for each heart. Grey coloured cells represent the hearts from pilot 
study and white colour cell represent the hearts analysed during the current study. 
  Sham MI + PBS MI + CDC-Ctl MI + CDCEng-iKO 
Density of 
muscularised 





0.0063 0.0161 0.0174 0.0191 
0.0087 0.0170 0.0175 0.0131 
0.0074 0.0126 0.0224 0.0102 
  0.0191 0.0214 0.0094 
  0.0195 0.0243 0.0125 
  0.0214 0.0103 0.0127 
  0.0188 0.0231 0.0111 
  0.0202 0.0154   




Consistent with the previous analysis, the statistical analysis of normalised data showed a 
significantly high density of muscularised vessels in MI+CDC-Ctl group compared to sham and 
MI+CDC-EngiKO hearts (Figure 6.9).  However, in contrast to previous analysis (Figure 6.8K) 
no difference in the density of muscularised vessels was observed in between PBS injected and 
control CDCs injected hearts. Interestingly, in Eng-iKO CDCs group a significant drop in the 
muscularised vessels density was observed compared to ‘MI+PBS’ group (Figure 6.9).  This 
data suggests that endoglin in CDCs might not be able to promote muscularisation in post MI 
hearts. However, lack of endoglin in CDCs does inhibit the process of vessel muscularisation. 
This could be a direct or indirect effect; however further studies are required to unveil the 
mechanism behind it.  
 
Figure 6.9: Quantification showed a significant reduction in percentage of muscularised vessels in MI hearts 
after transplantation of Eng-iKO CDCs. The percentage of muscularised vessels was calculated by normalising 
the number of muscularised vessels (Table 6.2) using mean CD31 stained area for each heart (Table 6.1). In 
contrast to the previous results, following infarction a significant increase in the density of muscularised vessels 
was observed in the trans-border-zone region of the PBS injected (0.0181±0.0010; n=8; p = 0.0012) and control 
CDCs injected (0.0190±0.0017, n=8; p = 0.0005) hearts. Furthermore, no difference was observed between PBS 
injected and control CDCs injected (p >0.9999) hearts. Consistent with previous results, injection of Eng-iKO 
CDCs (0.0126±0.0012, n=7) led to a significant reduction in the density of muscularised vessels compared to both 
PBS injected (p = 0.0382) and control CDCs injected (p = 0.0121) MI hearts. Percentage of muscularised vessels 
in Eng-iKO CDCs injected MI hearts was observed to be similar to sham hearts (p = 0.2823). Data shown as 
mean±SEM and analysed using one-way ANOVA (* p < 0.05, ** p <0.01, *** p <0.001). 
6.3. Discussion  
CDCs are currently being tested in CADUCEUS (CArdiosphere-Derived aUtologous stem 
CElls to reverse ventricular dySfunction) clinical setting for their ability to protect against 
ventricular dysfunction after MI (226). In this trial, myocardial infarction patients (over 18yrs 
of age) undergone successful PPCI with left ventricular ejection fraction of 25–45% were 
enrolled (2 to 4wks after MI). The patients with less than 3yrs life expectancy were excluded. 
During this trial, CDCs are delivered to the heart by intracoronary injection (3 to 5wks) and this 
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led to reduction in scar mass and increased viable myocardium mass. But unlike animal models, 
no significant change in the LV function was observed 6 and 12 months after the injection 
(226). A possible explanation for lack of translation of the beneficial of CDCs from pre-clinical 
studies is delay in transplantation of these cells. Therefore, another clinical trial (ALLSTAR) 
is underway using allogenic CDCs by the same group (227). Patients with similar criteria as 
CADUCEUS trial are enrolled with a history of MI in last 4 to 12months. During this study, 
allogenic CDCs are injected via an intra-coronary route post-MI.    
In case of most acute MI patients, PPCI is the most common treatment along with therapeutics 
(208). This treatment is effective but does not reverse the muscle damage and for better 
prognosis, PPCI need to be achieved at the earliest time possible. This is not always feasible 
leading complications such as heart failure. The best way to improve cardiac healing would be 
by reducing CM death post-MI (or initiating CM regeneration). One of the treatment strategies 
believed to be beneficial is transplantation of stem cells during or after PPCI and have proved 
to be beneficial in the clinical setting (220). The aim of this chapter was to further characterise 
these cells, specifically to understand the importance of endoglin in CDCs.  
All human CDCs express endoglin (327) while in this study 70% of murine CDCs express 
endoglin (Figure 6.2A) consistent with previous publications (326). As mentioned in the 
introduction (section 1.5.1), endothelial endoglin is essential during angiogenesis. The 
upregulation of endoglin expression was not only observed in angiogenic phases but also during 
inflammation and remains high throughout the phase (335). They also showed a significant 
increase in endoglin expression in diseased human skin, liver and lung tissue samples (335). 
This increase in endoglin was directly correlated with inflammatory cell infiltration. For 
instance, in skin samples, strong endoglin expression was observed in the ECs in the regions 
with increased infiltration of macrophages and T cells (335). 
In this chapter I show that endoglin is also essential in CDCs, a heterogeneous mesenchymal 
cell population, to promote a significant increase in vessel density in the infarct border zone 
following MI (Figure 6.5). This result confirms that the pro-angiogenic effect of CDCs was 
endoglin dependent. Endoglin is known to promote BMP9/ALK1 mediated to signalling to 
trigger ECs proliferation (130). In addition to this, it could also be promoting VEGF signalling 
in the infarct zone as discussed in the Chapter 5, section 5.3.4. Therefore, it would improve ECs 
proliferation in the infarcted zone. To test increased ECs proliferation, the sections from above 
hearts could be stained for proliferative marker pHH3 or mice could be injected with BrDU 
then hearts could be stained with BrDU and ECs cell marker PECAM1. It might also be 
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beneficial to understand which angiogenic factors (such as VEGF, angiotensin 1, FGF) are 
promoted by performing qPCR on cDNA or western blots/ angiogenic factor ELISA on protein 
lysates harvested from infarcted myocardium. 
Similar to other studies  (225, 327, 336), genetic tracing using GFP-expressing CDCs in my 
host laboratory showed that very few differentiated myocardial cells including endothelial cells 
or vSMCs originating from CDCs were observed in 4-weeks post-MI hearts (150), leading to 
the postulation that the pro-angiogenic effect of CDCs was driven via a paracrine route. To 
further confirm that CDCs act via paracrine route, CDCs conditional media was collected from 
control and Eng-iKO CDCs and added to matrigel seeded with mouse endothelial lung cells. 
This matrigel mixture was then subdermally injected into the mouse flanks and analysis of 
matrigel plugs after two weeks showed higher vessel density in matrigel supplemented with 
control CDC conditioned media compared to media from Eng-iKO CDCs (150). This 
experiment showed that CDCs drive angiogenic responses via a paracrine route consistent with 
previous studies (225) and confirmed that the pro-angiogenic effect of CDCs is endoglin 
dependent. 
The formation of new vessels is not sufficient for proper healing, because if these new vessels 
are not stabilised, they tend to regress after the proliferation phase (209). Vessels are stabilised 
through the recruitment of pericytes or vSMCs (depending on vessel type). During the vessel 
maturation phase, growth factors secreted by endothelium and SMCs play a critical role (30). 
Any disturbance in signalling of these molecules leads to leaky or ruptured vessels. For 
example, lack of smooth muscle derived PDGF leads to a defective smooth muscle layer (337). 
Similarly, lack of endoglin during embryogenesis is fatal due to problems with SMC 
recruitment (128). A similar requirement for endoglin during SMC recruitment is also reported 
in other studies (129, 330-333). I, therefore, studied the role of endoglin in CDC mediated 
vessel maturation. Based on the studies above, I hypothesised that loss of CDC-specific 
endoglin would lead to a reduction or delay in vessel maturation in post-MI hearts. 
Immunofluorescent image analysis revealed an increased density of muscularised vessels in 
control CDCs injected hearts (Figure 6.8, C&G) however this phenotype is potentially not due 
to CDCs as similar density of muscularised vessels were observed in PBS injected MI hearts 
(Figure 6.9). Interestingly, injection of endoglin knockdown CDCs showed a significantly 
reduced density of muscularised cells (Figure 6.9).  
The reduced number of muscularised vessels in ‘MI+CDC-Eng-iKO’ group was surprising. 
This could be direct or an indirect effect from Eng-iKO CDCs could cause either due to lack 
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angiogenic factors (Vegf, angiopoietin 1, FGF) or secretion of anti-angiogenic factors such as 
thrombospondin-2 (338). The presence of anti-angiogenic or absence of pro-angiogenic factors 
could be affecting signalling between the endothelium and mural cells required for recruitment 
of SMCs. To test this hypothesis in vitro, first conditional media collected from control and 
Eng-iKO CDCs would need to be analysed for the expression of these factors. Next, to study 
the signalling between endothelial and mural cells, contact co-culture would be carried using 
ECs and mural cells in presence of CDCs conditional media. Furthermore, to assess this 
hypothesis in vivo, MI hearts injected with control or Eng-iKO CDCs would need be collected 
at different time points from early to later time points (e.g. day 1, 3, 5 & 7 then week 2, 3 & 4). 
Once harvested, expression of angiogenic (for example, VEGF, FGF and CD105) and anti-
angiogenic (for example, soluble endoglin and thrombospondin-2) factors would need to be 
measured either using qPCR or western blots. Another explanation for reduced number of 
muscularised vessels in Eng-iKO CDCs groups could be a delay in the maturation process. To 
test this, hearts from all four groups would need to be harvested at a later time point, for instance 
around 6, 8 or 12weeks post-MI, and subjected to the same analysis as above. During this study, 
it might also be beneficial to analyse vessel perfusion by and time required for perfusion. As 
this could affect the muscularisation of vessels as well.  
Although the immunofluorescent data showed a positive effect of control CDCs on 
angiogenesis and potentially on vessel maturation; unfortunately, cardiac MRI analysis 
revealed there was no difference in cardiac function between all three MI groups analysed 
(150). Similarly, histological analysis using masson trichrome staining did not show any 
difference in scar size at 4-weeks post MI between the three MI groups (Arthur Lab, 
unpublished data). Lack of functional improvement following CDC treatment runs counter to 
previous publications (225, 327, 336) and could be partly due to the experimental design. 
Firstly, animals with large infarcts (judged by the paler of the myocardium after ligation of 
LAD) were selected for this study to reduce the variability in the group (339). Large permanent 
infarcts affect almost all the free left ventricular wall, making it extremely challenging to gain 
functional improvement. Second, CDCs/ PBS injections were given via intra-myocardial route 
which could also trigger an inflammatory response that could lead to a longer inflammatory 
phase resulting in poor heart function. Repeating the experiment on mice with small and 
moderate sized infarcts and including an MI only control group (without any intra-myocardial 
injections) would help to address these possible factors. Alternatively, as our data agree with 
the clinical studies using CDCs which reveal no functional benefit, our data may reflect the 
limited capacity of CDCs to promote heart repair. Another factor to be consider is the time 
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between cardiomyocyte death and angiogenesis induction. Hypoxia caused due to MI leads to 
CM death potentially within 2hrs however, this not enough time for formation of new stable 
vessels. Therefore, angiogenesis alone probably would not be able to rescue the heart function 
post MI. However, increased angiogenesis would definitely help to reduce the apoptosis of 
surrounding CMs and may be improve function in smaller infarcts. 
Another possibility for lack of functional improvement using CDCs could be lack of coronary 
reperfusion, as the permanent ligation model was used for this study. As mentioned above, 
reperfusion is essential for better prognosis (203, 340). To test this hypothesis, the experiment 
would need to be repeated using an ischemia-reperfusion (IR) mouse model. This model mimics 
the clinical setting and would aid in generating useful data for better translation of CDC therapy 
into the clinical setting. In another study, CDCs were injected intra-myocardially in a rat IR 
model (341). Results from this study showed significantly higher ejection fraction in CDC 
treated group compared to control mice at 6 weeks after CDC transplantation. In contrast, in 
the current study mice were tested only 4 weeks after injection. Considering this, as mentioned 
previously, for future studies it would be beneficial to study the heart function at later time-
points, potentially at 8- or 12-weeks post-MI. Another difference between current and Carr et 
al. (341) study was that, CDCs were injected in two waves via two different routes: (i) 
immediately after reperfusion via intra-myocardial route which potentially increased 
angiogenesis and (ii) 2 days after reperfusion via a systemic route. This would significantly 
boost the quantity of paracrine factors released by CDCs during cardiac healing.  
Despite the lack of functional improvement, it is evident from this study that CDCs help in 
revascularisation of the infarcted region and may be have an indirect effect on stabilisation of 
neo-vessels. This positive effect of CDCs on angiogenesis was endoglin dependent. Endoglin 
as mentioned in the introduction (Sections 1.4.2 and 1.5.1), is a TGFβ type 3 co-receptor. In 
ECs endoglin promotes signalling via ALK1 receptor and supresses ALK5 mediated signalling 
(144). In my host laboratory, in vitro experiments using control and Eng-iKO CDCs showed 
that this positive effect of CDCs secreted endoglin on vasculature repair in post-MI hearts was 
due to BMP9 signalling via SMAD1/5/8 (Figure 1.19). Another striking effect of this pathway 
is the positive feedback loop between endoglin and BMP9. Endoglin promotes the binding of 
BMP9 to ALK1 which helps to maintain a high level of endoglin  expression (150). This is 
crucial result as expression of high levels of endoglin would help to obtain most pro-angiogenic 















The aim of the work described in this thesis was to understand the importance of endoglin in 
coronary vasculature development, in adult ECs homeostasis and in stem cell mediated cardiac 
repair.  
In chapter 3, I mapped the expression of endoglin in developing, post-natal and adult heart in 
different cell types. The expression of endoglin was observed in endothelium and endocardium 
throughout development and in adult hearts. The quantification of this expression showed 
strongest endoglin expression in coronary vein ECs and capillaries while a weaker expression 
was observed in coronary arteries. I speculated that as venous ECs start to express arterial 
markers, endoglin expression will be reduced. I also observed expression of endoglin in the 
mesenchymal cells of developing AV cushions and in developing myocardium. These 
myocardial mesenchymal cells were presumed as EPDCs as they migrate through the 
myocardium from E12 onwards (54) and express endoglin in vitro (64). Interestingly, 
quantification of this data showed that expression of endoglin in these mesenchymal cells was 
significantly lower than the adjacent endocardium/endothelium. In valvular mesenchymal cells, 
endoglin is required for endocardial cell EMT, mesenchymal cell migration and proliferation 
(127, 128, 161, 239, 242). However, the importance of endoglin in EPDCs in vivo is unknown 
and was analysed in chapter 4. Based on endoglin’s role in valvular mesenchymal cells, I 
hypothesised a similar role of endoglin in EPDCs.   
In vivo analysis showed expression of endoglin in minor subset of EPDCs and depletion of 
endoglin in these EPDCs using Wt1Cre-ERT2 did lead to reduced number of EPDCs in E15.5 
hearts. However, this loss of EPDCs did not lead to any cardiac, endothelium or SMCs related 
defects in E17.5 hearts. This data suggested that endoglin might play a role potentially during 
some EPDCs proliferation however, it is not required for EPDC differentiation. It might also 
be possible that another factor might have compensated in the absence of endoglin such as β-
glycan. EPDCs also known to differentiate into cardiac fibroblasts (54, 70-75) and expression 
of endoglin is reported in myofibroblasts after an injury (215, 216). Therefore, it is possible 
endoglin knockdown in EPDCs could affect the cardiac fibroblasts population however further 
studies are required to analyse this.  
In chapter 5, I analysed the role of endoglin during development of coronary ECs in embryonic 
and early post-natal development as well as the importance of endoglin in adult vascular 
maintenance. I hypothesized that lack of endothelial endoglin would have a detrimental effect 
on coronary vessels development and would imbalance the vascular homeostasis in adult mice. 
However, the mouse line (Dll4in3Cre-ERT2) used to study the embryonic coronary development 
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was not efficient and knockdown of endoglin in ECs using of VE-CadCre-ERT2 mouse line in 
post-natal mice did not lead to any coronary vasculature related defects. These results could 
either mean that endoglin is not necessary this late in coronary vessel development or else 
development of coronary vessels is not dependent on endoglin expression. The latter option is 
unlikely as various in vivo (131, 213, 214, 335) and in vitro (144, 342) studies showed the 
importance of endoglin in ECs. To elucidate this, further studies would be required to be 
performed during embryonic development preferably using a mouse line specific to coronary 
vasculature. Interestingly, Engfl/fl; VE-CadCre-ERT2 mouse line used during this study is also used 
to as an inducible mouse model to study HHT1. However, the cardiac phenotype (enlarged 
hearts coupled with CM hypertrophy) observed during the current project was not reported in 
any previous studies (188, 294). In the current study, these mice were speculated to be suffering 
from eccentric cardiomyopathy due to increase cardiac workload caused by reduced systemic 
resistance initiated by formation of AVMs. However, cardiac functional studies are required to 
confirm eccentric cardiomyopathy phenotype.  
As mentioned above, endoglin knockdown in early post-natal life (P2&P4) led to formation of 
systemic vasculature abnormalities (AVMs) that did affect the cardiac development/ 
maturation. Occurrence of AVMs due to endoglin deficiency are associated with HHT1. 
Patients suffering from HHT1 have a haplo-deficiency of endoglin and suffer from various 
vascular malformation including AVMs. In some HHT patients, larger AVMs in liver also lead 
to HOHF (170-172). Interestingly, in the current study depletion of endoglin in ECs using VE-
CadCre-ERT2 mouse line slightly later in post-natal development (P5&P6) or in adult quiescent 
ECs (10 to 12wks) also led to similar cardiac phenotype (enlarged hearts coupled with CM 
hypertrophy) coupled with AV shunts. In adult mice, this cardiac phenotype was confirmed to 
be HOHF by performing cardiac functional analysis using MRI. The data generated from the 
current study shows that continuous endoglin expression is vital during development and to 
maintain adult vasculature.  
This study also provides a non-invasive HOHF mouse model. HOHF is a rare complication in 
HHT patients (170-172). It is generally caused due to reduced vascular resistance linked with 
either anaemia, vasodilation or formation of AVMs and if left untreated could lead to cardiac 
arrest (295-297). However, this defect is not well characterised  and currently multiple studies 
are underway to understand the mechanism behind HOHF (297). Furthermore, to study HOHF 
mouse models are generated by surgical intervention (343). However, the mouse model used 
during this study leads to development of HOHF in short time and with 100% efficiency.  
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In chapter 5, I also observed HHT1 phenotype (AVMs and enlarged hearts) in a novel mouse 
line (ApjCre-ERT2). This mouse line allows to knockdown endoglin only in venous and capillaries 
ECs. Interestingly, the presence of endoglin in arterial cells did not prevent the incidence of this 
phenotype. This result along with higher endoglin expression observed in veins and capillaries 
during the expression analysis in chapter 3 and 5, strongly indicate that endoglin expression in 
veins and capillaries is vital for normal vascular development. Further assessment of this mouse 
model would provide invaluable insights into the role of venous and capillary endoglin on AVM 
formation. It would also be useful to assess if similar phenotype occurs after arterial ECs 
specific endoglin knockdown.  
The results generated so far strongly indicate that this cardiac phenotype observed after ECs 
specific endoglin knockdown was due to AV shunts or dilated vessels. Therefore, I 
hypothesised that therapeutic interventions to treat these AVMs would ameliorate the cardiac 
phenotype. Endoglin has high affinity for BMP9 and BMP10 (130, 134) and is known to signal 
via Alk1 receptor in ECs (144, 344). Lack of BMP9 and BMP10 ligands also led to development 
of retinal and cerebral AVMs (192, 293). Therefore, I postulate that treatment with exogenous 
BMP9 would either rescue or prevent the AV shunts which in turn would rescue the cardiac 
phenotype. Unfortunately, this pilot study was not successful due to technical difficulties. 
Nevertheless, it is a viable hypothesis based on the evidence so far generated through various 
studies. Long et al. (313) showed that IP injection of BMP9 was able to treat PAH phenotype 
observed in Bmpr2+/R899X mice. Therefore, it might have a similar effect on the HHT1 mice. 
To analyse this, further studies potentially involving IP injection of BMP9 would help to accept 
or dismiss this hypothesis.  
In chapter 6, I analysed the role of endoglin in cardiac stem cells (CDCs) mediated heart repair 
post MI with primary focus on angiogenesis. Multiple studies have shown that transplantation 
of CDCs in post-MI hearts led to functional improvements as well as increased angiogenesis in 
animal models (225, 327, 336, 341). However, full benefits of CDCs are not observed in the 
clinical settings (226, 227). Therefore, I characterised these cells further during this project. 
CDCs are shown to express high level of endoglin (326) and coupled with previous studies, I 
hypothesised that the proangiogenic effect of CDCs is endoglin dependent. Consistent with 
previous studies, in vivo analysis in 4-weeks post-MI hearts showed an increase angiogenesis 
in the transborder zone region after CDC injection. This pro-angiogenic effect was lost in the 
absence of endoglin thus confirming the initial hypothesis. Furthermore, I also analysed the 
effect of CDCs on vessels muscularisation. Surprising, my results showed that CDCs do not 
promote this process however, Eng-iKO CDCs had a detrimental effect on vessel 
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muscularisation. This interesting finding would need further investigation to identify the 
proteins involved during this process. This study did not show any functional improvement in 
4-weeks post-MI hearts potentially due to the size of the infarct. This result does suggest that 
functional improvement with CDCs are potentially linked with the size and severity of the 
infarct. This hypothesis would need to be tested in animal studies with small to moderate sized 
infarcts. 
In conclusion, this thesis showed that endoglin is expressed in the endothelium from 
development onwards and that this expression of endoglin is vital for normal vascular 
development as well as to maintain normal adult vasculature. Endoglin is also responsible for 
pro-angiogenic effect seen during stem cells mediated cardiac repair. In addition to this, the 
current study as also provides a novel mouse model for HHT1 research and well as a non-















Appendix 1: List of Solutions 
Solution Preparation Comments 
0.5M NaOH 500mg of NaOH in 25ml of Millipore filtered H2O Autoclaved and stored at RT 
Solution 1 
2.5ml of 0.5M NaOH + 20μl of 0.5M EDTA in 50ml 
of autoclaved Millipore filtered H2O (approximate 
pH 12) 
Stored at RT 
0.5M Tris-HCl 
3.94gms of Tris-HCL in 50ml of Millipore filtered 
H2O 
Autoclaved and stored at RT 
Solution 2 
4ml of 0.5M Tris-HCl in 46ml of autoclaved 
Millipore filtered H2O (approximate pH 5) 
Stored at RT 
50x TAE 
242.0gms Trizma Base + 57.1ml Acetic Acid + 
100.0ml 0.5M EDTA in 1L (~840ml) of Millipore 
filtered H2O  
Autoclaved and stored at RT 
1x TAE 20ml of 50x TAE in 980ml of Millipore filtered H2O  Stored at RT 
100bp DNA 
Ladder 
50ul of Loading Dye into 250ul of DNA ladder 
solution 
Stored at RT 
Acid-Alcohol 3ml of 37% HCl + 297ml of 70% EtOH Always use fresh, stored at RT 
10xPBS 
80.0gms NaCl + 2.0gms KCl + 11.5gms Na2HPO4 + 
2.0gms KH2PO4 in 1L of Millipore filtered H2O (pH 
to 7.4 using 5M NaOH or 1M HCl) 
Autoclaved and stored at RT 
1xPBS 
100ml of 10xPBS (pH 7.4) in 900ml of Millipore 
filtered H2O 
Stored at RT 
2xPBS 
200ml of 10xPBS (pH 7.4) in 900ml of Millipore 
filtered H2O 
Stored at RT 
0.1M KCl 
75.0mgs of KCl in 100ml of autoclaved 1xPBS (pH 
7.4) 
Autoclaved and stored at RT 
4% PFA (in 
1xPBS) 
40.0gms of PFA in 1L of autoclaved 1xPBS 50ml aliquots stored at -20°C 
1% PFA 
50ml of 4% PFA diluted in 150ml of autoclaved 
1xPBS (pH7.4) 
50ml aliquots stored at -20°C 
0.2% PFA 
50ml of 4% PFA diluted in 950ml of autoclaved 
1xPBS (pH7.4) 
50ml aliquots stored at -20°C 
4% PFA (in 
2xPBS) 
20.0gms of PFA in 500ml of autoclaved 2xPBS 15ml aliquots stored at -20°C 
30% Sucrose 
300gms of sucrose in 1L of autoclaved 1xPBS 
(pH7.4) 
50ml aliquots stored at -20°C 
15% Sucrose 
50ml of 30% Sucrose in 50ml of autoclaved 1xPBS 
(pH7.4) 
50ml aliquots stored at -20°C 
1M Tris-HCL 
(pH7.5) 
121g Trizma Base in 1L of Millipore filtered H2O 
(pH to 7.5 using 1M HCl) 
Autoclaved and stored at RT 
1xTBS 
100ml 1M Tris-HCL (pH7.5) + 30ml 5M NaCl in 
870ml of Millipore filtered H2O  
Stored at RT 
TBS-Tx 1L TBS plus 5ml Triton x-100 Stored at RT 
3% H2O2 
90ml of 30% Stock solution (stored at 4°C) in 210ml 
of 1xPBS 
Always use fresh 
5M NaCl 290g NaCl in 1L of Millipore filtered H2O Autoclaved and stored at RT 
1M HCl 
16.6ml of 37% HCl in 183.4ml of autoclaved 
Millipore filtered H2O 
Stored at RT 
0.01M Citrate 
Buffer (pH6 to 
6.3) 
1.92g citric acid in 1L of Millipore filtered H2O (pH 
with 5M NaOH) 
Autoclaved and stored at RT 
5M NaOH 
100.0gms of NaOH in 500ml of Millipore filtered 
H2O 
Autoclaved and stored at RT 
AB Complex 
(Standard) 
250μl 1M Tris-HCL (pH7.5) + 4.75ml of autoclaved 
Millipore filtered H2O + 1 drop A + 1 drop B (stored 
at 4˚C) 




0.25ml of DAB substrate + 1 drop of H2O2 + 2 drops 
of Liquid DAB (kit stored at 4°C) in 25ml of 
autoclaved Millipore filtered H2O 
Always use fresh 
50% EtOH 
150ml of absolute ethanol + 150ml of Millipore 
filtered H2O 
Stored at RT 
70% EtOH 
210ml of absolute ethanol + 90ml of Millipore 
filtered H2O 
Stored at RT 
90% EtOH 
270ml of absolute ethanol + 30ml of Millipore 
filtered H2O 
Stored at RT 
95% EtOH 
285ml of absolute ethanol + 15ml of Millipore 
filtered H2O 
Stored at RT 





Appendix 2: CDC Cell Culture 
Culture Media Growth Factor Final Concentration 
Complete Explant 
Media (CEM) 
IMDM media with L-glutamine 500ml 
Heat inactivated FBS 20% 












IMDM without serum 17.5% 
DMEM/F-12 (with 1% L-glutamine and 1% Pen/Strep) 65% 
FBS Stock Heat inactivated for 30mins at 56ᵒC 






Appendix 3: List of Chemicals and Consumables 
Item Name Company Cat. No. 
0.05% Trypsin-EDTA (1x) phenol red ThermoFisher 25300054 
0.5M EDTA Sigma Aldrich E7889 
100bp DNA Ladder Promega G2101 
1ml Syringe VWR 613-4897 
30% Hydrogen Peroxide (H2O2) VWR 23622.298 
4-Hydroxy Tamoxifen SLS Ltd H7904 
AB Complex (Standard) Vector Labs PK-4000 
Absolute Ethanol VWR 85651.32 
Accutase eBioscience 00-4555-56 
Acetic Acid VWR 20102.292 
Agarose nbs biologicals NBS-AG500 
B27 ThermoFisher 17504-044 
Basal Serum Albumin (low in endotoxins) VWR 422381B 
Basic Fibroblast Growth Factor (FGF) Peprotech 100-18B 
BMP9 Peprotech  
Bovine Serum Albumin lyophilized powder Sigma Aldrich A7638 
Citric Acid Sigma Aldrich C0759 
DMEM/ F-12 ThermoFisher 31330-038 
Eosin (aqueous 1%) RA Lamb LAMB-100-D 
Epidermal Growth Factor (EGF) Peprotech AF100-15 
Ethidium Bromide (EtBr) Sigma Aldrich E7637 
Foetal Bovine Serum, qualified, E.U.- approved, South 
America origin 
ThermoFisher 10270106 
Fibronectin Sigma F1141 
Fluoresbrite® YG Microspheres 45.0µm Polysciences, Inc. 18242-2 
FluoSpheres™ Polystyrene Microspheres, 15µm, carmine 
fluorescent (580/620), for blood flow determination 
ThermoFisher F21013 
Foetal Bovine Serum (Heat Inactivated) Origin: EU Approved 
(South American) 
ThermoFisher 10500064 
Genotyping Primers IDT n/a 
GoTaq Master Mix Promega M7422 
Hamilton Syringe (10 µL, Model 1701 LT SYR) Hamilton 80001 
Histobond Twinfrosted adhesion slides VWR 631-0624 
Histoclear SLS Ltd HS-202 
Histomount SLS Ltd HS-103 
Hypodermic needle 25G 16mm Greiner Bio-One Ltd N2516 
Hypodermic needle 27G 20mm VWR 613-2013 
Hypodermic needle 30G 12mm VWR 613-2011 
ImmEdge Pen (hydrophobic barrier pen) Vector Labs H-4000 
Insulin Syringe with 29G needle VWR 613-4897 
Iscove’s modified Dulbecco’s medium (IMDM) ThermoFisher 21980032 
Liquid DAB Substrate Pack, Concentrated BioGenex HK153-5K 
Mayer's Haematoxylin Sigma-Aldrich MHS16 
Methanol VWR 20864.32 
Monobasic potassium phosphate (KH2PO4) Sigma-Aldrich P5655 
MX35 Premier Disposable Low-Profile Microtome Blades ThermoFisher 3051835 
Normal Donkey Serum Sigma Aldrich D9663 
Normal Goat Serum Vector Labs S-1000 
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OCT CellPath KMA-0100-00A 
Peanut Oil Sigma Aldrich P2144 
Penicillin-Streptomycin ThermoFisher 15070063 
Plastic and Glassware 
VWR, Thermofisher and Scientific 
Laboratory Supplies 
Poly-D-Lysine Sigma P7280 
Potassium Chloride (KCl) Sigma Aldrich P9541 
Prolong gold antifade agent ThermoFisher P36930 
Prolong gold antifade agent with DAPI ThermoFisher P36931 
Recombinant Murine Cardiotrophin-1 Peprotech 250-25 
Sodium Chloride (NaCl) Sigma Aldrich S9625 
Sodium Hydroxide (NaOH) VWR 28244.295 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich S0876 
Sterile PBS (pH 7.2) ThermoFisher 20012019 
Sterile PBS (pH 7.4) ThermoFisher 10010023 
Sucrose Sigma Aldrich S0389 
Superfrost slides Fisher Scientific 10149870 
Tamoxifen Sigma-Aldrich T5648 
Thrombin Sigma-Aldrich T4393 
Tris-HCl Sigma Aldrich T3253 
Triton X-100 Sigma Aldrich T9284 
Trizma Base Sigma Aldrich 20252.244 
Tween-20 Sigma Aldrich P1379 
Versene ThermoFisher 15040033 
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